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Abstract 
Schizophrenia is a debilitating disease that affects about 1% of the population. Current 
therapeutic interventions mostly target dopaminergic neurotransmission but are not effective 
in treating all symptoms. There is growing evidence to support involvement of glutamatergic 
neurotransmission, which may better account for the symptomatology of schizophrenia.  
Glutamate concentrations can be measured in vivo using magnetic resonance spectroscopy 
(MRS). Stronger magnetic field strengths provide benefits for MRS, but they also present 
challenges.  Simulations were designed to examine how MRI field strength influences 
metabolite quantification. Glutamate and its metabolic precursor, glutamine, were more 
reliably and independently quantified with higher MRI field strengths, showing a clear 
benefit for MRS.  
Using a 7 T MRI, voxels were placed within the dorsal anterior cingulate cortex (dACC) and 
thalamus of volunteers with schizophrenia, a psychiatric control group of volunteers with 
major depressive disorder (MDD), and healthy controls.  Glutamine and glycine, both 
involved in glutamate neurotransmission, were lower in the thalamus in schizophrenia 
relative to healthy controls, whereas dACC glutamate concentrations were higher, 
demonstrating glutamatergic abnormalities in schizophrenia at rest. 
Prior MRS studies of schizophrenia have been in resting conditions. In a proof of concept 
study with healthy controls, it was shown that the Stroop Task was able elicit a significant 
glutamate increase in the dACC when in a functional state (glutamate fMRS) relative to 
resting conditions using the 7 T MRI. This was then explored in the same schizophrenic and 
MDD subjects as the resting MRS study. Glutamate significantly increased in the healthy 
controls, but not in the schizophrenic and MDD groups. The schizophrenic group had a 
slower glutamatergic response followed by a slower recovery, and, was the only group to 
demonstrate significant glutamine increases when activated, indicating potential 
abnormalities in glutamate dynamics. 
Using a 7 T MRI, glutamate was explored in resting and activated conditions in 
schizophrenia. Glycine was demonstrated to be lower in schizophrenia using MRS for the 
first time, and the first functional MRS study was performed in a psychiatric population. The 
 iii 
 
studies were made stronger by inclusion of a psychiatric control group. Future studies of 
schizophrenia with glutamate fMRS should focus on the delayed glutamatergic response to 
functional activation and abnormal recovery.  
Keywords 
Schizophrenia, major depressive disorder, glutamate, glutamine, glycine, 7 T, fMRS, MRS, 
simulations, metabolite quantification, Stroop task, anterior cingulate cortex (ACC), 
thalamus. 
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Chapter 1  
1 Introduction 
The ultimate objective of this thesis is to gain insight into the state of glutamate and its 
metabolic affiliates in the brains of individuals with schizophrenia using advanced MRI 
hardware and methodology. This is, of course, a very general statement, as a brief 
overview of schizophrenia and MRI physics is necessary to fully appreciate the specific 
intentions and methods of the works in this thesis.  This chapter will serve as a thorough 
tutorial towards the development of specific hypotheses outlined in this work, and will 
provide additional background information for the otherwise self-contained chapters 2, 3, 
4 and 5.   
 
1.1 Schizophrenia; background and physiology 
1.1.1 From dementia praecox to schizophrenia 
Schizophrenia (SZ) was first separated from other psychoses by Emil Kraeplin in 1899, 
who at the time called the disorder “dementia praecox”1. Krapelin’s descriptions of 
dementia praecox were very similar to the modern classification of SZ in the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-
TR)1.  The term “dementia praecox” was eventually replaced by SZ in 19112. Although 
the classification of SZ is relatively recent, the disease is believed to have been with 
humans throughout civilization, given early descriptions of similar illnesses in historical 
texts1,3,4.  
The prevalence of SZ in the population is approximately 1%, with a similar incidence 
among men and women5,6. The typical age of onset is in the adolescent phase of a 
person’s life (usually early twenties), with the onset being 3-4 years earlier in men than in 
women5. Although onset typically occurs beyond puberty, subtle symptoms have been 
identified retrospectively in childhood prior to disease diagnosis7.  The cause of SZ is still 
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unknown, although there are convincing arguments pointing towards the idea that there is 
both a genetic and an environmental component. One meta-analysis of 12 studies of twins 
(both monozygotic and dizygotic) found an 81% heritability component due to genetics 
and an 11% heritability component due to the environment, such as exposure to 
infectious agents, dietary characteristics, etc8. It is probable that there are in fact multiple 
factors that can lead to the final common pathway of SZ2,9. What is clear is that, at the 
point when a diagnosis of SZ would be made, there is a substantial contribution of 
neurotransmitter anomalies influencing the symptoms of SZ. 
   
1.1.2 Neural physiology of schizophrenia 
The symptoms of SZ are variable in each individual, but generally can be subdivided as 
either positive (i.e. auditory hallucinations and delusions), negative (i.e. asociality, 
avolition, anhedonia, affective flattening, and alogia) or cognitive (i.e. attention and 
working memory deficits, visual and verbal learning memory, reasoning and problem 
solving)7,10,11. Most current antipsychotics offer effective relief from positive symptoms 
by targeting dopaminergic neurotransmission but most do little to offer relief from the 
negative and cognitive symptoms7,12–14 and can actually worsen cognitive symptoms15. 
The negative and cognitive symptoms are present in 40-80% of people with SZ10 and are 
better indicators of functional outcome7,9,10,13,14.  There are currently no approved 
treatments that target negative and cognitive symptoms specifically. The drugs that can 
treat both positive and negative symptoms typically come with heavy undesirable side 
effects (e.g. clozapine increases risk for agranulocytosis and requires regular blood 
tests)12,16, which can influence patient compliance with regularly taking their prescribed 
medication. These poorly treated negative and cognitive symptoms lead to progressive 
deterioration in functioning throughout their lives10,15.  
Differences in the effectiveness of drug interventions are likely due to the underlying 
differences in brain physiology between positive, negative, and cognitive symptoms. 
Positive symptoms have been connected to dopaminergic pathways originating in the 
ventral tegmental area and projecting to the nucleus accumbens2, and, as such, the current 
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antipsychotics generally target the D2 dopamine receptors in this area15. It is believed that 
different brain pathophysiology is implicated in the negative and cognitive symptoms7, 
and it is likely that the physiology of positive, negative, and cognitive symptoms are 
connected through neural circuits, known as the basal ganglia thalamo-cortical circuits 
(BGTHC)2,12 (Fig 1-1).   
  
Figure 1-1. A few neurotransmitter pathways within the limbic basal ganglia 
thalamocortical circuits.  
ACC=anterior cingulate cortex; PFC=prefrontal cortex; NA=nucleus accumbens; 
HIP=hippocampus; VT=ventral tegmental area; TH=thalamus; CB=cerebellum. 
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The BGTHC are essential links between motivation and action in the brain, and are 
important when learning new behaviours2. As the name implies, these are circuits that 
cycle from the cortex, to the basal ganglia, through to the thalamus, and then back out to 
the cortex, creating a flow of cyclical communication through these brain areas2,17. The 
communication throughout each circuit is largely mediated by the main excitatory 
neurotransmitter, glutamate (GLU; Fig 1-2A), with contributions from both dopamine 
and the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). One BGTHC of 
particular interest in the pathophysiology of SZ, the limbic BGTHC, completes a circuit 
through the dopaminergic pathway from the ventral tegmental area (VTA) to the nucleus 
accumbens, a pathway central to explaining the positive symptoms of SZ. The anterior 
cingulate cortex (ACC)2,13,18–25, and the thalamus2,22,24–30 are key nodes within circuits 
that are repeatedly implicated through the negative symptoms of SZ.  The thalamus, 
being a central hub of each BGTHC, is an area of interest in studies of SZ that have 
demonstrated  structural abnormalities26,27, abnormal functional connectivity27,28 and 
metabolic abnormalities22,24–26,31,32.  The dorsal component of the ACC, believed to be 
involved in selective encoding of stimulus properties33, attention34 , and organization of 
conflicting stimuli35,36, is associated with negative and cognitive symptoms in SZ7,13 and 
is another important structure within the limbic BGTHC.  Functional MRI (fMRI) studies 
have demonstrated hypofunction in the ACC upon completion of complex tasks such as a 
word-fluency task20 and the color-word Stroop task19 in people with SZ compared to 
Figure 1-2. The chemical structure of (A) glutamate and (B) glutamine 
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healthy controls. The ACC is an area that is heavily innervated with GLU neurons that 
mediate the communication with functionally connected brain regions.  Therefore, it is 
possible that the positive, negative, and cognitive symptoms of SZ are due to the actions 
of impaired GLU neurotransmission within areas of the BGTHC, with the dopamine 
levels causing the positive symptoms as a downstream effect. Much of the current 
understanding of the neural physiology of SZ actually comes from studies involving 
drugs that act on GLU receptors, such phencyclidine (PCP) and ketamine37–39.  These 
drugs are antagonist of the N-methyl-D-aspartate (NMDA) ionotropic GLU receptor37–40.  
They have been shown to induce both positive and negative symptoms when 
administered to healthy controls, but will exacerbate existing symptoms in people with 
SZ41,42. The prevalent stance in the GLU theory of SZ postulates that the presence of 
localized NMDA receptor hypofunction as a likely cause of reduced efficiency or 
function of GLU neurotransmission in connected regions12,43. There is also some 
evidence pointing towards the presence of glutamate excitotoxicity in SZ in a small 
number of studies (n=7)44.  The exact biochemical mechanism of GLU neurotransmission 
deficiency in SZ is still unknown but it is likely located somewhere within the glutamate-
glutamine (GLU-GLN) cycle. 
 
1.1.3 The glutamate-glutamine cycle in a healthy state 
The efficient recycling of GLU is an essential component to neural function. It is 
estimated that 60-80% of neuronal glucose consumption directly supports the GLU-GLN 
cycle45 (Fig. 1-3). Neuronal GLU is first created when glucose enters the Kreb’s cycle 
(Tricarboxylic acid cycle) in the neuronal mitochondria.  After citrate reacts with NAD+ 
to form alpha-ketoglutarate, CO2, NADH+ and H
+, the alpha-ketoglutarate exits the 
Kreb’s cycle and binds with an alpha-amino acid using aminotransferase to facilitate the 
reaction46–48. This creates the amino acid GLU. Approximately 4000 GLU molecules are 
then packaged into a vesicle for exocytosis into the synapse at a rate of 1.2 vesicles per 
second, or 4800 GLU molecules per second49. After release into the synapse, GLU binds 
with ionotropic receptors (NMDA, kainate, AMPA) or metabotropic receptors (mGluR1-
6 
 
8) on the post-synaptic membrane, an event modulated by certain agonists
7,40,48,49. For 
example, there is a glycine (GLY)/D-serine site on the NMDA receptor that needs to be 
filled for GLU neurotransmission to be possible on that receptor50. With both GLU and 
GLY sites bound, the NMDA channel opens and results in a Ca2+ influx into postsynaptic 
neuron. The GLU molecule is eventually released from the receptor. A small percentage 
will be reabsorbed into the presynaptic neuron, but the majority will be rapidly taken up 
into the adjacent glial cell (astrocyte) by excitatory amino acid transporters (EAAT), 
primarily EAAT2, to avoid excitotoxicity49,51. Each EAAT2 can transport a GLU 
molecule once every 70 ms, so hundreds of them need to be present49. This is an active 
transport of GLU which requires ATP45.  In the glial cell, GLU can either be oxidized or 
can undergo an amination reaction via glutamine synthetase (GS), an enzyme located 
exclusively in the glial cell46,47,52, that will convert the GLU to glutamine (GLN; Fig 1-
2B)45–47,49,53.  The GLN can then be passively transported back into the neuron where the 
phosphate activated enzyme glutaminase (PAG) can convert it to GLU through 
hydrolysis for re-use in neurotransmission46,47. Approximately ¾ of the GLU will 
undergo the amination reaction to GLN in the glial cell, and the remaining ¼ will be 
oxidized using glutamate dehydrogenase46,47 to convert it to alpha-ketoglutarate54, which 
can be fully degraded to CO2 and water within the glial cell for energy purposes
55. 
Therefore, each GLU molecule is only used a few times before it is ultimately oxidized 
for energy46,47,49.   This process of recycling GLU after it has been used for 
neurotransmission is the GLU-GLN cycle, a process that is tightly coupled to neuronal 
energy consumption from glucose45. Without glucose to resupply the loss of GLU 
through oxidation, the GLU supply will be depleted in approximately 1 minute49. There 
are, therefore, many metabolic processes within the GLU-GLN cycle that could 
ultimately lead to hypofunction of GLU neurotransmission if they are not operating 
efficiently (e.g. reduction in enzymatic levels, reduction in transporters, reduction in 
number of receptors, dysfunctional receptors, etc). If there is a dysfunction somewhere in 
the GLU-GLN cycle, one would expect an offset in the equilibrium concentration of 
GLU and/or GLN. SZ does not spontaneously occur in animals other than humans and 
laboratory animal models of SZ tend to only mimic a very specific feature of SZ (i.e. 
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dopamine hyperresponsivity). Fortunately, there are methods by which GLU and GLN 
can be measured non-invasively in human brains affected by SZ.  
 
Figure 1-3. A simplified diagram of the GLU-GLN cycle in a healthy state.   
GLU is created in the mitochondria, packaged into vesicles to be released in the 
synaptic cleft where it binds with receptors on the post-synaptic membrane. This 
reaction is mediated by local GLY.  GLU is then actively transported into the 
adjacent glial cell (via EAAT), where it is converted to GLN via GS. GLN is then 
passively transported back into the neuron, where it can be converted back into 
GLU via PAG. GLU = glutamate; GLN = glutamine; GLY = glycine; NMDA = N-
methyl-d-Aspartate; EAAT = excitatory amino acid transporters; GS = glutamine 
synthetase; PAG = phosphate-activated glutaminase  
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1.1.4 Measuring components of the GLU-GLN cycle in SZ 
1.1.4.1 Glutamate/Glutamine 
Since the first lines of evidence for the GLU theory of SZ emerged, there have been 
many studies examining GLU and GLN in SZ.  Although the GLU theory has evolved 
throughout the years56, there has been relatively little progression given the number of 
studies and the massive efforts put forth by researchers, demonstrating that it is a 
complex disorder and there are still many obstacles to overcome.  There have been useful 
post-mortem studies of brain tissues from people with SZ that have found abnormalities 
in the expression of proteins related to synaptic activity and GLU 
neurotransmission32,51,57,58. However, post-mortem studies have limited results because 
the tissues are typically from people with chronic SZ who have been heavily medicated 
throughout the duration of their illness. This is a problem because there has been 
substantial evidence showing that the GLU and GLN concentrations likely change 
throughout the course of the disorder18,25 and that medications can influence their 
concentrations in the human brain59,60. Another challenge of GLU and GLN studies in SZ 
is that it appears to be a uniquely human disorder2 and although symptom analogs have 
been well documented and studied in animal models (i.e. ketamine administrations61), 
this fact still limits the translational potential of animal studies. Genetic studies have 
identified some gene variants that affect the NMDA pathway and the susceptibility for 
SZ7 but, so far, there has not been a “schizophrenia gene” identified.  Therefore, it is 
desirable to be able to non-invasively detect GLU and GLN concentrations in the brains 
of humans with SZ in vivo. One method that has been extensively used for this is proton 
magnetic resonance spectroscopy (1H-MRS). 
There have been many 1H-MRS studies of SZ to date in various areas of the 
brain12,18,62,63.  Unfortunately, many of the studies are difficult to compare considering all 
the possible factors that influence the results.  As mentioned already, whether the SZ 
subjects are first-episode, anti-psychotic naïve or chronic patients will influence the 
results18,25,59,60. Studies are performed on different magnetic field strength scanners (1.5 T 
-7 T), using different 1H-MRS acquisition pulse sequences and parameters, with different 
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post-processing methods and different fitting algorithms63.  Some studies use water to 
determine the metabolite concentration (explained below) and others simply examine 
ratios of metabolites to creatine, another metabolite detectable with 1H-MRS.  Different 
voxel sizes are used, and the placement of a voxel can be very different from one study to 
the next. For example, the ACC is a structure that is much larger than a typical 1H-MRS 
voxel size (1.5cm3 – 8cm3) with very different functions from one location to another2. 
Not all studies specify all the metabolites that they fit, and, specifically, many studies do 
not explain what metabolites are included in their GLU definition.  At lower magnetic 
field strengths, it can be necessary to combine GLU and GLN into one unitary 
concentration, as the metabolites cannot be reliably separated for quantification.  It is 
then common to define “GLX” as GLU+GLN, but this is not always made clear, leading 
one to assume that GLX could actually be a combination of GLU, GLN, and any other 
metabolites (GABA, glutathione) or macromolecules that overlap their spectra. Even with 
all these limitations in comparing studies, GLU, GLN, or GLX concentrations are 
consistently implicated in voxels throughout the brain in SZ.  
A recent meta-analysis was completed of 28 1H-MRS studies with 647 subjects with SZ 
and 608 healthy controls at various voxel sizes and field strengths18, of which 9 studies 
were completed in the medial frontal lobe (including the ACC and medial prefrontal 
cortex)22,24,64–71. The study determined that GLU concentrations are typically lower than 
controls at the onset of the disease, whereas GLN is typically higher than controls.  Both 
GLU and GLN decreased in concentration faster as the SZ subjects aged than in the 
healthy controls. The same meta-analysis has examined GLU concentrations in 3 studies 
in the thalamus, but determined no significant difference in SZ from healthy controls.  
There were not enough studies in the meta-analysis to determine an effect of GLN in the 
thalamus, but it has previously been demonstrated that there is increased GLN in first-
episode, antipsychotic naïve subjects with SZ22 and chronic SZ24 relative to controls, with 
the GLN concentration decreasing after 30 months of antipsychotic treatment25.   
One particularly interesting 1H-MRS study of the ACC involved healthy controls being 
challenged with a sub-anesthetic dose of the NMDA antagonist ketamine72.  This study 
observed an increase in ACC GLN after the healthy controls had been exposed to 
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ketamine, which returned to normal ten minutes later. This observation is consistent with 
the GLU theory of NMDA hypofunction in SZ, as it has been observed that when the 
NMDA receptor is in a condition of hypofunction there is an increase in the activity of 
GLN synthetase leading to higher GLN concentrations synthesized73. Therefore, 
increased GLN observed in people with SZ provides strong support for the GLU theory 
of SZ.   
 
1.1.4.2 Dynamic measurements of GLU and GLN 
Static measurements of 1H-MRS have been paramount in moving research forward into 
the possibility of GLU dysfunction in SZ, but a limitation of these studies is that all were 
acquired in a resting condition, at only one time point.  This is based on the assumptions 
that the metabolite concentrations are not dynamic, and that the brain at rest is truly at 
rest.  It has since been demonstrated that the concentrations of some metabolites will 
change when the tissue within the voxel is stimulated74–85.  This technique is called 
functional 1H-MRS (1H-fMRS). The first 1H-fMRS studies were largely looking at lactate 
concentrations in the occipital lobe after visual stimulation in dyslexic children84, and in 
subjects with migraines83. Since then, there have been reports that show that local GLU 
(or GLX) concentrations will increase when an area of the brain is stimulated using a 
visual task in the occipital lobe75–77,81, a finger tapping paradigm in the motor cortex80, 
pain paradigms in the ACC78 and inferior parietal cortex79, and a sexual arousal task in 
the ACC82.  It is likely that the GLU increase is related to the creation of new GLU for 
neurotransmission de novo from glucose, while the remaining GLU undergoes recycling 
via the GLU-GLN cycle.  In a dynamic state while the GLU-GLN cycle is being 
challenged, it is possible that a dysfunction somewhere in the GLU-GLN cycle would 
manifest itself as a significantly different response of GLU than in healthy controls, or 
possibly even a change in GLN.  
The previously mentioned 1H-fMRS studies of the brain have been pivotal in 
demonstrating that metabolic changes can be observed as a result of functional activation. 
A limitation of past studies is that no study has yet demonstrated that GLU increases can 
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be seen using a cognitive behavioural task or in a psychiatric disorder. A behavioural task 
is desirable if the technique is going to be extended to the study of psychiatric disorders 
featuring impaired cognitive processing, such as SZ.  
There are many possible cognitive tasks that could be chosen as the functional paradigm 
for 1H-fMRS but there are also multiple considerations. First, the task needs to stimulate 
a specific area of the brain, much like the visual tasks stimulate the occipital lobe75–77,81 
and the motor tasks stimulate the motor cortex80. The first decision, then, needs to be in 
what area of the brain is the voxel going to be placed.  For a 1H-fMRS study of SZ, it 
would be interesting to observe metabolic changes in an area implicated through the 
negative symptoms.  The task must also be able to actively engage the participant for an 
extended period of time.  If the participant loses interest or is not finding the task 
particularly challenging anymore it is likely that the area of interest will also not be 
stimulated as strongly, potentially biasing the results to any attentional impairment. This 
is an important aspect to consider given that behavioural tasks already do not illicit as 
strong of a neural response (according to measurements of the blood-oxygen level 
dependent (BOLD) effect) as the visual and motor tasks86. It has been postulated that the 
deficiencies in SZ may arise from an increased number of subprocesses that are involved 
in the encoding of cognitive stimuli into task facilitative formats33,87. The color-word 
Stroop Task88–92 is one such cognitive task that requires encoding operations in the 
presence of interfering information that activates the ACC19,35,36,93–95. 
The color-word Stroop Task is a common psychiatric battery that people in SZ find more 
challenging (lower time efficiency) than healthy controls, although with a similar rate of 
correct answers19,67,96. It involves the presentation of a color-word written in a certain 
color of ink in a congruent condition (i.e. the word “red” written in red ink), incongruent 
condition (i.e. the word “green” written in red ink), color-only condition (i.e. letters 
(“XXXX”), or a nonsense word written in red ink) or word-only condition (the word 
“red” written in white ink). The color of the ink is the expected correct response in all but 
the word-only condition, where the word is the expected correct response (i.e. “Red” 
would be the correct response in each of the previous examples). The organization of 
conflicting or complex stimuli is often attributed to activity in the dorsal ACC20,35,36, 
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which the color-word Stroop Task robustly and reproducibly activates19,35,93,95,97. 
Therefore, due to the implication of ACC in negative and cognitive symptoms, the Stroop 
Task appears to be a good cognitive paradigm for a 1H-fMRS study of SZ.    
In a neuropsychiatric disorder like SZ, where one of the leading hypotheses is related to 
hypofunction of the GLU-GLN cycle, 1H-fMRS has the potential to utilize the added 
dimension of time to identify possible metabolic steps within the GLU-GLN cycle that 
are functionally deficient, based on GLU or GLN accumulations (or lack thereof ). While 
1H-fMRS in SZ should provide valuable information on the glutamatergic system, there 
is certainly still a role for static 1H-MRS measurements of brain tissue in a controlled 
resting state. As technology has improved, so has the quality of 1H-MRS spectra. This 
can translate to improved measurements of metabolites that are of low concentration and 
have been traditionally difficult to quantify. One such metabolite that plays a pivotal role 
in GLU neurotransmission is GLY. 
 
1.1.4.3 Glycine 
One of the growing ideas for potential pharmaceutical interventions of the NMDA 
hypofunction is to try to increase GLY concentrations in glutamatergic neurons. There is 
a GLU site and a GLY/D-serine site on the NMDA receptor (the NR2 and NR1 subunits, 
respectively) that needs to be filled for successful GLU neurotransmission7,12,40,50,98. 
Without an adequate supply of GLY (or D-serine) present in the synaptic cleft the 
NMDA receptor will not operate optimally. This could be a target for pharmacological 
intervention to increase the local concentrations.  However, there are some obstacles to 
overcome. First, GLY is also an inhibitory neurotransmitter, so increasing the 
concentration throughout the brain may have some adverse effects.  Another issue is that 
GLY crosses the blood brain barrier very poorly99 so to increase concentrations in the 
synaptic cleft just from the diet, there needs to be a large dose of GLY ingested, although 
one study has demonstrated that increased GLY concentrations can be detected in the 
brain using 1H-MRS after 2 weeks of ingesting it100. A molecule that is similar to GLY 
but can cross the blood-brain barrier could be ingested, but GLY has such a small 
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chemical structure that there is really not much leeway in creating a similar molecule50. 
Alternatively, there could be a way to redirect more GLY into the synaptic cleft. One 
such method lies in targeting GLY transport inhibitors. 
There are two GLY transport inhibitors in the brain, GLYt1 and GLYt2, and they both 
have very different functional mechanisms50. GLYt2 is located at the GLY inhibitory 
neurons, and GLYt1 is located on glial and neuronal membranes and controls the GLY 
concentration within the synaptic cleft50. It is possible to selectively target the GLYt1 
receptor with 99% specificity over the GLYt250. Therefore, GLY and its transport 
inhibitors are an exciting possibility for future drug interventions to improve NMDA 
efficiency, but so far there has only been limited success40,50,98,101.  
To date, there have only been limited studies of GLY in SZ. One study examined the 
serum of people with SZ receiving either first-generation antipsychotics (FGA), second 
generation antipsychotics (SGA), or the atypical antipsychotic clozapine102 and found the 
patients receiving clozapine had lower serum GLY levels than patients taking FGA or 
SGA. This is interesting because clozapine is one of the few currently approved 
antipsychotics that has some effectiveness in treating negative symptoms2. Another study 
examined GLY levels in the plasma of people with treatment-resistant SZ before and 
after clozapine treatment103. This study found significantly increased plasma GLY levels 
after clozapine treatment in the SZ group, which was also significantly higher after 
treatment when compared to controls.  Although the results of this study are somewhat 
contradictory, they do both implicate GLY in the pathophysiology of SZ. It is also 
important to note that treatment-resistant SZ may operate under different mechanisms 
than SZ that can be successfully treated with FGA or SGA, going back to the notion that 
SZ may be a final common pathway of multiple sub-disorders. However, a number of 
other plasma/serum studies of GLY have shown increased, neutral, or decreased levels of 
GLY, meaning that the results have been fairly inconsistent103. One of the limitations of 
plasma/serum studies is that it is not necessarily an indication of tissue GLY levels, and 
the results are not specific to one area of the brain. It would be ideal if GLY could be 
measured accurately in vivo in a localized area of the brain.  One possible technique to do 
this would be 1H-MRS.  
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The spectral signature of GLY consists of a single resonance at 3.548 ppm104.  It is a 
challenging metabolite to quantify reliably with 1H-MRS due to its low concentration and 
the proximity of its spectral peak with the spectral signature of myo-inositol (MYO), a 
high concentration metabolite with a complicated spectral signature (strong J-coupling). 
Two studies have been able to detect GLY reliably on 4 T MRI scanners by using a 
special pulse sequence called echo-time averaging sequence100,105. One of these studies 
examined GLY concentrations in the occipital cortex before and after a 2 week period of 
oral GLY supplementation and found that they were able to detect a significant increase 
in GLY concentration after the 2 week period100.  Another study used a 7 T MRI to detect 
GLY reliably, again in the occipital lobe106. All these 1H-MRS studies have been in 
healthy controls, and, to date, there have been no published studies on GLY 
measurements in vivo in SZ using 1H-MRS63.  
 
1.1.5 Summary of 1H-MRS in SZ 
As technology has improved, so has the potential to achieve higher quality 1H-MRS 
spectra. To advance the understanding of SZ it is necessary to utilize these advances and 
push the limits of what can be achieved.  Reliable measurements of GLY concentrations 
along with static and dynamic measurements of GLU and GLN in SZ in implicated areas 
within the brain would provide some critical information concerning the health of GLU 
neurotransmission in SZ. Optimizing 1H-MRS spectra is critical to be able to reliably 
make these measurements. This will require basic understandings of MRI and 1H-MRS 
principles. 
 
1.2 Magnetic Resonance Spectroscopy 
This will be a brief introduction to concepts and processes involved in acquiring, 
processing and quantifying 1H-MRS data. For a more thorough review of these topics, 
please see references107–113.  
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1.2.1 Origin of the signal 
To understand the mechanisms of 1H-MRS and 1H-fMRS, it is important to first 
understand some basic principles of nuclear magnetic resonance (NMR). The first 
requirement for any signal in NMR is a nucleus with a magnetic moment. The magnetic 
moment comes from a particle’s spin, which is a basic property of any nucleus, along 
with mass, magnetism, and electric charge. Generally, all nuclei with an even mass are 
bosons and will have full integer spin (i.e. -1, 0, 1), and all nuclei with an odd mass are 
fermions and will have a half-integer spin (i.e. -½, ½). For any nucleus, there are |2*Spin| 
+ 1 stable spin states. In the absence of an external magnetic field (B0), every one of these 
stable rotational states are considered degenerate, meaning they will have the same 
potential energy. When a B0 is applied, the degeneracy is removed and there will be an 
energy separation between the quantum rotational states. This is called the Zeeman effect, 
or Zeeman splitting, which underlies every observation in NMR spectroscopy.  
A 1H nucleus has a ½ spin. It, therefore, has |2*(½)| + 1 = 2 stable spin states. When a B0 
is applied, the magnetic moment of the 1H will precess about the B0 in one of its two 
stable energy states, which is either parallel or anti-parallel to the B0 (Fig 1-4). The 
parallel alignment is the lower energy state, so, at body temperatures, there will be a 
small excess of nuclei in the parallel state relative to the anti-parallel. The interaction of 
B0 with the particle’s magnetic moment results in a torque that will cause the precession 
of the nuclei about the B0, and the speed of this precession is proportional to the strength 
of the B0. This relationship between the precession frequency (ω) and the B0 is the 
Larmor equation: 
 𝜔0 =  𝛾 ∗ 𝐵0  1.1 
where γ is the gyromagnetic ratio, a nucleus specific value for the ratio between the 
magnetic moment and the spin angular momentum. In a 1H nucleus, γ is equal to 
267.52*106 rad/(s*T). Due to the excess number of 1H nuclei in the parallel orientation, 
there is an accumulation of magnetic moments that leads to a bulk magnetization (M0z) in 
the longitudinal axis (z-axis). By applying an additional magnetic field (B1) 
perpendicularly to B0 and at the resonant frequency ω0 it is possible to tip M0 out of 
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alignment with B0 and into the transverse (xy) plane (M0xy) (Fig. 1-5). Figure 1.5 assumes 
that the axes are precessing about B0 at ω0. This is called the rotating frame of reference.  
By choosing to view the magnetization with this rotating frame of reference, it is easy to 
visualize the magnetization being tipped by the B1 pulse: 
 𝜃 =  𝜔1 ∗ 𝑇  1.2 
where θ is the nutation angle, T is the pulse duration, and ω1 is the frequency in the 
rotating frame: 
 𝜔1 =  𝛾 ∗ 𝐵1 1.3 
The transfer of M0z to M0xy is known as an “excitation pulse”, and it enables the detection 
of the precessing magnetization via an electromotive force induced into a nearby 
radiofrequency (RF) coil. The electromotive force can be measured as a voltage using a 
digital voltmeter with a high sampling rate (~1GHz). This voltage is what is typically 
known as the NMR signal.  
 
1.2.2 Relaxation 
After Mz has been transferred to Mxy, the magnetization will gradually return back to Mz. 
This process is called spin-lattice relaxation, or T1 relaxation: 
 
𝑀𝑧(𝑡) = 𝑀0 ∗ (1 − 𝑒
−
𝑡
𝑇1) 1.4 
where Mz(t) is Mz with respect to time, M0 is the magnitude of the equilibrium 
magnetization vector, t is time, and T1 is the time required for the signal to recover (1-e
-1) 
of Mz. The greatest amount of signal is induced into the RF coils when Mz = 0, and all the 
magnetization is in the Mxy plane (Mxy=M0). In this case, the excitation pulse is known as 
a 90° flip angle. The T1 relaxation is an important factor in determining the time between 
successive excitations. If Mz has not recovered sufficiently there will be less 
magnetization transferred into Mxy in the following acquisition. The most basic NMR 
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Figure 1-4. The precession of spin-1/2 nuclei in the presence of a magnetic field (B0) 
will preferentially orient parallel to the applied field 
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Figure 1-5. Excitation and refocusing of the magnetization in a spin-echo sequence 
(A) In the presence of an external magnetic field, B0, the magnetization in the z-axis, 
Mz, is initially equivalent to the resting magnetization, M0. (B) After a 90° excitation, 
the Mz component is fully transferred to the transverse magnetization, Mxy and (C) 
will immediately begin to dephase. (D) After applying a 180° pulse, the Mxy is flipped 
and begins to rephase. (E) This can be visualized by examining the signal in the time 
domain.  
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pulse sequence, the “pulse-acquire” sequence, consists of one 90° excitation RF pulse 
tipping Mz into Mxy immediately followed by a signal recording the induced 
electromotive force into the RF coil. This signal is recorded as a free-induction decay 
(FID), which is heavily influenced by another form of relaxation called spin-spin 
relaxation or T2 relaxation.   
To reiterate, the ω0 is determined by the γ and the B0. Although efforts are made to make 
the local magnetic field over the volume of interest as homogenous as possible, the B0 
produced by the MRI and the magnetic characteristics of local environments at the 
microscopic scale (i.e. local sources of magnetic field distortions, such as blood vessels 
and interaction between intra- and extra-molecular spins) are still going to be 
heterogeneous (static dephasing) and fluctuate randomly in time (dynamic dephasing).  
The relaxation of the Mxy in the xy-plane due to the presence of fluctuations in the local 
magnetic environments of individual spins at the microscopic level is the cause of T2 
relaxation. The Mxy will eventually decay to 0 due to this relaxation. The overall effective 
decay rate observed during as FID, T2
*
, has two components: 
 1
𝑇2∗
=  
1
𝑇2
+  
1
𝑇2′
 1.5 
where T2 represents the irreversible decay, T2
’ represents a reversible component. The 
Mxy decay is an exponential decay:  
 
𝑀𝑥𝑦(𝑡) = 𝑀0 ∗ 𝑒
−
𝑡
𝑇2∗ 1.6 
where Mxy(t) is the magnitude of the transverse magnetization changing in time, and T2
* is 
the observed time for Mxy to decay to e
-1 of its original value.  T2 relaxation is specific to 
the transverse magnetization, while T1 relaxation is specific to the longitudinal 
magnetization. During T2 decay, the bulk magnetization is still in Mxy, it is just out of 
phase. Within a voxel, there are many pockets of spins that experience the same local and 
relatively unchanging magnetic field called isochromats. These isochromats will accrue 
phase differences relative to each other. By applying a 180° pulse, the Mxy will flip and 
the isochromats will rephase forming an “echo” (Fig 1-5). Most 1H-MRS pulse sequences 
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utilize some echo formation method to refocus some of the reversible decay. As the rate 
of T2 decay is slower than the rate of T2
*, echo formation allows for a significant delay 
between the excitation pulse and the sampling of the signal. This delay is required to 
implement the essential step of spatial encoding of the MR signal allowing the selection 
of signals from a given volume of interest rather than from the entire sample.  
  
1.2.3 Electron shielding and chemical shift 
If all 1H nuclei experienced the same magnetic field, they would all resonate at the same 
ω0.  Fortunately for 1H-MRS, the local magnetic field differs from B0 due to the 
weakening of B0 from the electron spins surrounding adjacent nuclei within the chemical 
structure of a molecule. This phenomenon is called electron shielding.  1H-MRS would 
not yield useful information without the frequency difference that results from electron 
shielding as each 1H will resonate at a specific frequency determined by both B0 and its 
local magnetic environment. The contributions to the local magnetic environment from 
surrounding nuclei is much smaller than the contribution of the B0. It translates to a 
difference in frequency on the order of Hz, which is considerably smaller than 
frequencies in the MHz range from the main B0.  This shift in frequency is called the 
chemical shift: 
 𝜔𝑠ℎ𝑖𝑒𝑙𝑑 = 𝛾 ∗ 𝐵0(1 − ) 1.7 
where ωshield is the resonant frequency of the shielded resonance, and  is the shielding 
constant. It is common to refer to the chemical shift in a parts per million (ppm) scale: 
          =  
𝜔0−𝜔𝑠ℎ𝑖𝑒𝑙𝑑
𝜔0
 𝑥 106   1.8 
with  as the resonance frequency in ppm and 𝜔0 as the frequency of a resonance at B0. 
In 1H NMR, 0 ppm is represented by tetramethylsilane (TMS). TMS contains 4 CH3 
groups attached to one Si. Each of the 1H nuclei are maximally shielded by surrounding 
electrons. As shielding decreases, the ppm value increases. The ppm scale is convenient 
because there are multiple common B0 utilized in MRI studies and the  of each 1H nuclei 
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does not change with B0. For example, creatine resonates at 191.6 Hz relative to TMS at 
1.5 T, 383.2 Hz on a 3 T and 894.1 Hz on a 7 T. Using ppm values, creatine resonates at 
3.02 ppm relative to TMS at all fields. Electron shielding determines the ω, but the 
shapes of spectra originating from molecules with more than one proton are complicated 
by the intra-molecular interaction of spins (via their electron spin), an effect known as J-
coupling. 
 
1.2.4 J-coupling 
Also known as peak-splitting, J-coupling refers to the possibility that multiple local 
magnetic field environments are possible within a molecule, which can reduce one strong 
singlet peak into multiple smaller peaks (Fig 1-6).  This can best be understood with an 
example. The molecular structure of GLU is shown in Figure 1-2A, featuring five protons 
(hydrogen nuclei).  Each 1H nuclei attached to the C4 (carbon atom number 4) can align 
itself with or against B0. They both can be up, they both can be down, or one can be up 
and one can be down with the latter option having twice the probability.  This means 
there are three different local magnetic fields possible that the 1H nuclei on the C3 can 
experience due to the 1H nuclei on the C4, splitting a singlet from a 1H on the C3 into a 
triplet. The triplet is then further split into a complicated multiplet due to significant 
interaction with the 1H nuclei on the C2, which can also align themselves with or against 
the magnetic field.  Peak splitting reduces the amplitude of the signal from resonances 
closer to the level of noise, and widens the spectral signature for a given metabolite, 
further complicating quantification.  
Spin pairs can be strongly coupled (AB) or weakly coupled (AX).  J-coupling leads to 
phase cancellation within a multiplet, called J-dephasing. Stronger coupling accentuates 
these effects and further complicates the relative amplitudes of the peaks that are being 
split.  Weak coupling will perform in very predictable ratios according to Pascal’s 
triangle, while strong coupling will skew the proportions based on how strongly they are 
coupled (Fig. 1-6). The coupling strength is determined by the relative magnitude of the 
J-coupling constant to the differences in resonance frequency. For example, heteronuclear 
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coupling (i.e. between a 1H spin and a 13C spin) would be very weakly coupled due to the 
large differences in their resonant frequencies (i.e. MHz). GLU and GLN are examples of 
two metabolites that experience strong J-coupling resulting in broader spectral patterns. 
Due to the similar chemical structures between GLU and GLN, this broadening of the 
spectral patterns leads to much overlap and can make them very hard to differentiate in 
1H-MRS. Fortunately, it is possible to reduce the influence of J-dephasing. The local  
 
 
Figure 1-6. The splitting of peaks in coupled spin systems. 
When the J-constant between two resonances, JAB, is comparable to the relative 
difference between the centers of the two resonant frequencies, ωA and ωB, the pair 
is deemed to be strongly coupled (i.e. AB). When JAB is not comparable to the 
difference between ωA and ωB, as in heteronuclear systems, for example, the pair is 
considered to be weakly coupled (i.e. AX). 
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magnetic field differences due to the multiple possible spin orientations that cause J-
coupling are not influenced by B0. Therefore, on a ppm scale, as B0 increases, the shape 
of the multiplets slowly begin to converge towards being a single peak (unresolved 
multiplet). This increases the peaks’ signal above the noise, and reduces the peaks’ 
overlap with other spectral signatures.  This effect will be described in greater detail in 
chapter 2. 
 
1.2.5 Ultra-High Field (≥ 7 T) Spectroscopy 
One of the biggest determinants of spectral quality is the B0 strength of the MRI. 
Although stronger B0 MRI scanners can be expensive, there are many potential benefits. 
As mentioned in the above section, strong B0 reduces the influence of strong J-coupling 
on the spectral lineshape on a ppm scale. By a similar argument, the spectral dispersion 
of the spectra also improves. That is, the ratio of the distance between peaks of two 
different 1H nuclei and their Lorentzian linewidths is increased, which results in sharper 
peaks and less spectral overlap between metabolites. Some of the improvements in 
spectral dispersion are countered by increased Lorentzian linewidths (decreased T2*) at 
stronger B0 that increase in vivo at a rate of 1.35 Hz/T
114. The linewidths are a measure of 
the exponential T2* decay of the signal, such that slowly decaying signals (i.e. long T2*) 
will have sharper spectral peaks than fast decaying signals (i.e. short T2*). Even with this 
broadening of the resonance, there is still a net reduction in spectral overlap when B0 
increases (assuming similar conditions).  
A stronger B0 causes more 
1H nuclei to align themselves parallel to the field. It also 
induces more torque on the spin, leading to a faster ω (in accordance with the Larmor 
frequency, Eq 1.1).  All together, the SNR improves as B0 strengthens with an 
approximately linear relationship when scanning humans115. 1H-MRS is a traditionally 
low SNR technique and requires many signal averages (addition of repeated 
measurements). In NMR, SNR is essentially a currency that can be traded for smaller 
voxels to reduce partial volume effect on small brain structures, faster scan times (by 
reducing averages) to reduce patient motion during the scan (and perhaps scan more 
24 
 
voxels), or it can simply be used for improved quantification of the data. Therefore, there 
are huge potential improvements that can be realized using ultra-high field B0, but there 
are also challenges to overcome.  
As the main B0 increases, so do the technical limitations. For example, the wavelength of 
a B1 pulse in human brain tissue at 3 T is approximately 30cm. At 7 T, this wavelength is 
approximately 13cm, which is also approximately the width of the human head. This is a 
problem in imaging because there will be bright and dark spots throughout the volume 
due to the nodes of the electromagnetic B1 pulse.  Fortunately for spectroscopy, the phase 
of the B1 pulse does not change substantially over a typically sized voxel. This problem 
can effectively be mitigated in 1H-MRS by using an increased number of transmitters and 
B1 shimming
116. 
A limitation of ultra-high field B0 
1H-MRS is that the power required for a B1 pulse to 
achieve a given ω1 increases with B0117. Although B1 shimming can help this issue, 
hardware limitations and increased thermal energy deposition, or specific absorption rate 
(SAR), are real problems at high B0. This needs to be considered during sequence 
development. 
 
1.2.6 Voxel localization 
In vivo 1H-MRS is generally divided into single-voxel 1H-MRS (SVS) techniques and 
chemical shift imaging (CSI) techniques.  CSI outputs spectra from a slab or volume of 
voxels, while SVS generally only outputs a spectrum from one or two voxels. There are 
advantages and disadvantages to both techniques.  With CSI it is obviously a benefit to 
have multiple spectra from throughout the volume. This is especially good for observing 
the three strongest singlet signals in 1H-MRS, namely N-acetylaspartate (NAA), creatine 
(Cr), and choline (Cho). The disadvantages to CSI include the potentially very long 
acquisition times, the contamination of the spectra from signals outside each voxel (point 
spread function), and the increased linewidths from poorer B0 shims throughout the brain 
that lead to reduced spectral quality111. SVS has superior spectral quality to CSI. It is 
25 
 
much easier to shim over one localized voxel than it is to shim over the entire brain, the 
SVS spectra can be acquired individually then easily frequency and phase corrected, 
signals from outside the voxel can be suppressed using outer volume suppression (OVS) 
techniques and there is usually sufficient time to acquire a water unsuppressed spectrum 
and a metabolite suppressed spectrum (discussed below) to strongly improve overall 
quantification of metabolites. Only SVS spectra were acquired for this thesis due to the 
superior spectral quality required for quantification of glutamate and glutamine.  For the 
remainder of the thesis, 1H-MRS will refer to SVS. 
As previously mentioned, most 1H-MRS pulse sequences utilize some method to refocus 
Mxy.  This is more of a necessity because 
1H-MRS pulse sequences require voxel 
localization. Voxel localization is the process by which the tissue within a specific 
volume becomes excited while leaving the area around it in a relaxed or un-refocused 
state.  This is typically done using three slice-selective B1 pulses and orthogonal magnetic 
field gradients. Magnetic field gradient pulses create magnetic field intensity distributions 
throughout the volume that vary linearly along a selected direction.  A slice-selective RF 
pulse with a specific carrier frequency, excitation bandwidth, and gradient amplitude 
alters B0 (and, therefore, ω0) along the axis of the gradient pulse and will excite a specific 
slab within the volume (Fig 1-7). If this is done along all three axes then there will be a 
rectangular volume at the intersection of all three slabs, the 1H-MRS voxel, from which 
1H-MRS signal will be refocused (generation of an echo signal). This process allows 
selection of voxel position, shape, and volume. The two most common 1H-MRS 
techniques for voxel localization are Stimulated Echo Acquisition Mode (STEAM)118 and 
Point-Resolved Spectroscopy (PRESS)119, both of which have their advantages and 
disadvantages120. 
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Figure 1-7. Slice-selection frequency bandwidth for a slice thickness and position. 
A slice-select gradient, given by the equation ω= γ * (B0+Gz*z), can create a 
difference in the local magnetic field in one direction across a volume. Therefore, a 
specific excitation bandwidth, Δω, can be used to excite a specific slice, Δz, while 
leaving the remaining volume unexcited.  
PRESS is a powerful technique that utilizes a slice-selective 90° pulse followed by two 
slice selective 180° pulses.  The initial 90° pulse will excite a slab by flipping the signal 
from the longitudinal axis into the transverse axis (Mz to Mxy). The first 180° pulse will 
excite another slab along a different axis, which will effectively flip the Mxy 
magnetization about the z-axis in the voxel of interest. The final 180° pulse excites the 
final slab that flips the magnetization within the voxel one more time about the z-axis and 
leads to a spin echo from the voxel at a certain echo time (TE).  
STEAM (Fig 1-8) utilizes three 90° pulses instead of the 90°, 180°, 180° combination for 
PRESS.  The first 90° pulse excites a slab similar to the first pulse in PRESS.  The 
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second 90° pulse then flips the signal from the voxel into the longitudinal axis for a 
duration known as the mixing time (TM), before the final 90° pulse flips the signal back 
into the transverse plane to form a stimulated echo. The 90° pulses require less power and 
deposit less thermal energy, or SAR, into the volume. At high B0, power and SAR 
become serious limitations during sequence development. The 90° pulses also have better 
slice profiles, which means that the spectra will have less contributions from signals 
outside the nominal voxel volume (the theoretical rectangular prism defining the desired 
voxel boundaries). The TM can be much longer than the TE, which means that additional 
saturation pulses and crusher gradients can be played out during this time without 
reducing the signal (with the exception of some T1 relaxation). In addition, due to the 
temporary storage of the magnetization into the longitudinal axis during the TM, the 
sequence can have a shorter TE than a PRESS sequence. Lower TE reduce the amount of 
signal decay from T2 relaxation and reduce the signal lost to J-dephasing in J-coupled 
metabolites.  Due to the strong coupling of GLU and GLN signals, lower TE are 
desirable. A downside to the STEAM sequence is that only half of the magnetization gets 
restored into the transverse plane, leading to half of the measured signal from the voxel 
and reduces the SNR. However, this is partially compensated by the reduced achievable 
TE. There are many benefits to STEAM at high B0, so it will be used for all 
1H-MRS 
measurements in this thesis and has been used by our lab previously22,24 
 
1.2.7 Water Saturation 
One of the obstacles to overcome with 1H-MRS is the overwhelming signal from the two 
1H nuclei in water molecules.  In the human brain, the concentration of water is 
approximately 37 mol/L121.  This is huge in comparison to the concentrations of 
metabolites of interest that are generally in the 1-10mmol/L range, approximately four 
orders of magnitude smaller. It would not be possible to reliably measure metabolites in 
vivo 1H-MRS without an effective means to remove the water signal peak located at 4.7 
ppm. The typical method to do this involves a hard narrowband B1 pulse centered on 4.7 
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Figure 1-8. The 1H-MRS STEAM pulse sequence with VAPOR water suppression. 
The sequence begins with VAPOR water suppression, which has 8 radiofrequency 
(RF) pulses that are chemical shift selective (CHESS) and 1 block of outer volume 
suppression (OVS) interleaved between the 7 Th and 8th pulses. Voxel selection is 
then performed by a STEAM sequence that has three slice-selective pulses one in 
each axis. An additional water suppression pulse has been added in-between the 2nd 
and 3rd slice-selective pulses. Gx, Gy and Gz represent gradients that are played out 
in each of the x, y, and z axis, respectively.  
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ppm that selectively excites the water signal into Mxy prior to the start of the voxel 
localization sequence. The water signal is then sufficiently crushed using magnetic field 
gradients, eliminating the detectable component of the water signal. It is common 
practice to use multiple B1 pulses to provide more efficient suppression. One such 
sequence, Variable Power and Optimized Relaxation Delays (VAPOR)122, involves eight 
B1 pulses separated by crusher gradients and timing intervals is particularly insensitive to 
small variations in B1 pulse power, which typically needs to be optimized at the start of 
each acquisition. An example of a VAPOR water suppression sequence that could be 
played out prior to a STEAM sequence is in Fig. 1-8. 
 
1.2.8 Post-processing 
After the FID for the spectra have been recorded there are multiple processing steps 
necessary before the data is ready to be quantified.  
 
1.2.8.1 Receiver combination 
Most head coils have a multiple-receiver setup, especially if the brain area of interest is 
not located on the periphery. Each coil will record a FID for every 1H-MRS acquisition.  
Some of these coils will be close to the signal source, while others may be far away and 
acquiring lower signal (mostly noise). Most resulting FIDs will be out of phase with each 
other. For these reasons, spectra should not simply all be added together. This could add 
noise unnecessarily, and the out of phase components will add at least somewhat 
destructively. A method has been developed for optimal receiver combination that uses 
the phases and amplitudes of the unsuppressed water peaks123. The phase of the water 
signal from each coil is recorded and adjusted relative to the signal in the first coil.  The 
spectra can then be added constructively. The amplitudes of the water signal determine 
the relative weighting of each spectrum so that the water suppressed spectra that are 
acquiring mostly noise will contribute much less than spectra with lots of signal. After 
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the receivers have been combined, the spectra are ready for frequency and phase 
correction.  
  
1.2.8.2 Frequency and phase correction 
1H-MRS acquisitions often require the combination of many spectra to acquire a 
spectrum with adequate SNR.  During long acquisitions, some frequency drift may occur 
due to the heating up of the gradients and some phase shifts may occur due to subject 
motion. That’s why it is important to collect the spectra individually and correct the 
frequency and phase prior to averaging the spectra together. If left uncorrected, the 
frequency shift between successive spectra will blur the resulting combined spectrum and 
the phase offset between successive spectra will cause destructive addition. To correct the 
frequency of each individual spectrum, one simply tracks the frequency of a prominent 
spectral peak (i.e. Cr, Cho, NAA) and adjusts the frequency to each spectrum relative to 
that of the first spectrum. To correct the phase, examine the phase of the first few points 
of the FID and adjust the phase of each spectrum relative to that of the first spectrum. 
This will ensure the optimal combination of the data (i.e. frequency- and phase-coherent 
averaging). 
 
1.2.8.3 Averaging 
Now that the spectra from each of the receive channels have been combined and the data 
have been frequency and phase corrected, the individually acquired spectra may now be 
combined into one higher quality spectrum. With all the preprocessing complete, all that 
is necessary is to add the spectra together.  This will improve the SNR of the spectra at a 
rate proportional to the root of the number of averages: 
 𝑆𝑁𝑅 α √𝑁𝐴𝑉𝐺 1.9 
where NAVG  is the number of averages.  This is another reason why stronger B0 is important 
for increasing the SNR, as it takes four times as many averages to double the SNR from an 
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acquisition. For example, it would take 3 minutes 12 seconds to acquire a 64 average 
spectrum at 7 T. To acquire a spectrum with the same SNR at 3 T, this would take 17 
minutes 25 seconds (5.4 times as long), assuming similar voxel conditions (i.e. volume, 
location, etc) and the main source of the noise is the sample. 
 
1.2.8.4 Lineshape correction 
When a FID is acquired it typically does not decay with the perfect lineshape that would 
be predicted from Eq 1.4. The main contributions to lineshape imperfections come from 
magnetic field inhomogeneities and eddy-current artifacts. The magnetic field 
inhomogeneities are often unavoidable but can be minimized by using a good B0 
shimming algorithm.  The eddy-current artifacts come from ramping magnetic field 
gradients pulses shortly prior to signal acquisitions. This induces currents into the 
cryostat of the scanner, which induces temporally decaying B0 offsets.  These eddy 
currents tend to be more pronounced in short-TE spectra because the last crusher gradient 
is played out right before the acquisition of the FID (A longer TE would allow the eddy-
currents to dissipate). These can greatly distort the lineshapes of spectral peaks and 
ultimately make it difficult to predict the lineshape to use for fitting. Through a process 
called Quality Eddy Current Correction (QUECC), it is possible to remove the eddy 
current artifacts and remove the majority of the lineshape imperfections due to magnetic 
field inhomogeneities124.  QUECC requires a reference lineshape to deconvolve form the 
spectrum. This lineshape reference is typically the water peak obtained from a water-
unsuppressed spectrum. It is, therefore, necessary to acquire a water-unsuppressed 
spectrum that produces the same eddy-current artifacts as those observed in the water-
suppressed acquisition (matched gradient waveforms, i.e. only RF off). Essentially, the 
water suppressed data is divided (complex division) by the water unsuppressed data and 
convolved with a Lorentzian function to make all peaks in the spectrum Lorentzian. This 
is done only until the water signal approaches 0 else there will be a characteristic artifact 
in the data. The remainder of the signal undergoes phase corrections only (no division by 
amplitude of reference, only its phase term). QUECC allows one to use the working 
assumption that the spectral lineshapes are Lorentzian for the purpose of data modelling. 
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1.2.9 Spectral Fitting 
Now that the post-processing is complete, the next step is to quantify the data. Every 
peak (excluding spectral noise) represents signal from the 1H of a particular metabolite 
and the area underneath the peak will be proportional to the concentration of that 
metabolite in the volume of interest. There are usually contributions from 1H nuclei of 
many metabolites that often overlap and can make the spectrum very complicated.  To 
isolate a metabolite’s contribution to the signal, it is first necessary to know their unique 
spectral signatures.  
 
1.2.9.1 A priori information 
Fitting a 1H-MRS spectrum requires a priori information (prior knowledge) about the 
relative distribution of resonances from each metabolite’s 1H nuclei. Each metabolite has 
a characteristic pattern of resonances with predictable relative amplitudes and chemical 
shifts known as a spectral signature. Every resonance from a metabolite varies in 
amplitude together so it is possible to model the spectral signatures by constraining the 
predictable information together. There are multiple methods to determine the relative 
resonances for each metabolite with a specific 1H-MRS pulse sequence and B0 (because 
both will influence the fit).  First, in vitro metabolite solutions (i.e. phantoms) containing 
only one metabolite and a reference (TMS for reference at 0 ppm) can be scanned and 
modelled. This will provide a spectrum with the predictable resonance pattern that can be 
modelled iteratively with the relative amplitudes, chemical shifts, phases, and linewidths 
of each resonance of the pattern appropriately constrained. This information would be 
located in two files known as a .ges or a .cst files. The .cst file or “constraint” file, holds 
all the set relationships between the properties of individual peaks within the metabolite’s 
spectral signature (Fig 1-9A), while the spectrum specific initial parameter estimates for 
each metabolite (not each resonance) are located in the .ges files (i.e. “guess” file; Fig 1-
9B). The information in the .ges file is used to seed the iterative fitting algorithm that will 
provide an estimate of each metabolite’s concentration. 
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Another method to determine the spectral signatures for each metabolite is to simulate 
responses of a given spin system with known chemical shifts and coupling constants104,125 
to a particular pulse sequence using density operator calculations or product operator 
formalism.  The advantage to the simulation method is that it can quickly produce exact 
representations of the spectral signatures for a given TE and TM of the STEAM sequence 
that can readily be incorporated into .ges and .cst files. Of course, the development of the 
simulation package for a specific pulse sequence is a specific scientific effort and was not 
part of this thesis (more details provided in chapter 2)125.  
A full template that can be used for metabolite quantification of in vivo spectra can be 
made by combining .ges and .cst files from each metabolite into one pair of large .ges and 
.cst files. This works well if a complete list of metabolites contained in the spectrum is 
known. This is not always the case.  For example, the exact molecules producing the 
broad, so called macromolecular, resonances part of short-TE human brain spectra are 
typically not known. 
 
1.2.9.2 Macromolecular fitting 
One of the biggest challenges in quantification of short-echo 1H-MRS spectra is the issue 
of modeling the broad, fast-relaxing macromolecular components that overlap metabolite 
signals throughout the spectrum. This macromolecular baseline is composed of DNA, 
RNA, proteins and phospholipids. The signal is most prominent at low TE, so one way to 
reduce their influence in the spectrum is by using very long TE. However, this is not a 
practical approach for quantifying strongly coupled metabolites such as GLU and GLN 
that have highest signal at low TE63. Another way to account for the macromolecules is to 
acquire a separate metabolite- (and water-) suppressed spectrum that will leave only 
signal from the macromolecules remaining. One method to go about this is to use 
multiple well-timed inversion recovery pulses that effectively saturate the metabolite 
signal prior to the STEAM acquisition. This macromolecular signal can then be modeled 
using a Hankel-Lanczos Singular Value Decomposition (HLSVD; Fig.1-10)126,127 fit,  
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Figure 1-9. Resonance information as it would be listed in (A) .cst and (B) .ges files. 
The .cst file contains the fitting parameters denoted by the { and } brackets, which 
contain individual modifications for each resonance. The parameters that would be 
constrained include the chemical shift (i.e. {shift}), the Lorentzian linewidth (i.e. 
{lw}), the metabolite specific amplitude parameter (i.e. {glu} for glutamate), the 
phase (i.e. {ph}), the delay time (i.e. {DT}), and the Gaussian linewidth (i.e. {WG}). 
The “@” symbol indicates that the final value for the fit should be taken directly 
from the .ges file.  The .ges file includes the initial “guesses” for each parameter. 
Values are only needed the first time a fitting parameter is used (or if there is an 
“@” in the .cst file), which is why in this example only peak 1 has any values. The 
*glu value is a variable that would be specific for modifying glutamate 
concentrations, located for convenience at the top of the file.  Due to the QUECC 
lineshape correction employed in our lab, all Gaussian widths are set to 0. 
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which will output a list of resonances that fit the data. These resonances can be 
constrained together into a macromolecular spectral signature, and then added to the 
quantification template.     
 
1.2.9.3 fitMAN 
Now that a template has been built with the resonances of each metabolite (and the 
macromolecules) modelled and constrained, it is time to fit the spectrum using the time-
domain iterative fitting algorithm, fitMAN128.  The fitting algorithm takes the initial 
estimate of the fit (constructed from the information in the .ges and .cst files) and 
iteratively modifies the model parameters, within the given set of constraints, until the 
difference between the data (from a .dat file) and the model (i.e. the residuals) is 
minimized (i.e. the residuals are below a pre-defined acceptable level or after a 
predefined maximum number of iterations has been reached as indicated in the header of 
the .cst file). Upon completion, fitMAN will output the final fit parameters for every 
resonance into a separate .out file to be used in determining the metabolite 
concentrations.  
 
1.2.9.4 Quantification 
The amplitude of each resonance represents the signal contribution at t=0 in the time 
domain. The total area occupied by the resonances of each metabolite can be determined 
by adding up the amplitudes of each metabolite’s resonances from the .out file.  This 
estimate of the metabolite’s area can be used to estimate the metabolite’s concentration, 
[Met], by using the area of the water signal as a reference of known concentration129:  
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Figure 1-10. datSub, a user interface for the HLSVD fitting of macromolecules. 
This program allows a user to overlay the (A) water suppressed spectrum with the 
(B) macromolecular (metabolite and water suppressed) spectrum and (C) perform 
an HLSVD fit of the macromolecules. (D) The residuals between the HLSVD fit and 
the macromolecular spectrum can be viewed amplified by a factor of 10. 
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where AM and AW is the spectral area of the metabolite and water, respectively, NAVG_M  
and NAVG_W is the number of averages of the water suppressed spectrum and water 
unsuppressed spectrum, respectively, GM and GW is the gain used in the water suppressed 
acquisition and water unsuppressed spectrum, respectively, ScaleM and ScaleW is a 
metabolite and water scaling factor (used for scaling the real and imaginary points of the 
data spectrum), respectively, that can be found in the header of the original .dat files, 36.9 
mol/L is the concentration of water in the brain, #protons is the number of protons 
contributing to the metabolite’s spectral area, and %W is the percentage of tissue that is 
water from that voxel.  The %W is determined based on the amount of gray matter, white 
matter, and CSF in the tissue129: 
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 1.11 
where fgray, fwhite, and fCSF are the fractions of gray matter, white matter, and CSF in the 
voxel, waterdensity is the density of water at body temperature (0.99299g/cm
3), 
watermolecularWeight is the molecular weight of water at body temperature (18.0152 g/mol), 
0.81 is the fraction of water content in grey matter and 0.71 is the fraction of water 
content in white matter129. Using this formula, it is possible to determine the 
concentrations of metabolite spectra acquired in vivo. The typical concentration range of 
detectable metabolites in vivo is 0.5-15 mmol/l for realistic acquisition times and voxel 
sizes. 
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1.3 Thesis Objectives 
The ultimate purpose of this thesis is to learn more about the health of the glutamatergic 
system in SZ using advanced hardware and methodology. Outlined below are specific 
objectives with their associated hypothesis for chapters 2-5 of this thesis, respectively.  
 
1.3.1 Demonstrate the benefits of ultra-high field for GLU and GLN 
1H-MRS 
Prior to embarking on a challenging study using the new, advanced brain imaging 
infrastructure that is the 7 T MRI scanner, it is wise to first demonstrate that the resulting 
benefits are worth the significant effort involved. The first objective is to determine what 
improvements in quantification can be expected as the B0 increases. One approach 
consists in using a spectral simulation framework, such as the one previously mentioned 
while describing the fitting process, to create metabolite quantification templates. These 
simulations can generate spectra with known concentrations of a known list of 
metabolites for a range of B0 and SNR, then use a Monte Carlo approach to repeatedly fit 
noisy realizations of the simulated spectrum. With such large simulated datasets, one can 
evaluate the factors affecting the precision and accuracy of the quantification procedure.  
It is hypothesized that improvements in B0 and SNR will generally improve the 
coefficients of variation of metabolite concentration estimates with the greatest 
improvements being in J-coupled metabolites (i.e. GLU and GLN), while decreasing the 
correlations between different metabolite concentration estimates due to the reduced 
spectral overlap at higher B0 and reduced influence of noise on the variability of the fit 
with higher SNR.  
As B0 increases so do the number of metabolite peaks that rise above the level of the 
noise and should be accounted for in the quantification template. Forming a complete list 
of the metabolites that should be part of the quantification template is not a simple task. 
There is currently no data-driven method to determine which metabolite should be 
included versus omitted. The addition of extraneous metabolite signatures in the 
quantification template increases the dimensionality of the spectral modelling problem 
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and negatively affects the precision of all metabolites. If metabolites that should be 
included are omitted, the spectral fitting algorithm will attempt to minimize residuals by 
over- or under-estimating other metabolite considerations. This raises the question as to 
which metabolites absorb the residual signal from these unaccounted metabolites, and 
how could an incomplete quantification template influence the interpretation of the 
existing large body of human brain MRS literature.  It is hypothesized that metabolites 
that overlap with each other will be influenced the most by an omitted metabolite, and 
this will be more pronounced at lower B0 due to decreased spectral dispersion. 
This thesis objective is explored in greater details in the article presented in chapter 2, 
which was submitted for publication in Magnetic Resonance in Medicine. Revisions have 
been requested by the reviewers prior to resubmission. These have been addressed in 
chapter 6 of this thesis. 
   
1.3.2 Examine glutamate, glutamine, and glycine in schizophrenia 
The ACC and the thalamus are key nodes implicated in the symptoms of SZ, with 
NMDA hypofunction as one of the leading theories.  Past studies have implicated GLU 
and GLN in SZ using 1H-MRS at lower B0
18,22,24. These studies should be replicated and 
validated using the expected improvements in metabolite quantification of a 7 T MRI. 
One limitation of previous studies is that the comparison is only of SZ to healthy 
controls.  The reality is that many of the symptoms of SZ are overlapped with other 
disorders as well, such as in major depressive disorder (MDD). The inclusion of a 
psychiatric control group would benefit the study and help improve the specificity of the 
results. Therefore, metabolite concentrations will be assessed in the SZ group relative to 
healthy controls and also to a psychiatric control group of MDD.  It is possible that 
NMDA hypofunction could be due abnormalities in GLU and GLN or to the 
unavailability of GLY (lower glycine concentrations) in the synaptic cleft. It is 
hypothesized that there will be increases in GLN and decreases in GLU in the SZ group 
relative to the control groups based on the literature18,22,24.  In addition, no study to date 
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has examined GLY in SZ with 1H-MRS.  It is hypothesized that there will be abnormal 
GLY concentration in the SZ group relative to the control groups.  
Our exploration of “resting” levels of GLU, GLN, and GLY in SZ compared to healthy 
and MDD control groups is presented in chapter 3. This article has been prepared for 
submission to The British Journal of Psychiatry. 
 
1.3.3 Demonstrate glutamate changes with 1H-fMRS in the ACC 
using a cognitive task 
There have been many 1H-MRS studies that have demonstrated GLU and GLN 
dysfunction in SZ. A limitation of these studies is that the concentrations have all been 
measured in an uncontrolled “resting” state and at one time point. Of course, glutamate 
concentrations are adjusted dynamically, at the microscopic level, when transitioning 
from periods of rest (lower neuronal spiking activity) and periods of activity (higher 
neuronal firing rates) in glutamatergic neurons. One way to assess the health of the GLU-
GLN cycle is to perform 1H-fMRS and assess GLU and GLN concentrations dynamically 
during prolonged periods of controlled rest (visual fixation) versus periods of prolonged 
functional activation (i.e. a cognitive task).  There are no studies to date using 1H-fMRS 
at 7 T to show GLU changes during a cognitive task, so the ability of 1H-fMRS to detect 
such dynamic regulation of glutamate will first need to be demonstrated in healthy 
controls.  Based on other 1H-fMRS studies that have demonstrated GLU changes after 
visual or motor stimulation75–77,80,81, it is hypothesized that a color-word Stroop task will 
stimulate the ACC and increase GLU concentrations upon functional activation. 
The results of the study conducted based on these scientific questions have been 
published in NeuroReport and form the contents of chapter 4. 
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1.3.4 Examine 1H-fMRS in the ACC using a cognitive task in 
schizophrenia 
Once the 1H-fMRS in the ACC has been established in healthy controls, the next step is 
to implement this in individuals with SZ and MDD (psychiatric control group). Due to 
the abnormal GLU and GLN concentrations that have been reported in “resting” 1H-MRS 
studies in SZ, it is hypothesized that dysfunctions of the GLU-GLN cycle will manifest 
themselves as abnormal modulation of either GLU or GLN concentrations in response to 
functional activation.  
The results of this study have been accepted for publication in npj Schizophrenia and 
form the contents of chapter 5.  
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Chapter 2  
2 Sources of Variability in the quantification of short-echo 
time human brain 1H-MRS spectra 
The work presented in this chapter was done to learn more about how specific sources of 
variability can influence metabolite quantification, with a focus on J-coupled metabolites 
and magnetic field strength.  A version of this work is currently being edited for a 
resubmission to publish in Magnetic Resonance in Medicine.  The reviewers’ comments 
to the initial submission are addressed in chapter 6. 
 
2.1 Introduction 
Proton MR Spectroscopy (1H-MRS) is a useful technique for non-invasively determining 
in-vivo metabolite concentrations of the human brain.  Brain disorders, such as 
neuropsychiatric illnesses, have been studied extensively with 1H-MRS1. Detection of 
Glutamate (GLU) and glutamine (GLN) with 1H-MRS is of particular interest in 
neuropsychiatric disorders thought to feature abnormalities of neurotransmitter 
metabolism2. GLU and GLN have only slightly different molecular structures and, as 
such, the protons have similar electromagnetic environments.  In a 1H-MRS spectrum, 
this translates to overlapping spectral signatures and makes independent estimates of their 
concentration more challenging. Quantitative estimates of metabolite concentrations are 
also influenced by 1H-MRS data quality, modeling method and model completeness. 
Low signal-to-noise ratios (SNR) are an inherent feature of 1H-MRS spectra, often 
making it difficult to differentiate metabolite signals from background noise. Previous 
publications have used simulations to study how SNR influences 1H-MRS quantitation of 
metabolites3–5. It was shown that the SNR had an effect on the standard deviation of 
metabolite concentrations estimates. Therefore, SNR is an important variable to control 
for in any simulation study. 
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It is often difficult to observe metabolite spectral peaks independently due to strong 
spectral overlap. It is believed that as peak overlap is reduced there is less covariation in 
metabolite concentration estimates. Mitigation of overlap can be achieved through 
various strategies. One strategy, increasing the external magnetic field strength (B0), 
leads to increased spectral dispersion, reduced influence of J-dephasing for metabolites 
with strongly coupled spin (higher-order J-coupling) and a linear SNR increase 
(assuming body noise dominance). Particularly, higher B0 reduces overlap in GLU and 
GLN signals (C4 protons) and reduces signal loss through J-dephasing (Fig. 2-1). 
However, even at B0 as high as 7.0T, there is still much overlap as some of the gain in 
peak separation from spectral dispersion is offset by shortening of T2
*(increased peak 
linewidths (LW)). It is expected that spectral dispersion linewidths and J-coupling will 
affect the quantification precision (modeling) of data from coupled metabolites. 
 
Figure 2-1. Simulated chemical signatures of GLU and GLN. 
GLU and GLN are two strongly coupled and overlapping metabolites in 1H-MRS 
spectra. They are simulated across four B0, demonstrating apparent decreased 
overlap as B0 increases.  
Metabolite peak separation will influence the quantification algorithm’s ability to 
converge to correct metabolite concentrations. Many metabolite quantification algorithms 
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utilize a priori information for the metabolites’ spectral signatures6–8, which are 
determined individually by acquiring the signal from a metabolite phantom or through the 
use of simulation software.   Fitting parameters for a metabolite’s peaks need to be 
constrained to have specific, pre-determined amplitude ratios, 0th order phase offsets, 
chemical shift offsets and LW offsets. Iterative fitting algorithms will require initial 
values (seed values) for these parameters in order to compute the residual between the 
data and the model.  The algorithm will perform repeated trials of parameter changes 
until convergence toward minimum residuals is achieved. When searching a vast 
multidimensional minimization space for a global minimum, the final solution returned 
by the fitting algorithm can become sensitive to the accuracy of the initialization 
parameters and converge toward a local minimum. If it were possible to initialize the 
algorithm with the known correct answer, the only source of metabolite concentration 
variability would be random noise. Of course, this is not possible with in vivo data as the 
correct answer is not known with certainty. Therefore, for in vivo 1H-MRS data, 
variability due to noise cannot be separated from variability due to intra- and inter-
individual variability.   
The 1H-MRS spectrum is composed of contributions from the protons of many 
metabolites. Many of these are often not included in basis sets for quantification because 
they are not represented by prominent peaks in human brain 1H-MRS spectra. This can 
be due to low concentrations or because their peaks have been split into too broad of a 
multiplet and as a result are on the order of the spectral noise. The inclusion of such 
contributions is thought to unnecessarily complicate fits and increase overall variability 
of concentration estimates. Either way, a metabolite that is not accounted for by the basis 
set will leave additional spectral area that the fitting algorithm will still try to minimize 
given the basis set provided. This can lead to errors in the estimates of metabolite 
concentrations and it is not well known how these areas will propagate (only nearby 
metabolites or remote metabolites). Therefore, if a basis set is not complete, 
measurements of metabolite concentrations may actually represent contributions from a 
number of metabolites and may decrease the quantification accuracy. 
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The goal of this paper is to study factors influencing the quantification precision of brain 
metabolites in controlled conditions similar to those encountered in vivo. Specifically, 
simulations were conducted in this study to isolate and examine the effects of spectral 
dispersion, weakened J-coupling versus changes in B0, the effect of noise, the effect of 
inaccurate seeding values and the effect of template incompleteness on the variability of 
metabolite concentration estimates.  
 
2.1.1 Hypotheses 
Due to the increased metabolite separation as B0 increases, the correlations between 
metabolite concentration estimates in metabolites that experience strong coupling at low 
B0 should generally decrease as B0 increases. This should also increase the precision of 
metabolite concentration quantification.  
It is hypothesized that higher SNR will result in higher inter-metabolite correlation 
coefficient (r(METa,METb)) between the concentration estimates of two metabolite (a and b) 
due to the decreasing interference of  noise with the iterative modelling of the spectrum. 
While fitting algorithms blindly perform the mathematical act of minimizing residuals, 
spectral area from a metabolite not included in the quantification template can be 
incorrectly assigned to another metabolite part of the template.  It is hypothesized that 
any metabolite omitted from a spectral basis set will result in corresponding 
quantification errors in overlapping metabolites and that omitted metabolites will have 
greater influence at lower B0 as there is greater spectral overlap between metabolites.We 
hypothesize that the more inaccurate seed values of the fitting algorithm will result in 
poorer precision of metabolite concentration estimates and greater amplitudes of inter-
metabolite correlations coefficients. 
Finally, it is expected that the accuracy (measured mean concentrations minus expected 
mean concentrations) will be generally unaffected by variations in B0, SNR, and initial 
seed values of the fitting algorithm, whereas omitted metabolites will translate to reduced 
accuracy of metabolites overlapping the omitted metabolite. 
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2.2 Methods 
Two sets of simulations were designed for this study. The first set thoroughly analyzed 
the influences of B0, SNR, and the initial seeding of the quantification template. The 
second set examined completeness of the basis set for quantification. They were all made 
to be representative of in vivo human brain spectra at four common B0 (1.5 T, 3 T, 4 T, 7 
T) that would be acquired with an ultra-short echo STEAM sequence (TE=6ms, 
TM=32ms)9  and two SNR representative of what could be acquired with the averages 
(nt) set to 64 and 256. TE values within 2ms have been used previously at all these B0
9–12. 
The metabolite spectra included spectral signatures from 22 metabolites (glutamate 
(GLU), glutamine (GLN), N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), 
creatine (Cr), phosphocreatine (PCr),  myo-inositol (Myo), choline (Cho), 
Phosphorylcholine (PCho), glycerophosphorylcholine (GPCho), gamma aminobutyric 
acid (GABA), serine (Ser), glycine (GLY), scyllo-inositol (Scy), phosphorylethanolamine 
(PE), α-glucose (α-glc), β-glucose (β-glc), aspartate (Asp), alanine (Ala), glutathione 
(GSH), lactate (Lac), taurine (Tau)). To provide an amplitude reference for calibration of 
the SNR of simulated spectra that would be comparable to that commonly used in SNR 
measurements of in vivo spectra, a singlet equivalent in concentration to the CH3 singlet 
of NAA (10.3mmol/kgww)
13 was added to the simulation, set upfield at 0.0 ppm so as to 
not interfere with quantification. SNR was determined using the peak area definition of 
SNR, which comes from the relative amplitude of the signal in the time-domain at t=0 
compared to the standard deviation of the noise. The peak area definition is advantageous 
because it is not influenced by the T2
* changes with B0.  Reference values from the 
literature14 along with the assumption of linear SNR change with B0 and the common 
SNR-to-nt (averages) relationship SNR1/SNR2=(nt1/nt2)
0.5 were used to determine 
representative SNR for nt=256 and nt=64. The resulting SNR for each B0 were 117 and 
58.5 (7 T), 67 and 33.5 (4 T), 50 and 25 (3 T), 25 and 12.5 (1.5 T), for nt of 256 and 64, 
respectively. Figure 2-2 shows example spectra for each B0 with nt=256. Additional 
simulations were created for each B0 at an SNR of 1024 to minimize the variability 
associated with the random distribution of noise. Each spectral signature was simulated 
using GAVAgui, an in-house program designed by a medical physicist (J.T.). The 
program is an interface to code designed by Brian Soher that uses the GAMMA 
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simulations package to predict the response of spin systems to the STEAM pulse 
sequence15. The interface allows the selection of a given echo time (TE), mixing time 
(TM), B0 and spin system and transforms the output of the GAMMA simulation in a list 
of the predicted resonances and their relative parameters compatible with the file format 
of the Lawson Fitman Spectral Analysis Suite7,16. J-coupling constants and chemical 
shifts used were derived from the literature13,17.   A macromolecule (MM) signature was 
added as well, composed of 15 resonances with combinations of Gaussian and Lorentzian 
lineshapes, empirically determined to match a typical MM spectra (Fig. 2-3). 
To model a spectrum containing MR signals from more than one metabolite, the 
superposition of metabolites’ respective resonances must be constrained in order to 
preserve their natural relative chemical shift (), LW, amplitude (An), 0th order phase (0) 
and 1st order phase (d).  Model constraints reduce the degrees of freedom of the 
minimization problem submitted to the iterative fitting algorithm.  Specifically, , LW, 
0, and d of each resonance were linked within and between metabolites, whereas the 
amplitudes of each resonance were linked within metabolites only (AMET(1-22)) and within 
MM resonances (AMM). An additional chemical shift constraint was placed on the MM 
signals, leading to a total of 28 fitting parameters (, MM, LW, 0, d, Amet (1-22), AMM).   0 
and d order phases were initialized to 0. The LW has been shown to influence the 
standard deviation of metabolite concentration estimates3,5 so, it will be set  to 1.35 Hz/T 
for each B0 based on work by Deelchand et al
18.  
To evaluate precision, 200 noisy realizations were produced and fit (in the time domain) 
using fitMAN analysis software7 for each B0 and fitting template.  The quantification 
algorithm was seeded with the correct parameter values (exact seeding) and again with 
two inexact metabolite templates that randomly varied the initial estimates of all fitting 
parameters (inexact seeding). These inexact seeds more realistically represent the 
variability associated with the manual iterative algorithm seeding step used to provide the 
starting point of in vivo data modelling. Seed values for parameters 0, LW, , MM, Amet 
(1-22), AMM varied with a Gaussian distribution around 0.05 rad, 5%, 0.0025 ppm, 0.0025 
ppm, 10% and 10%, respectively, for the first inexact seeding (IE1) and double these 
values for the second inexact seeding (IE2) approach.  Pseudo-random noise with  
61 
 
Figure 2-2. The full simulated set (top) of metabolites (middle) and macromolecules 
(bottom). 
 
Gaussian distribution was added to each simulated spectra using Datsim, a program 
developed in-house (J.T.) and part of the Lawson Fitman Spectral Analysis Suite7,16 
Once all 200 noisy realizations have been fit for each B0, SNR, and template seeding 
combination, the mean concentration (µ) of each metabolite is computed along with its 
standard deviation () to get the Coefficient of Variation (CV): 
 
%100


CV  2.1 
The CV is taken to represent the quantification precision of a given metabolite’s 
concentration. CV was chosen instead of Cramer-Rao Lower Bounds (CRLB)19 because 
CV is a measure of the observed amount of variability including all sources, whereas 
CRLBs are related to the minimum amount of variability observable given a specific 
spectral quantification model. The interaction of the metabolite models during  
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quantification can be assessed using the following formula describing the inter-metabolite 
correlation coefficient of metabolite ‘a’ (METa) and metabolite ‘b’ (METb): 
 
METbMETa
METbMETa
METbMETar

),,(
),(
cov
     2.2 
where σMETa and σMETb  are the standard deviations and cov(METa,METb) is the covariation, 
represented by: 
 
2
cov
222
)(
),(
METbMETaMETbMETa
METbMETa
 


   2.3 
where σ2(METa+METb) represents the variance of the sum of the two metabolites’ 
amplitudes.  
Figure 2-3. Example spectra for each B0 with 256 averages 
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The accuracy will be assessed by comparing the mean concentration estimates for each 
metabolite over all 200 noisy realizations relative to the actual known concentration. 
Together, the CV, accuracy, and r(METa,METb) allow for a quantitative assessment of the 
variability of concentration estimates of metabolite pairs and their interactions. Pearson’s 
correlation were calculated and Sidak’s adjustment for multiple correlations corrected the 
alpha value accordingly (p<0.00004 from p<0.01).  
The same experimental design was used to evaluate the influence of a metabolite’s 
omission from the basis set with IE1 seeding for 3 T and 7 T, with nt=64. Individual 
metabolites were removed from the full quantification template, and 200 noisy 
realizations of the complete spectra were then fit with the metabolite omitted.  Omission 
of the MM baseline was similarly explored. The correct concentration of each metabolite 
is known, making it possible to determine which metabolites assume the remaining 
spectral area of an omitted metabolite. The total spectral quantification error is defined to 
be the resultant cumulative error in the remaining metabolites' concentration estimates 
(measured-expected, µmol/g) when a metabolite is removed from the fitting template. In 
total, 16800 simulated spectra were fit.  
 
2.3 Results 
Quantification precision (CV), accuracy, and r(METa,METb) were analyzed for every set of 
simulations, excluding the metabolite omission simulations, which only looked at 
accuracy of metabolite concentration estimates.  Correlation tables were created for each 
B0, SNR, and template seeding combination, with 253 possible correlations per table. 
Significant r(METa,METb) are summarized in Table 2-1. The SNR had little impact on the 
total significant r(METa,METb) (positive or negative) when the template was seeded with the 
correct final answer. When seeded using IE1 or IE2, the total number of significant 
r(METa,METb) increased with SNR. IE2 generally had more significant r(METa,METb) than IE1.    
 The magnitude of r(METa,METb) decreases with B0 when GLU and other coupled 
metabolites (GLN, GABA, NAAG) are part of the metabolite pairs (Fig.2-4b). Metabolite 
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pairs that make up the three largest singlet peaks in the spectrum at 2.01 ppm (NAA-
NAAG), 3.03 ppm (Cr-PCr), and 3.21 ppm (GPCho-PCho) all still had strong r(METa,METb) 
that did not seem to fluctuate with B0 (Fig 2-4c). Some metabolite pairs with GSH 
seemed to initially decrease the magnitude of r(METa,METb) to a level below the significance 
level, but eventually reached significance with opposite polarity from 1.5 T to 7 T (Fig. 
2-4a).  
 
 
Table 2-1. Significant correlations between metabolite concentration estimates 
  EXa IE1b IE2c 
SNR B0 +d -e Total + - Total + - Total 
1024 
7 T7 T 2 4 6 57 59 116 58 59 117 
4 T 6 3 9 56 61 117 56 60 116 
3 T 6 4 10 61 66 127 65 75 140 
1.5 T 7 3 10 62 70 132 72 67 139 
ntf=256 
7 T7 T 3 6 9 37 44 81 44 45 89 
4 T 7 4 11 35 45 80 49 53 102 
3 T 5 6 11 33 48 81 46 59 105 
1.5 T 8 3 11 29 37 66 41 45 86 
nt=64 
7 T7 T 2 7 9 26 37 63  31 42 73 
4 T 8 6 14 23 35 58 32 45 77 
3 T 8 4 12 22 22 44 29 45 74 
1.5 T 7 4 11 18 27 45 21 33 54 
a Exact seeding 
b, c Inexact seeding 1 and inexact seeding 2, as described in the "Methods" section 
d, e Number of significant positive  or negative correlations (p<0.01, Bonferroni corrected to 
p<0.00004) 
f Number of averages 
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Table 2-2. Metabolite precision (CV; %) across B0 with the SNR=1024 and IE1 
 
 1.5 T 3 T 4 T 7 T 
GLN 0.50 0.44 0.35 0.30 
GLU 0.56 0.34 0.29 0.23 
NAAG 1.82 2.38 2.54 2.35 
GABA 4.18 2.14 2.29 1.98 
GSH 0.38 0.50 0.46 0.29 
Tau 4.14 4.08 3.18 2.57 
Ser 17.23 27.42 20.38 19.35 
Cho 9.75 10.63 9.82 9.75 
PCho 8.55 8.24 9.69 8.45 
GPCho 4.40 4.28 4.78 4.10 
Cr 3.56 4.04 4.60 4.35 
PCr 5.89 5.59 7.14 6.58 
Asp 2.09 3.91 5.65 6.79 
α-Glc 2.72 5.39 4.71 2.85 
β-Glc 2.31 3.48 3.98 4.14 
NAA 0.72 0.84 0.94 0.97 
Ala 3.53 3.76 4.01 2.81 
Myo 0.88 0.85 0.66 0.39 
PE 3.37 4.79 1.85 2.35 
Lac 3.10 4.92 4.75 4.27 
GLY 4.71 4.32 3.52 1.39 
Scy 2.57 1.37 1.33 1.06 
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Figure 2-4. Correlations between metabolite concentration estimates.  
Some of the main correlations found between metabolite concentration estimates as a 
function of B0 with the IE1 template are displayed with linear lines of best fit. 
Interacting metabolites are shown together in the legend. The dashed line in each 
figure represents the significance threshold. A) Coupled metabolites are paired with 
other coupled metabolites. B) Overlapping metabolites that make up the tallest 
spectral peaks are paired. C)  Metabolites paired with GSH that seemed to reverse 
the polarity of the correlation strength 
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Table 2-3. The increase in CV due to doubling initial fit seeding offsets  
 
 
 
 
 
 
 
 
 
 
a Inexact seeding 1 and 2, as defined in the "Methods" section 
 
. 
 
Figure 2-5. Metabolite spectra (top) with their fits overlaid along with the residual 
from the fits (bottom) A) when MM has been omitted and B) with a complete 
template 
 
 
 
  
SNR IE2/IE1a 
1.5 T 
12.5 1.36 
25 1.40 
1024 1.60 
3 T 
25 1.42 
50 1.41 
1024 1.80 
4 T 
33.5 1.47 
67 1.31 
1024 1.90 
 7 T 
58.5 1.45 
117 1.37 
1024 1.88 
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Table 2-4. Metabolite precision (%) across B0 with nt=256 and IE1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.5 T 3 T 4 T 7 T 
GLN 5.18 3.07 1.82 0.97 
GLU 3.37 1.67 1.12 0.68 
NAAG 13.30 13.13 10.47 5.43 
GABA 20.29 10.27 8.23 4.26 
GSH 4.64 2.88 2.22 1.17 
Tau 17.79 15.62 13.67 7.22 
Ser 52.29 42.59 29.70 31.38 
Cho 13.25 13.17 14.46 14.41 
PCho 9.45 9.44 8.85 9.18 
GPCho 6.26 5.74 5.63 4.67 
Cr 6.76 6.37 6.26 5.70 
PCr 8.57 6.97 8.81 8.05 
Asp 20.17 18.60 18.05 12.69 
α-Glc 20.69 13.56 11.30 8.52 
β-Glc 19.69 17.07 16.96 11.25 
NAA 4.81 4.43 3.83 2.26 
Ala 18.44 13.48 10.07 7.19 
Myo 3.57 2.40 1.87 1.04 
PE 14.06 10.78 7.75 6.52 
Lac 24.47 18.57 16.77 9.37 
GLY 10.24 10.24 9.41 5.21 
Scy 8.56 5.65 5.87 4.01 
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Table 2-5. Metabolite omissions from the fitting template (nt=64, IE1) 
 
  7 T 3 T 
Met 
removeda 
Total Spectral 
Quantification 
errorb (µmol/g) 
Largest 
Errorc (Met, 
µmol/g) 
Total Spectral 
Quantification 
error (µmol/g) 
Largest Error 
(Met, µmol/g) 
Noned 0.13 Cr 0.03 0.30 NAA -0.05 
GLN 4.62 GLU 1.81 6.30 GLU 2.61 
GLU 10.02 GLN 3.34 13.37 GLN 5.05 
NAAG 3.09 GLU 0.69 3.16 GLU 0.79 
Cr 8.39 PCr 4.04 9.92 PCr 3.80 
Myo 4.79 α-Glc 0.60 7.04 GLY 2.52 
Tau 1.84 β-Glc 0.57 1.75 β-Glc 0.45 
Ser 0.77 PE 0.28 1.05 PCr 0.26 
Cho 0.71 PE 0.21 1.03 PCr 0.35 
PCho 1.93 GPCho 0.49 5.56 NAA -1.33 
GABA 2.63 GLU 0.42 3.27 GLU 1.01 
GSH 4.79 GLN 1.20 10.18 α-Glc 2.11 
Lac 0.28 Ser -0.05 0.46 NAA 0.06 
Asp 1.13 Ser 0.25 0.92 Tau 0.33 
α-Glc 1.39 Ser 0.36 1.54 Ser 0.23 
β-Glc 0.90 Tau 0.32 1.40 Tau 0.45 
NAA 19.94 NAAG 7.13 19.37 NAAG 8.23 
Ala 0.48 α-Glc 0.09 0.45 α-Glc 0.08 
PCr 5.82 Cr 2.31 7.24 Cr 1.79 
PE 2.16 Ser 0.89 2.57 Ser 0.76 
GPCho 4.89 PE 1.72 4.82 PE 2.00 
MM 24.92 NAAG 2.80 23.16 Lac 3.18 
GLY 1.17 Myo 0.49 1.30 Myo 0.67 
Scy 0.93 Cho -0.14 1.67 Tau 0.68 
 
a 200 noisy realizations of the same data were fit with one (or zero) metabolites removed from the 
fitting template 
b The resultant cumulative error in the remaining metabolites' concentration estimates (measured-
expected, µmol/g) when a metabolite is removed from the fitting template 
c The metabolite that had the largest spectral quantification error  
d No metabolites were removed from the fitting template 
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The SNR, B0, and the seeding of the template all had important influences on the CV of 
concentration estimates. When SNR doubled (from nt=64 to nt=256) the CV improved by 
a factor of 1.96 on average over all metabolites and over all B0 using exact seeding of the 
fitting algorithm. Using the IE1 and IE2 seeds, doubling SNR improved the CV by 1.52 
and 1.47, respectively. Table 2-2 shows that there is lower CV at low B0 and high SNR 
(1024) when exact seeding is used, but this is not consistent with the inexact seeding 
models. There were improvements in some metabolites, namely GLU, GLN, GABA, 
Myo, Tau, Scy, and GLY, while the remaining metabolites showed little variation, with 
the exception of Asp and β-Glc, which seemed to get worse as B0 increased. There is also 
a reduction in precision observed over all metabolite concentration estimates when going 
from IE1 to IE2 (Table 2-3). This reduction factor increases at very high SNR 
To isolate the influences on the CV specifically due to the changes in spectral signatures 
of metabolites when the B0 changes, the SNR had to be equated.  This was achieved by 
running simulations with the SNR set to 1024 for all B0.   The CV increased for every 
metabolite as the B0 increased from 1.5 T to 7 T when using the exact seeding. However, 
using the inexact seeding approach, GLU, GABA, GLN, Myo, Scy, GLY, and Tau all 
exhibited decreased CV’s going from 1.5 T to 7 T for both the IE1 (Table 2-2) and IE2 
(not shown) seeding techniques. All the remaining metabolites either had no change or 
increased CV’s when B0 increased. Table 2-4 demonstrates improved CV’s at higher B0 
when nt=256 at realistic SNR for each B0. 
An additional evaluation of the influence of spectral lineshape changes due to B0 on CV 
comes from the 1.5 T spectra with nt=256 and the 3 T spectra with nt=64 that both have 
an SNR of 25. The quantity of significant r(METa,METb)
 
were similar for exact seeding, but 
were reduced in both the IE1 and IE2 seeding templates (Table 2-1) at 3 T compared to 
1.5 T. The CV’s for GLU and GABA improved by factors of 1.34 and 1.35, respectively, 
for 3 T using IE1, but, on average, all metabolite CV’s were 8% lower at 1.5 T. 
The accuracy of the metabolites did not seem to be affected by the SNR, B0, nor the type 
of seeding used. It was only the metabolite omissions that affected accuracy. 
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The total spectral quantification error increased when any metabolite was excluded from 
the basis set (Table 2-5).  For comparison, the typical error that would be expected from 
the full spectrum (i.e. no metabolite omissions) is also included in Table 2-5. As would 
be expected, excluding the MM from the template created the largest errors in the fit as 
its spectral area is broad and extends across all metabolites.  
 
The fitting algorithm was able to efficiently account for the MM spectral area using the 
remaining metabolites when the MM were not included in the basis set (Fig. 2-5). Where 
there is little overlap between MM and other metabolites, the residual spectral area 
resembles the corresponding portion of the MM spectrum with the exception of the 
enlarged Lac doublet. However, where metabolites and MM overlap there is little 
residual remaining. Omitting MM decreased total fitted spectral area by 10.10% and 
8.82% at 3 T and 7 T, respectively. The only metabolite (with MM not considered to be a 
metabolite) to alter the total spectral area of fitted metabolites by more than 1% when 
omitted was NAA. The omission of NAA lead to total increases of 2.70% at 3 T and 
2.56% at 7 T.  Serine concentration estimates were the most susceptible to fitting errors 
from incomplete fitting templates and were not within 10% of the correct concentration 
when any metabolite was omitted. 
 
2.4 Discussion 
In this study, simulations were used to isolate some of the sources of variation 
encountered in 1H-MRS such as:  B0, SNR, algorithm seeding accuracy and 
quantification template completeness. Quantitative understanding of these sources of 
variability is important for study protocol optimization. Simulations were chosen to 
minimize or remove competing sources of variability.  A large number of simulated 
spectra could easily be generated to improve statistical confidence.   
Inexact seeding was chosen to examine variability associated with the initialization of the 
quantification algorithm parameters. Iterative fitting algorithms are more likely to 
72 
 
encounter a local minimum and return an incorrect parameter estimate when poorly 
seeded. Therefore, when one parameter is fit poorly the other parameters must 
compensate. This led to correlation between metabolite concentration estimates as there 
were more correlations and decreased precision observed when the initial parameters 
were fit with greater seeding variability.  Quantitative relationships between IE1 and IE2 
are more apparent when the influence of noise is minimized. With high SNR (1024) the 
CV’s of IE2 are almost twice that of IE1. Therefore, greater seeding variability resulted 
in a near linear increase in CV in the absence of noise. This demonstrates that a 
substantial improvement can be seen in the CV of metabolite estimates by taking the time 
to provide accurate initial estimates of the parameters to the fitting algorithm.  Future 
studies that aim to use simulations to study quantitative relationships should consider 
using inexact fitting templates to better represent in vivo fitting.  
The variability introduced with the initial seeding of the basis set can also be seen when 
comparing to the exact seeding data with SNR of 1024. With the noise minimized and the 
variability associated with the initial seeding removed, the main sources of variability 
become the spectral separation and the linewidths. Both spectral separation and 
metabolite linewidths increase with B0, so it would be expected that the spectral 
separation would improve quantification precision while the linewidth would worsen it.  
Because the precision was worse at higher B0, the increase in metabolite linewidths 
influenced the fit more than the increase in spectral dispersion. This was not observed 
when using inexact seeding, but can be explained by looking at the signal in the time 
domain. The SNR definition chosen for this study corresponded to the amplitude of the 
signal in the time domain at t=0, relative to the standard deviation of the noise. T2
* 
reduces as B0 increases leading to faster signal decay.  Although the SNR, by definition, 
remains the same between the different B0 examined, there is more signal at low B0 than 
that which remains above the level of the noise during the sampling of the FID at higher 
B0. The inexact seeding model better represents how the spectral dispersion and J-
coupling will affect the quantification precision, so the reduced CV at high B0 in J-
coupled metabolites indicates that the relative reduction in J-coupling (in ppm only) 
improves the quantification precision, despite T2
* reduction. 
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When SNR=1024, two strongly coupled metabolites, GLU and GABA, showed 
improvements in CV and reduced quantity of r(METa,METb)
 
at 3 T compared to 1.5 T with 
inexact seeding. This illustrates the benefits of weaker higher order J-coupling at higher 
field strengths. In contrast, the majority of metabolites showed a slight reduction in CV at 
1.5 T. The observed slight improvement in CV at 1.5 T compared to 3 T in most 
metabolites is likely due to the signal decaying much slower at 1.5 T, resulting in more 
points above the noise threshold to help the fitting algorithm converge to a final estimate. 
Therefore, in the absence of the natural improvement in SNR at 3 T, the increased peak 
separation did not translate to improved CV for the majority of metabolites.  
Doubling SNR improved metabolite quantification, which agrees well with what has been 
observed in previous studies3,4, and was consistent at each B0. The nearly two-fold (1.96) 
increase in quantification precision when SNR is doubled using exact seeding 
demonstrates an almost linear relationship between SNR and quantification precision. 
The exact seeding presents an upper limit of improvements in CV from SNR alone so it 
makes sense that quantification precision is reduced from this ideal relationship when 
seeding variability is introduced. As the SNR increased, so did the number of significant 
r(METa,METb)
 
. It is likely that at low SNR the metabolite estimates are more heavily 
influenced by the local noise around the spectral peaks than the overlapping metabolites, 
and as the SNR improves more correlations become apparent.   
Almost all metabolites showed large reductions in CV when increasing B0 using SNR 
values that could be acquired in vivo (Table 2-2) with GLU, GLN, GABA, Myo, and 
GSH having the greatest reductions. There seems to be additive improvements in CV 
coming from both the increase in SNR and the weakened J-coupling at 7 T. This agrees 
with Bartha et al20 who demonstrated an average increase in metabolite quantification 
precision in vivo at 4 T compared to 1.5 T. However, Cho, PCho, GPCho, Cr, and PCr 
did not have CV’s that varied greatly. This is somewhat surprising, as it would be 
expected that their precision would improve as the influence of noise is reduced.  These 
metabolites must be easier to fit even in low SNR conditions due to their strong singlets.   
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Despite a reduction in the number of significant correlations observed at 1.5 T compared 
to 7 T, there still remain many correlations significant at 7 T. This is perhaps not 
surprising, as the 1H-MRS spectrum is a superposition of spectral signatures from many 
metabolites in close proximity. However, the magnitude of significant correlations of J-
coupled metabolites paired with GLU was generally decreased, which indicates that there 
are indeed improvements in metabolite quantification due to the separation of some 
metabolites at higher B0. It is apparent, through the strong dependency of the GLU-GLN 
correlation on Bo, that GLU and GLN are increasingly more independently quantified at 
higher B0 despite increases in LW. Metabolite pairs with spectral signatures dominated 
by strong singlets and overlapping heavily (Fig. 2-4b) will have strong r(METa,METb) even at 
high B0. The improvements in spectral dispersion appear to be insufficient to separate 
their quantitative dependence on each other. Therefore, any incorrect estimate in one 
metabolite is likely to introduce error into the other. 
GSH demonstrated unexpected behavior as it moved from one polarity of r(METa,METb) to 
the other as B0 increased (Fig. 2-4c).  It may be because changes in spectral dispersion 
and J-coupling can also lead to increased spectral overlap as peaks are shifting from 
multiple metabolites. It would be interesting to see if these GSH pairings would continue 
to approach maximum correlation (r(METa,METb)=1 or -1) when B0 increased further or if 
they would reverse the trend and reduce correlation strength.   
One study examined r(METa,METb)at 2.9T using a 2D J-resolved 
1H-MRS sequence in the 
anterior cingulate and the posterior cingulate21. Some of the correlations from the anterior 
cingulate that the authors chose to highlight include GLU-GLN, GLU-GABA, GABA-
CR, GLY-Myo, GPCho-PCho, NAA-NAAG. The same metabolite pairs were significant 
in this study (using 3 T, nt=256, IE1 seeding, for comparison). However, there are some 
notable differences between the two studies. Prescot et al21 determined the r(METa,METb) 
from the inverted Fisher matrix, so they represent lower bounds of the covariance rather 
than the measured or observed variance. They employed a 2D J-resolved PRESS 
sequence, whereas the simulations in this study were made to represent the STEAM 
sequence.  As the authors mentioned, they did not include a MM basis set for 
quantification. This had a substantial influence on concentration estimates in this study, 
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although there was likely a greater presence of the fast relaxing MM due to the short TE. 
Finally, Prescot et al21 conducted an in vivo study whereas this study used simulations.  
By using simulations, the experiment was able to be repeated many times with potential 
sources of variation, which would be present in an in vivo study, minimized or removed. 
Considering this, it is difficult to truly compare the results, but it is encouraging that 
similar significantly correlated metabolite pairs were discovered.  
The SNR, B0, and type of seeding used had no influence on the accuracy of concentration 
estimates. This means that these variables did not lead to errors consistently above or 
below any metabolite’s known concentration, it was only the variance around the 
estimate that changed. Macri et al.22 observed that when SNR was decreased by a factor 
of 2 there were variations in some metabolites’ amplitudes. The difference in results is 
likely due to the difference in methods.  Macri et al.22 used the simulated deterioration of 
in vivo spectra, whereas this study used fully simulated results with exact concentrations 
known. 
The omission of any metabolite leads to increased error from decreased accuracy in 
estimates of metabolite concentrations (although Lac and Ala had very small influences). 
This agrees with what has been found in a previous study, in that exclusion of lower 
concentration metabolites during the fit can reduce accuracy of GLU and GLN 
quantitation23.  Metabolites that do not share spectral area with a particular metabolite can 
still influence its concentration estimate indirectly through correlations with other 
metabolites. The whole metabolite spectral signature, which often consists of many 
resonances, must be increased uniformly due to the amplitude constraints put on each 
metabolite. This can lead to compensatory variations throughout the spectrum. The fitting 
algorithm can come to very different final results with only one metabolite’s spectral 
signature omitted. 
There were comparable consequences for omitting a metabolite at 7 T and 3 T. Although 
it is common for high field 1H-MRS studies to include large quantification templates due 
to the increased spectral dispersion and SNR, lower field strengths may require full 
metabolite templates as well. It is important to include as many metabolites as reasonably 
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possible (based on limitations of data quality) for reliable Ser estimates, for example. 
Strict constraints would be necessary for metabolites with peak amplitudes on the order 
of noise to reduce implications of inaccurate fits. Caution is to be taken and careful 
interpretations of results are required when looking at any study with a limited basis set. 
For example, in many studies GLU is fit as “GLX”, which can mean anything from GLU 
+ GLN, to everything within that area (GLU, GLN, GABA, NAAG, GSH, MM). The 
GLU spectral signature accounted for GLN, NAAG, and GABA spectral areas more than 
other metabolites. If these metabolites are not included in the basis set, “GLX” would 
include a large contribution from each.  
As it was hypothesized, the strongly coupled metabolites benefited the most from 
increases in B0. Other metabolites with strong singlets, such as Cr and Cho, did not show 
much improvement in quantification, meaning studies with these metabolites of interest 
may not require a high field scanner. Definite improvements can be seen in quantification 
by including as many metabolites as possible in the template, and by providing accurate 
first estimates of the fitting parameters. Attempts should always be made to maximize 
SNR as well. 
The main limitation of this study is also its main strength, in that it does not use in vivo 
data.  It would not be feasible to do such a study with in vivo data as there would be too 
many variables. For example, both eddy current distortions and chemical shift 
displacement would be difficult issues to address across B0, but both can be removed by 
using simulations. This study used a parameterized MM baseline that was known to be 
correct in the simulations. In vivo, MM are more difficult to parameterize. This could 
increase the observed CVs in this study. An ultra-short TE STEAM sequence was chosen 
due to its availability and popularity at all B0. However, others have demonstrated that 
STEAM is not the ideal sequence at some B0
24–26. Future studies should address how 
other pulse sequences and perhaps different echo times would respond to the sources of 
variation identified in this work.  
This study has explored specific sources of quantification variability commonly found in 
human brain 1H-MRS spectra. Quantitative knowledge of the influence of these sources 
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of variability is important in acquisition protocol design and in data analysis method 
design. The results of this study suggest that for most reliable concentration estimates of 
GLU and GLN, one requires the highest field strength, highest SNR, most complete 
template, and high accuracy seeding of the iterative fitting algorithm. Even in those 
conditions, the largest sources of variability for GLU and GLN are overlap/correlation 
with each other, NAAG, and GABA. 
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 Chapter 3 
3 Neurometabolic abnormalities observed with magnetic 
resonance spectroscopy at 7 T in the anterior cingulate 
cortex and thalamus of patients with schizophrenia and 
Major Depressive Disorder  
The work presented in this chapter examined brain areas that are commonly implicated in 
SZ using an ultra-high field MRI and 1H-MRS.  A version of this chapter is currently 
being edited for submission to the British Journal of Psychiatry. 
 
3.1 Introduction 
Current treatments of schizophrenia mostly target dopaminergic neurotransmission via 
dopamine receptors and are effective at alleviating positive symptoms, but are often 
unable to reduce negative and cognitive symptoms. Drugs that do have some degree of 
effectiveness in treating cognitive and negative symptoms typically come with 
undesirable side effects, and their mechanism is only partly understood1,2. To better 
understand the source of SZ symptoms, an alternative mechanism to dopamine 
abnormalities must be explored.  
Glutamatergic theories of SZ propose that positive, negative, and cognitive symptoms in 
SZ share a common origin in dysfunction of glutamate (GLU) neurotransmission3–5.  This 
proposal largely originated from animal studies that observed that agonist towards the N-
methyl-D-aspartate (NMDA) receptors, specifically, ketamine and phencyclidine (PCP), 
replicate symptoms of SZ in their otherwise healthy hosts6.  Later studies of humans 
confirmed that the drugs similarly induce symptoms in healthy controls, and actually 
worsen symptoms in people with SZ6.   
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The exact mechanism by which GLU dysfunction could occur is not yet understood, but 
the NMDA receptor may be involved. In the neuron, GLU is stored in vesicles until it is 
required for neurotransmission and released into the synaptic cleft. GLU will then bind 
with one of a number of receptors on the post-synaptic membrane, including the NMDA 
receptor. When GLU has been released from the post-synaptic membrane receptor it is 
actively transported into the adjacent glial cell where it can be converted to glutamine 
(GLN) via glutamine synthetase and safely transported back into the presynaptic neuron 
and effectively recycled for re-use in neurotransmission7. Both GLU and GLN have been 
somehow implicated in SZ through studies using proton magnetic resonance 
spectroscopy (1H-MRS) that have demonstrated abnormal concentrations throughout the 
brain, with a tendency for GLN to be increased and GLU to be decreased early in the 
illness with faster decline with age relative to controls8.  
Another possible source of dysfunction in glutamatergic neurotransmission is glycine 
(GLY), an agonist for the NMDA receptor. For GLU to successfully bind with the 
NMDA receptor, GLY is also required to bind with the receptor at a separate site. The 
GLY pathway has been the target of new drug interventions with limited success so 
far2,5,9. To date, there have been no 1H-MRS studies of GLY in SZ, but it would be ideal 
to be able to study this in vivo and in a localized area of the brain.   
Of particular interest in SZ is the involvement of GLU, GLN, and GLY in critical brain 
pathways that seem to be implicated in SZ known as the limbic basal ganglia thalamo-
cortical (BGTHC) circuits10 by which motivation is translated to behaviour. Each circuit 
cycles through the basal ganglia and through to the thalamus before reaching back out to 
the cortex. The thalamus, therefore, plays a critical role in motivation and behaviour. The 
anterior cingulate cortex (ACC) is another node of a BGTHC that has been implicated in 
SZ through 1H-MRS8,11 and functional magnetic resonance imaging studies12.  The dorsal 
component of the ACC is involved in error detection and organization of conflicting 
stimuli, to which activities that stimulate the ACC have demonstrated hypofunction in SZ 
12.  Both the thalamus and the ACC are good brain areas to study a potential dysfunction 
in glutamatergic neurotransmission in SZ.  
82 
 
Most 1H-MRS studies of the ACC and thalamus in SZ have been quantified at lower 
magnetic resonance imaging (MRI) field strengths, where GLU and GLN spectral 
signatures overlap and difficult to reliably quantify individually. Recent advances in 
technology have created stronger magnetic field strength MRI facilities. Stronger 
magnetic field strengths translate to an increase in sample magnetization and a linear 
increase in the signal-to-noise ratio (SNR), assuming body noise dominance. This is very 
important in 1H-MRS acquisitions, as 1H-MRS is a low-SNR technique that can require 
long scan times to acquire one quality spectrum from a localized voxel in the brain, and 
longer scans increase the likelihood of subject movement during a scan. An additional 
essential feature of stronger MRI field strengths is increased metabolite separation in the 
1H-MRS spectra, as the ratio of the magnitude of metabolites’ J-coupling constants to 
their chemical shift dispersion (both measure in Hertz) decreases. This means that 
metabolites that overlap significantly at low MRI field strengths, such as GLU and GLN, 
become more resolvable at higher field strengths. It also becomes more likely that 
reliable detection of lower concentration metabolites that are traditionally difficult to 
quantify, such as GLY, may be quantifiable with the higher SNR and improved 
metabolite spectral signature separation. 
Specificity of results is difficult to address in studies comparing a psychiatric group to 
healthy controls.  Major Depressive Disorder (MDD) has previously been assessed with 
1H-MRS although findings have been inconsistent13. As symptoms of SZ can overlap 
with those of MDD and GLU has also been implicated in mood disorders, the purpose of 
this study was to examine metabolite signals in voxels located in the ACC and thalamus 
of patients with SZ compared to healthy controls and a psychiatric control group of 
people with MDD using 1H-MRS with a 7 Tesla head-only MRI.   
Due to the previous findings of increased GLN8,11, and decreased GLU8 early in frontal 
brain areas in SZ, these changes were expected in the ACC and TH of volunteers with SZ 
relative to the healthy controls and the MDD group.  GLY abnormalities were also 
expected, but it is unknown which direction to expect the abnormalities. It has recently 
been demonstrated that there is reduced myo-inositol (MYO) in MDD13–15, which was 
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also expected in the present study. No specific hypotheses were made regarding 
remaining metabolites. 
 
3.2 Methods 
3.2.1 Participants 
There were 16 participants in the SZ group, 17 in the MDD group, and 18 in the healthy 
control group. All gave informed written consent according to the guidelines of the 
Review Board for Health Sciences Research Involving Human Subjects at the University 
of Western Ontario. Volunteers with neurological or major medical illnesses, clinically 
significant head injury, other psychiatric disorders, MRI contra-indications, or substance 
abuse within the previous year were excluded from the study. Any healthy volunteer with 
a known family history of psychiatric disorder in a first or second degree relative was 
also excluded. 
A consensus diagnosis was established on all participants by a psychiatrist and trained 
assistant with the Structured Clinical Interview for DSM-IV16. SZ subjects were rated 
with the Scale for Assessment of Negative Symptoms and the Scale for the Assessment 
of Positive Symptoms17,18 and MDD patients were assessed with the Montgomery Asberg 
Depression Scale19 and the Young Mania Rating Scale20. Fourteen SZ patients were 
being treated with atypical neuroleptics (Chlorpromazine Equivalent 409 ± 293mg) and 2 
patients were not medicated. Eleven of the 17 MDD patients were being treated with 
antidepressant medications at the time of the scan. Demographic information including 
age, gender, handedness, education, parental education, clinical rating scores, and length 
of illness were collected as in our previous study21 and are shown in Table 3-1.  
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Table 3-1. Participant demographics 
Group Controls MDD SZ p 
n  18   17   16   
Age 23.9 ± 4.6 22.5 ± 4.6 22.7 ± 2.9 0.570 
M/F 11/7 6/11 13/3 0.018 
R/L 16/2 15/2 15/1 0.824 
Educ 3.1 ± 0.8 2.6 ± 0.6 2.2 ± 0.8 0.010 
PEduc 3.1 ± 0.9 2.9 ± 0.8 3.3 ± 0.8 0.424 
HAM-A  12.8 ± 10.5   
HAM-D  12.8 ± 8.9   
Mania  5.1 ± 6.7   
Montg  18.0 ± 10.4   
CPZ (mg)   358 ± 307  
SANS   9.7 ± 7.7  
SAPS     7.6 ± 10.4  
Illness Duration 
(months) 
   28.6     ±     14.4 29.5 ± 15.7 
 
 
M/F – male/female 
R/L – right/left 
Educ – education rating of the participant (1- gr. 10 or lower, 2- completed high school, 3- 1-3 years of college/university, 4- >3 years 
of college/university) 
Peduc – education rating of the participant’s parent (1- gr.10 or lower, 2- completed high school, 3- 1-3 years of college/university, 
4- >3 years of college/university) 
H Anx – Hamilton Anxiety Scale 
H Dep – Hamilton Depression Scale 
Mania – mania rating from the Young Mania Rating Scale 
Montg – result of the Montgomery Asperg Depression Scale 
CPZ – chlorapromazine equivalent 
SANS – Scale for Assessment of Negative Symptoms 
SAPS – Scale for Assessment of Positive Symptoms 
p – ANOVA test for significance (alpha=0.05, two-tailed), bolded values indicate significance  
 
 
3.2.2 1H-MRS Data Collection and Analysis 
All measurements were acquired on a 7.0 T Agilent/Magnex head-only MRI (Agilent, 
Inc, Walnut Creek, California, USA) with a Siemens AC84 head gradient coil (Siemens, 
Erlangen, Germany), located at the Center for Functional and Metabolic Mapping at 
Western University. A transmit-only, receive-only (TORO) head coil with 15 transmitters 
and 23 receivers22 was used for all scans. A map of the transmit field for each transmitter 
85 
 
was acquired at the beginning of the session to facilitate optimized homogeneity 
correction of the transmit field for each scan using an automated B1-shimming 
approach23.  The magnetic field uniformity (B0-shim) was adjusted automatically over 
the field of view with first-order and second-order shims using RASTAMAP24 before all 
acquisitions.  
The 1H-MRS voxels were 2.0 x 2.0 x 2.0 cm (8cm3) in size and located in the left 
thalamus and left dorsal anterior cingulate.  Voxels were placed and angled using 
anatomical landmarks (Fig 3-1) on two, fast low-angle shot 2D anatomical imaging 
sequences in the sagittal (45 slices, repetition time (TR) = 950 ms, echo time (TE)=5.23 
ms, flip-angle (α)= 30°, gap between slices=1 mm, thickness= 2 mm, field of view (FOV) 
220 × 220 mm, and matrix size of 220 × 200) and axial (20 slices, TR = 500 ms, TE 
=5.23 ms, α =30°, gap between slices=1 mm, thickness= 2 mm, FOV =220 × 220 mm, 
and matrix size 220 × 220) directions, both with lipid saturation. 
Spectra were acquired using an ultra-short TE stimulated echo acquisition mode 
(STEAM) sequence with outer volume suppression25 (TR=3s, TE=10 ms, mixing time ™ 
=32ms, 4000 complex pairs, 4 steady state scans, 1s acquisition time, 8 step phase cycle). 
There were 64 averages of water suppressed spectra acquired individually for each voxel 
location, with 16 water-unsuppressed spectra acquired to correct metabolite lineshapes 
and as internal concentration reference.  An 8-pulse VAPOR preparation sequence with 
an additional water suppression pulse during the TM period25 was used for water 
suppression. A separate metabolite suppressed spectrum was acquired to assess the 
macromolecule content with inversion times as published in Penner et al26. Each 
acquisition produced 23 spectra, one for each receiver, which required channel 
combination before use27. Spectra were frequency and phase corrected before being 
averaged together in a phase- and frequency-coherent manner. QUality Eddy Current 
Correction (QUECC)28 reduced linewidth distortions before spectral fitting with fitMAN, 
a time-domain fitting algorithm29. Metabolite concentrations were corrected for gray and 
white matter content. All spectra were inspected visually for quality by a trained 
spectroscopist.  
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Figure 3-1. Sagittal and transverse cross-sections depicting the voxel locations.  
Voxel were located in the left anterior cingulate cortex (A,B) and the left thalamus 
(C,D) in neurological orientation. The AP line and midline shown as anatomical 
landmarks for the sagittal and transverse cross sections, respectively. 
Only metabolites with Cramer-Rao lower bounds (CRLB) less than 20% were included in 
the analysis, with the exception of GLY, which had a CRLB limit of 30%. Metabolite 
concentration estimates were also tested for outliers at the group-level. 
One-tailed t-tests (p<0.05/3) will be employed to explore the directional hypotheses of 
increased GLU and GLN in SZ relative to the healthy controls and the MDD group. A 
one-tailed test will also be used for the decreased MYO in the MDD group relative to 
controls and the SZ group. The statistical tests for GLY will be two-tailed t-tests 
(p<0.05/3).  A multivariate analysis of variance (MANOVA) will test for significant 
differences in the remaining metabolites (glutathione (GSH), taurine (TAU), aspartate 
(ASP), scyllo-inositol (SCY), ascorbate (ASC), total choline (TCH; choline + 
phoshporylcholine + glycerophosphorylcholine), total creatine (TCR; creatine + 
phosphocreatine), and total N-acetylaspartate (TNAA; N-acetylaspartate + N-
acetylaspartylglutamate)). All statistical tests were completed using SPSS v.20 (IBM 
Corp, Armonk, New York, USA). 
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3.3 Results: 
1H-MRS spectra were acquired with voxels in the ACC and thalamus of all participants 
with the exception of one healthy control who did not wish to finish the scan of the 
thalamus due to dizzyness. Average water linewidths were 13.2 ± 1.3Hz and 16.9 ± 2.1 
Hz for the healthy controls, 12.1 ± 0.9Hz and 16.0 ± 1.8Hz for the MDD group, and 12.8 
± 1.6Hz and 16.9 ± 2.2Hz for the SZ group in the ACC and thalamus, respectively, 
indicating well shimmed data. There were no significant differences in the water 
linewidths between groups. One spectrum from the ACC of volunteers from each of the 
MDD and SZ groups needed to be excluded due to poor quality spectra, likely due to 
excessive movement. Example spectra from each brain region along with the respective 
fits of GLU, GLN, and GLY can be seen in Fig.3-2.  In the thalamus, one subject from 
the SZ group and one healthy control each presented with GLY concentrations CRLB of 
35% and had to be excluded. The remaining GLY measurements were within the CRLB 
criterion.  
Increased GLN concentrations were observed in the thalamus of the SZ group relative to 
the healthy controls (p=0.009) but not to the MDD group (p=0.072).  There were no 
significant between-group differences in GLU concentrations in neither the ACC (Table 
3-2) nor the thalamus (Table 3-3). GLY concentrations were significantly reduced in the 
thalamus of the SZ group relative to both the healthy controls (p=0.017) and the MDD 
group (p=0.012), but no differences in GLY were observed in the ACC (p=0.385, 
p=0.184, respectively). MYO was reduced in the MDD group relative to the healthy 
controls (ACC: p=0.009; thalamus: p=0.014) and the SZ group (ACC: p=0.001; 
thalamus: p=0.002). The MANOVA for the remaining metabolites was not significant for 
the thalamus (p=0.126, Wilk’s Lambda) nor for the ACC (p=0.297, Wilk’s Lambda). 
Although the MANOVA was not significant, a closer look at the pairwise comparisons 
reveals a significant decrease in SCY in the ACC of the MDD group relative to the SZ 
group (p=0.004) and a trend when compared to the healthy controls (p=0.026).  
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Figure 3-2. Example 64 average spectra from (A) the ACC and (B) the thalamus. 
Spectral fits are shown for GLU, GLN, GLY, and all remaining metabolites, with 
the residual of the fit minus the data. 
 
Concentrations of each metabolite, with the pairwise comparisons for each group can be 
seen for the ACC and the thalamus in Table 3-2 and Table 3-3, respectively. 
 
3.4 Discussion 
3.4.1 GLU and GLN  
The significant increase in GLN concentrations in the thalamus in the SZ subject group 
was consistent with the originally stated hypothesis of increased GLN concentrations of 
subjects with SZ relative to healthy controls (p=0.009) and agrees with previous 
studies8,11. The increased GLN could mean a reduced efficiency of converting back to 
GLU via glutamine synthetase or it could be directly related to NMDA receptor  
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Table 3-2. Metabolite concentrations (mmol/kgww ± standard deviations) with statistical 
comparisons for each subject group for a voxel in the ACC 
ACC 
  HC MDD SZ p(HC-MDD) p(HC-SZ) p(MDD-SZ) 
GLU 10.01 ± 1.25 10.37 ± 0.66 10.73 ± 1.21 0.354 0.064 0.363 
GLN 2.04 ± 0.53 1.90 ± 0.72 1.96 ± 0.96 0.592 0.385 0.408 
GLY 0.88 ± 0.28 0.99 ± 0.22 0.86 ± 0.24 0.234 0.837 0.184 
GSH 1.28 ± 0.41 1.16 ± 0.24 1.41 ± 0.35 0.334 0.303 0.060 
TAU 1.64 ± 0.33 1.58 ± 0.39 1.73 ± 0.41 0.671 0.484 0.284 
ASP 2.81 ± 1.46 2.10 ± 1.19 2.86 ± 1.34 0.134 0.925 0.128 
MYO 8.02 ± 0.79 7.19 ± 0.72 8.36 ± 1.34 0.009 0.327 0.002 
SCY 0.51 ± 0.15 0.39 ± 0.11 0.55 ± 0.18 0.026 0.406 0.004 
ASC 1.11 ± 0.35 1.10 ± 0.71 1.37 ± 0.68 0.984 0.237 0.249 
TCH 2.38 ± 0.33 2.36 ± 0.22 2.40 ± 0.25 0.805 0.792 0.625 
TCR 8.89 ± 0.99 8.92 ± 0.74 9.52 ± 0.95 0.929 0.052 0.075 
TNAA 11.02 ± 1.36 11.45 ± 0.63 11.60 ± 0.82 0.236 0.107 0.673 
 
             
HC – healthy controls; MDD- major depressive disorder; SZ – schizophrenia 
GLU – glutamate; GLN – glutamine; GLY – glycine; GSH – glutathione; TAU – taurine; ASP – aspartate; MYO – myo-inositol; SCY – scyllo-inositol; ASC – ascorbate; TCH – total choline; TCR – total 
creatine; TNAA – total NAA. 
p(HC-MDD) – HC vs MDD, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance 
p(HC-SZ) – HC vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance 
p(MDD-SZ) – MDD vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance 
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Table 3-3. Metabolite concentrations (mmol/kgww ± standard deviations) with statistical comparisons for each subject group 
for a voxel in the TH 
Thalamus 
  HC MDD SZ p(HC-MDD) p(HC-SZ) p(MDD-SZ) 
GLU 7.38 ± 0.61 7.79 ± 0.85 7.39 ± 1.03 0.161 0.493 0.173 
GLN 1.27 ± 0.59 1.51 ± 0.69 1.85 ± 0.63 0.309 0.009 0.072 
GLY 0.91 ± 0.26 0.92 ± 0.25 0.72 ± 0.13 0.906 0.017 0.012 
GSH 1.31 ± 0.31 1.22 ± 0.24 1.41 ± 0.28 0.355 0.295 0.054 
TAU 1.93 ± 0.54 2.20 ± 0.58 2.32 ± 0.40 0.142 0.034 0.496 
ASP 2.53 ± 1.38 3.22 ± 1.76 3.38 ± 1.93 0.273 0.180 0.786 
MYO 7.18 ± 0.76 6.41 ± 1.21 7.44 ± 0.94 0.014 0.447 0.004 
SCY 0.37 ± 0.07 0.35 ± 0.07 0.39 ± 0.05 0.235 0.422 0.052 
ASC 0.94 ± 0.66 0.73 ± 0.51 1.16 ± 0.49 0.289 0.259 0.033 
TCH 2.18 ± 0.16 2.19 ± 0.16 2.16 ± 0.22 0.892 0.764 0.665 
TCR 6.52 ± 0.81 6.41 ± 0.86 6.45 ± 0.79 0.702 0.795 0.907 
TNAA 11.07 ± 0.86 10.95 ± 0.97 10.84 ± 0.87 0.722 0.465 0.703 
 
HC – healthy controls; MDD- major depressive disorder; SZ – schizophrenia 
GLU – glutamate; GLN – glutamine; GLY – glycine; GSH – glutathione; TAU – taurine; ASP – aspartate; MYO – myo-inositol; SCY – scyllo-inositol; ASC – ascorbate; TCH – total choline; TCR – total 
creatine; TNAA – total NAA. 
p(HC-MDD) – HC vs MDD, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance 
p(HC-SZ) – HC vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance 
p(MDD-SZ) – MDD vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance 
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hypofunction, which would cause increases in the glutamine synthetase activity and 
would lead to increased GLN30. 
The lack of findings in GLN and GLU concentrations in the ACC and in GLU 
concentrations in the thalamus did not agree with the originally stated hypothesis.  The 
absence of an observed significant increase in GLN in the ACC could be due to the 
duration of illness of the sample of SZ subjects, as it has also been shown that although 
SZ subjects have an initial increase at the onset of the illness, they also decrease their 
GLN concentrations faster than healthy controls.  With the average duration of illness 
being 29.50 ± 17.50 months, it is possible a significant decrease had already begun.  It is 
also possible that more subjects are necessary to observe any significant differences.  
There were no significant differences in either GLU or GLN in the SZ group compared to 
the MDD psychiatric control group, although a non-significant (trend-level) increase in 
GLN in the thalamus was observed (p=0.072). It is likely that with more participants a 
significant difference would be observed, but it is also possible that GLN changes relative 
to healthy controls are easier to observe in SZ participants compared to MDD participants 
due to the greater severity of negative and cognitive symptoms in SZ compared to MDD.   
The MDD group also did not significantly differ from the healthy control GLU and GLN 
concentrations.  It has previously been shown that decreased GLU (often observed as 
GLX (GLU+GLN)) is a common finding in MDD compared to healthy controls13,31, but 
this was not observed in this study.  
 
3.4.2 GLY as a potential therapeutic target 
Studies have examined the serum and plasma of people with SZ to examine GLY 
concentrations, among other neurotransmitters32,33, but no studies have examined GLY 
concentrations in SZ using 1H-MRS. This is partly due to the difficulty in examining 
GLY in vivo. At lower field strengths, the GLY peak overlaps strongly with the MYO 
peak. As magnetic field strength increases so does their peak separation.  In this study, 
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the use of a 7 T MRI provided adequate peak separation and signal to quantify GLY 
separately from MYO. Recent techniques, however, have demonstrated reliable GLY 
concentration changes can be detected following regular oral administration of GLY for 
two weeks using a 4 T MRI and a TE-averaged PRESS sequence34.  
The reduction in GLY observed in the thalamus of the SZ group corresponds very well 
with the observed increases in GLN. GLY is a co-agonist of the GLU NMDA receptor.  
Without an adequate supply of GLY, GLU neurotransmission, via the NMDA receptor, 
will be impeded.  The synaptic supply of GLY is normally maintained below the level of 
saturation9, so any decrease in GLY could directly reduce NMDA activity, increasing 
glutamine synthetase activity30 and potentially explaining the observed increases in the 
GLN concentrations.   
Many strategies towards altering glutamatergic activity via pharmacological interventions 
have been explored but have presented with various challenges. GLU itself does not cross 
the blood-brain barrier well35 and extracellular concentrations need to be controlled to 
prevent GLU excitotoxicity7. Other strategies have targeted GLY or GLY transporters. 
GLY is rapidly metabolized and does not cross the blood-brain barrier well either9, but 
oral administrations have led to detectable changes in the brain34. The GLY activity is 
modulated by GLY transporter proteins, GLYt2 and GLYt15. GLYt2 is involved in the 
inhibitory function of GLY and GLYt1 regulates the concentrations of GLY in the 
synaptic cleft9. New drug therapies are selectively targeting this GLYt1 transporter 
protein to increase the synaptic supply of GLY in hopes of saturating the NMDA receptor 
GLY subunit to increase its activity36,37.  A potential future study could use high-field 1H-
MRS to detect GLY and GLN concentrations in the thalamus before and after 
medication.  Decreased GLN from the baseline value would potentially indicate increased 
NMDA receptor activation causing reduced glutamine synthetase activity and less GLN 
present. One study found that GLY concentrations increased in the plasma of subjects 
with SZ after receiving clozapine treatment32 and another found that serum levels were 
significantly lower in patients taking clozapine33. It is now possible to monitor the effects 
of clozapine on brain levels of both GLY and GLN concentrations with reasonable 
precision using 1H-MRS. 
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3.4.3 Inositol in MDD 
The main finding in the MDD group was the reduced MYO observed in the ACC and TH 
and reduced SCY observed in the ACC.  MYO has many functions, including being an 
important osmolyte, a structural component of eukaryotic cells and a precursor for second 
messengers involved in neurotransmission38. Although MYO is consumed regularly in 
the average diet, it can be created de novo in the brain from glucose and it is readily lost 
from brain tissue when cell integrity is compromised38.  It has commonly been described 
as a marker of glial cell integrity, but this has been brought into question as many 
neurons contain just as much or more MYO than glial cells38. There is a possibility that 
reduced MYO is due to the significant gender differences between the MDD group and 
the other groups (p=0.018), but it is unlikely given that reduced MYO has previously 
been reported in MDD patients frontal lobes13,14,39 in post-mortem brain tissue15 and in 
cerebrospinal fluid40.  Other studies have shown a normalization or an increase in MYO 
in recovered MDD patients14,41 and it is believed that drugs that reduce mania in bipolar 
disorder act by reducing MYO content42.  MYO oral supplementation has been 
investigated as a treatment for MDD. Taylor et al43 examined the results of four studies 
consisting of unipolar and/or bipolar subjects taking daily inositol and found no 
significant effect. However, a more recent meta-analyses by Mukai et el44 examined 
seven studies of mixed MDD, bipolar, and premenstrual dysphoric disorder patients and 
suggests that inositol may have some therapeutic effect for people with depression. 
Although the MANOVA was not significant, it is interesting that SCY, an isomer of 
MYO that typically has a concentration of 5-12% that of MYO in the human brain38, had 
significantly reduced concentrations when looking at the pairwise comparisons of the 
remaining metabolites. It is becoming increasing evident that there may be a role for 
inositol in the regulation of mood. More studies are necessary to further elucidate the 
exact role played and whether MYO (or even SCY) could be a potential target of 
pharmacological intervention in MDD.  
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3.4.4 Future studies 
 There are a number of avenues to explore based on these results.  For the SZ group, a 
confirmation study finding reduced GLY in the thalamus could be performed, followed 
by a study investigating GLY concentrations as influenced by administration of oral GLY 
supplementation. It would also be interesting to see how GLY concentrations in SZ 
patients taking clozapine compare to those taking first or second generation 
antipsychotics. Similarly, in the MDD group, a 1H-MRS study investigating before and 
after effects of MYO supplementation in the diet should be explored. 
 
3.4.5 Conclusions 
As far as the authors are aware, this is the first 1H-MRS study of SZ or MDD using a 7 T 
MRI and the first 1H-MRS study looking at GLY in SZ.  No GLU differences were 
observed in either the ACC or the thalamus, but decreased GLY was observed in the 
thalamus along with increased GLN in the SZ group relative to healthy controls, 
supporting the notion of NMDA receptor hypofunction in SZ. Decreased MYO was 
observed in the MDD group relative to both the healthy control group and the SZ group 
in both the ACC and the thalamus.  Metabolic effects of drug interventions should be 
explored next.  
 
3.5 References: 
1. Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W. & Lieberman, J. a. 
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and 
clinical effects of current and future therapeutic agents. Mol. Psychiatry 17, 1206–1227 
(2012). 
2. Poels, E. M. P. et al. Imaging glutamate in schizophrenia: review of findings and 
implications for drug discovery. Mol. Psychiatry 19, 20–9 (2014). 
95 
 
3. Coyle, J. T. & Tsai, G. The NMDA receptor glycine modulatory site: a therapeutic target 
for improving cognition and reducing negative symptoms in schizophrenia. 
Psychopharmacology (Berl). 174, 32–38 (2004). 
4. Stone, J. M. Glutamatergic antipsychotic drugs: a new dawn in the treatment of 
schizophrenia? Ther. Adv. Psychopharmacol. 1, 5–18 (2011). 
5. Gilbert-Rahola, J. & Villena-Rodriguez, A. Glutamatergic drugs for schizophrenia 
treatment. Actas españolas Psiquiatr. 42, 234–241 (2014). 
6. Javitt, D. C., Zukin, S. R., Heresco-Levy, U. & Umbricht, D. Has an angel shown the way? 
Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. 
Schizophr. Bull. 38, 958–966 (2012). 
7. Mark, L. P. et al. Pictorial review of glutamate excitotoxicity: Fundamental concepts for 
neuroimaging. Am. J. Neuroradiol. 22, 1813–1824 (2001). 
8. Marsman, A. et al. Glutamate in schizophrenia: A focused review and meta-analysis of 
1H-MRS studies. Schizophr. Bull. 39, 120–129 (2013). 
9. Harvey, R. J. & Yee, B. K. Glycine transporters as novel therapeutic targets in 
schizophrenia, alcohol dependence and pain. Nat. Rev. Drug Discov. 12, 866–85 (2013). 
10. Williamson, P. Are anticorrelated networks in the brain relevant to schizophrenia? 
Schizophr. Bull. 33, 994–1003 (2007). 
11. Théberge, J. et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-
treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159, 1944–
1946 (2002). 
12. Boksman, K. et al. A 4.0-T fMRI study of brain connectivity during word fluency in first-
episode schizophrenia. Schizophr. Res. 75, 247–263 (2005). 
13. Yildiz-Yesiloglu, A. & Ankerst, D. P. Review of 1H magnetic resonance spectroscopy 
findings in major depressive disorder: A meta-analysis. Psychiatry Res. - Neuroimaging 
147, 1–25 (2006). 
96 
 
14. Chen, L. P., Dai, H. Y., Dai, Z. Z., Xu, C. T. & Wu, R. H. Anterior cingulate cortex and 
cerebellar hemisphere neurometabolite changes in depression treatment: A 1H magnetic 
resonance spectroscopy study. Psychiatry Clin. Neurosci. 68, 357–364 (2014). 
15. Coupland, N. J. et al. Decreased prefrontal myo-inositol in major depressive disorder. 
Biol. Psychiatry 57, 1526–1534 (2005). 
16. First, M., Spitzer, R., Gibbon, M. & Williams, J. Structured Clinical Interview (SCID) for 
DSM-IV Axis 1 Disorders. (American Psychiatric Press Inc, 1997). 
17. Andreasen, N. C. Scale for the Assessment of Positive Symptoms (SAPS). (The University of 
Iowa, 1984). 
18. Andreasen, N. C. Scale for the Assessment of Negative Symptoms (SANS). (The University 
of Iowa, 1984). 
19. Montgomery, S. A. & Asberg, M. Scale Designed to be Sensitive to Change. Br. J. 
Psychiatry 134, 382–9 (1979). 
20. Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania : reliability , 
validity and sensitivity A Rating Scale for Mania : Reliability , Validity and Sensitivity. Br. J. 
Psychiatry 133, 429–435 (2011). 
21. Aoyama, N. et al. Grey matter and social functioning correlates of glutamatergic 
metabolite loss in schizophrenia. Br. J. Psychiatry 198, 448–456 (2011). 
22. Gilbert, K. M., Curtis, A. T., Gati, J. S., Klassen, L. M. & Menon, R. S. A radiofrequency coil 
to facilitate B   1 + shimming and parallel imaging acceleration in three dimensions at 7 T. 
NMR Biomed. 24, 815–823 (2011). 
23. Curtis, A. T., Gilbert, K. M., Klassen, L. M., Gati, J. S. & Menon, R. S. Slice-by-slice B1+ 
shimming at 7 T. Magn. Reson. Med. 68, 1109–16 (2012). 
24. Klassen, L. M. & Menon, R. S. Robust Automated Shimming Technique Using Arbitrary 
Mapping Acquisition Parameters (RASTAMAP). Magn. Reson. Med. 51, 881–887 (2004). 
97 
 
25. Tkáć, I. & Gruetter, R. Methodology of 1 H NMR Spectroscopy of the Human Brain at Very 
High Magnetic Fields. Appl. Magn. Reson. 29, 139–157 (2005). 
26. Penner, J. & Bartha, R. Semi-LASER 1H MR spectroscopy at 7 Tesla in human brain: 
Metabolite quantification incorporating subject-specific macromolecule removal. Magn. 
Reson. Med. 00, 1–9 (2014). 
27. Brown, M. A. Time-domain combination of MR spectroscopy data acquired using phased-
array coils. Magn. Reson. Med. 52, 1207–1213 (2004). 
28. Bartha, R., Drost, D. J., Menon, R. S. & Williamson, P. C. Spectroscopic lineshape 
correction by QUECC: Combined QUALITY deconvolution and eddy current correction. 
Magn. Reson. Med. 44, 641–645 (2000). 
29. Bartha, R., Drost, D. J. & Williamson, P. C. Factors affecting the quantification of short 
echo in-vivo 1 H MR spectra : prior knowledge, peak elimination, and filtering. NMR 
Biomed. 12, 205–216 (1999). 
30. Rodrigo, R. & Felipo, V. Control of brain glutamine synthesis by NMDA receptors. Front. 
Biosci. 12, 883–890 (2007). 
31. Jun, C. et al. Disturbance of the glutamatergic system in mood disorders. Exp. Neurobiol. 
23, 28–35 (2014). 
32. Yamamori, H. et al. Changes in plasma d-serine, l-serine, and glycine levels in treatment-
resistant schizophrenia before and after clozapine treatment. Neurosci. Lett. 582, 93–98 
(2014). 
33. Hons, J., Vasatova, M., Cermakova, E., Doubek, P. & Libiger, J. Different serine and glycine 
metabolism in patients with schizophrenia receiving clozapine. J. Psychiatr. Res. 46, 811–
818 (2012). 
34. Kaufman, M. J. et al. Oral glycine administration increases brain glycine/creatine ratios in 
men: A proton magnetic resonance spectroscopy study. Psychiatry Res. - Neuroimaging 
173, 143–149 (2009). 
98 
 
35. Hawkins, R. A. The blood-brain barrier and glutamate 1–4. Am. J. Clin. Nutr. 90, 867–874 
(2009). 
36. Umbricht, D. et al. Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative 
Symptoms of Schizophrenia: A Randomized, Double-Blind, Proof-of-Concept Study. JAMA 
psychiatry 71, 637–46 (2014). 
37. Tsai, C. H. et al. Activation of N-methyl-D-aspartate receptor glycine site temporally 
ameliorates neuropsychiatric symptoms of Parkinson’s disease with dementia. Psychiatry 
Clin. Neurosci. 692–700 (2014). doi:10.1111/pcn.12175 
38. Fisher, S. K., Novak, J. E. & Agranoff, B. W. Inositol and higher inositol phosphates in 
neural tissues: Homeostasis, metabolism and functional significance. J. Neurochem. 82, 
736–754 (2002). 
39. Järnum, H. et al. Longitudinal MRI study of cortical thickness, perfusion, and metabolite 
levels in major depressive disorder. Acta Psychiatr. Scand. 124, 435–446 (2011). 
40. Barkai, A., Dunner, D., Gross, H., Mayo, P. & Fieve, R. Reduced myo-inositol levels in 
cerebrospinal fluid from patients with affective disorder. Biol. Psychiatry 13, 65–72 
(1978). 
41. Taylor, M. J., Selvaraj, S., Norbury, R., Jezzard, P. & Cowen, P. J. Normal glutamate but 
elevated myo-inositol in anterior cingulate cortex in recovered depressed patients. J. 
Affect. Disord. 119, 186–189 (2009). 
42. Kofman, O. & Belmaker, R. H. Ziskind-Somerfeld Research Award 1993. Biochemical, 
behavioral, and clinical studies of the role of inositol in lithium treatment and depression. 
Biol. Psychiatry 34, 839–852 (1993). 
43. Taylor, M. J., Wilder, H., Bhagwagar, Z. & Geddes, J. Inositol for depressive disorders. 
Cochrane Database Syst. Rev. CD004049 (2004). doi:10.1002/14651858.CD004049.pub2 
44. Mukai, T., Kishi, T., Matsuda, Y. & Iwata, N. A meta-analysis of inositol for depression and 
anxiety disorders. Hum. Psychopharmacol. 29, 55–63 (2014).  
99 
 
Chapter 4 
4 Increased glutamate levels observed upon functional 
activation in the anterior cingulate cortex using the 
Stroop Task and functional spectroscopy.  
 
The study presented in this chapter was performed to demonstrate that it is possible to 
detect changes in the main excitatory neurotransmitter, glutamate, upon functional 
activation using a cognitive functional paradigm using a 7 T MRI and functional 
magnetic resonance spectroscopy in a group of healthy controls. A cognitive task would 
be desirable for this technique because it could then be used to examine psychiatric 
disorders that have cognitive deficiencies. A version of this chapter has been published in 
NeuroReport (2015; 26:107-112). No permission letters are needed to reproduce this 
article in this dissertation. 
 
4.1 Introduction 
Proton magnetic resonance spectroscopy (1H-MRS) is a useful tool for the noninvasive 
study of the brain’s chemistry. 1H-MRS has an inherently low signal-to-noise ratio 
(SNR); thus, traditional studies have assumed constant metabolite concentrations during 
the long scan durations required to acquire a spectrum with sufficient SNR for accurate 
quantification. Advances in MRI technology such as higher magnetic field strengths, 
improvements in radiofrequency head coils, pre-amplification, and signal detection 
systems have considerably increased the available SNR for 1H-MRS. This has made it 
feasible to examine the brain in a dynamic state using functional 1H-MRS (1H-fMRS). It 
has been shown previously with 1H-fMRS that alterations in the local neurochemistry 
occur when a particular area of the brain becomes engaged in task transaction1–10. One 
metabolite of interest is glutamate (GLU), the main excitatory neurotransmitter in the 
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brain, which has been shown to be related directly to the brain’s consumption of glucose 
for the production of energy11 and has been implicated in the pathophysiology of 
psychiatric disorders, such as schizophrenia12,13.  
Few studies have used 1H-fMRS to date. Three studies have shown small (2–4%) but 
significant increases in the GLU concentration in the occipital cortex upon functional 
activation with a visual stimulus, such as a flickering checkerboard1,2,6. Recent results 
showed a 2% increase in the motor cortex upon functional activation with a finger-
tapping paradigm 3. Two other studies have used pain as a stimulus and have identified 
9.3 and 18.1% increases in the mean GLU concentration in the anterior cingulate cortex 
(ACC) and the anterior insular cortex, respectively, when the participants are exposed to 
the pain4,5. Finally, two studies have examined GLU changes in the lateral occipital 
cortex using a repetition suppression task and have found GLU increases of 11%9 and 
12%10.  
Cognitive tasks are generally less sensitive for detection when assessed through standard 
BOLD fMRI than visual (flickering checkerboard) or motor (finger tapping) tasks14. To 
the best of our knowledge, there has been only one study to date that has used fMRS to 
examine metabolite changes using a cognitive task as the activation paradigm8. This 
study did not find any changes in GLX [GLU +glutamine (GLN)], but they did find that 
GABA increased in concentration upon functional stimulation of the left dorsolateral 
prefrontal cortex and then decreased in subsequent runs of the task. Although GLX, in 
this case, combines GLU with GLN, it would be ideal to use a cognitive task to examine 
the response of GLU independent of GLN as both are crucial to brain function. As GLU 
abnormalities have been found in neuropsychiatric disorders in the ACC12,13, a cognitive 
task that robustly activates the ACC is desirable for the investigation of abnormalities in 
the dynamic regulation of GLU levels in this area.  
In addition to influencing our perception of pain, the ACC is implicated in many other 
cognitive functions, including selective encoding of stimulus properties15, general 
attention16, and organization of conflicting stimuli17. The aim of this exploratory study is 
to show that with 1H-fMRS of the ACC, it is feasible to detect GLU concentration 
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changes using a cognitive task as the activation paradigm. The color-word Stroop Task is 
a common psychological task that involves differentiating potentially conflicting word 
and color stimuli under congruent (i.e. the word ‘RED’ written in red ink) and 
incongruent (i.e. the word ‘BLUE’ written in red ink) conditions18. The Stroop Task was 
chosen for this study because it activates the ACC and has been implicated previously in 
schizophrenia17, a potential application of this technique.  
It has been proposed that GLU concentrations will increase upon functional activation of 
the ACC with a cognitive task because of the increase in the cycling rate of neuronal 
GLU with GLN with an approximate 1 : 1 stoichiometry to the neuronal glucose 
oxidation rate, which is directly related to functional MRI signal changes upon 
stimulation11. No other specific hypotheses have been made in terms of other metabolites. 
 
4.2 Methods 
Seven healthy control individuals (age 39.8 ± 3.8 years) provided informed written 
consent according to the guidelines of the Review Board for Health Sciences Research 
Involving Human Subjects at Western University. The participants included five men and 
two women.  
In this study, the Stroop Task involved four conditions, incongruent, congruent, word 
only (the name of the color written in white), and color only (written as ‘XXXX’), with 
each condition represented in 25% of the trials. Four colors were chosen for the task: red, 
green, blue, and yellow. The participants were asked to respond as quickly and accurately 
as possible on a four-button keypad. They were allotted 2 s to respond, and stimuli were 
separated by 1 s of cross fixation. The task was explained to each participant and 
rehearsed outside of the scanner until it could be performed consistently with 80% 
accuracy or greater. An angled mirror attached to the head coil allowed the participants to 
visualize the words of the Stroop Task projected on the screen in the scanner 
synchronously with the 1H-fMRS acquisition. Participants were initially positioned in the 
scanner with the button press keypad in their hands ready to perform the task. This 
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minimized additional movement at the onset of the Stroop Task. The fMRS acquisition 
began with a 4-min resting period in which the participants were asked to fixate on a 
cross in the center of the projection screen. The final 3 s of the resting period were used 
to prompt the participant that the Stroop Task was about to start with the word ‘Ready’ 
projected onto the screen. The Stroop paradigm then lasted for 4 min and was followed 
by a 4-min recovery period. The procedure was written using PsychoPy19. The accuracy 
and response times were recorded to ensure participants’ compliance.  
All measurements were acquired on a 7.0 T Agilent/ Magnex head-only MRI (Agilent, 
Inc, Walnut Creek, California, USA) with a Siemens AC84 head gradient coil (Siemens, 
Erlangen, Germany), located at the Center for Functional and Metabolic Mapping at 
Western University. A transmit-only receive-only (TORO) head coil with 15 transmitters 
and 23 receivers20 was used for all scans. A map of the transmit field for each transmitter 
was acquired at the beginning of the session to facilitate optimized homogeneity 
correction of the transmit field for each scan using a B1-shimming approach developed 
in-house21. The magnetic field uniformity (B0-shim) was adjusted automatically over the 
field of view with first-order and second-order shims using RASTAMAP22 before all 
acquisitions.  
The MRS voxels were 2.0 × 2.0 × 2.0 cm (8 cm3) in size. In every individual, a voxel 
was centered medially and encompassed the bilateral ACC using two fast low-angle shot 
2D anatomical imaging sequences in the sagittal [45 slices, repetition time (TR) = 950 
ms, echo time (TE)=5.23 ms, flip-angle (α)= 30°, gap between slices=1 mm, thickness= 2 
mm, field of view (FOV) 220 × 220 mm, and matrix size of 220 × 200] and axial (20 
slices, TR = 500 ms, TE =5.23 ms, α =30°, gap between slices=1 mm, thickness= 2 mm, 
FOV =220 × 220 mm, and matrix size 220 × 220) directions, both using lipid saturation. 
Voxel positions were prescribed by the scanner operator (R.T.) using anatomical 
landmarks as trained by a neuroanatomist (N.R.) to ensure consistent voxel placement 
(Fig. 4-1).  
103 
 
 
Figure 4-1. A sagittal cross-section of the brain with the MRS voxel placed in the 
anterior cingulate cortex. MRS = magnetic resonance spectroscopy 
MRS spectra were acquired individually during the performance of the Stroop paradigm 
using an ultra-short echo time stimulated echo acquisition mode sequence with outer 
volume suppression23 [TR =3 s, TE = 10 ms, mixing time (TM) = 32 ms, 4000 complex 
pairs, four steady state scans, 1 s acquisition time, eight-step phase cycle] with 16 water 
unsuppressed spectra and 240 water suppressed spectra, 80 spectra for each 4 min section 
of the Stroop paradigm (Rest, Stroop, Recovery). An eight-pulse VAPOR preparation 
sequence, with an additional water suppression pulse during the TM period23, provided 
efficient water suppression. A separate metabolite suppressed spectrum was acquired to 
assess the macromolecule content24. Each acquisition outputted 23 spectra, one for each 
receiver, which required channel combination before use25. After the channels had been 
combined, each spectrum was frequency and phase corrected before being averaged 
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together. Quality Eddy Current Correction (QUECC)26 reduced linewidth distortions 
before spectral fitting. Spectra were quantified using fitMAN, a time-domain fitting 
algorithm27. All spectra were inspected visually for quality.  
Because of our directional hypotheses for GLU concentrations, a three-level repeated-
measures analysis of variance (rmANOVA) design using the metabolite concentrations at 
each 4 min (80 spectral averages) section of the functional paradigm was examined using 
SPSS v.20 (IBM Corp, Armonk, New York, USA) to determine significant variations 
over time for GLU (α= 0.025, one tailed with Bonferroni correction). Because of the 
exploratory nature of this paper, the remaining metabolites were also tested for 
significance using a repeated measures multivariate analysis of variance (rmMANOVA) 
(α =0.025, two tailed with Bonferroni correction). Only metabolites with Cramer–Rao 
lower bounds less than 20% were included in the analysis. 
 
4.3 Results 
The average linewidths of the unsuppressed water signal were 12.8 ± 2.0 Hz after first-
order and second-order shim adjustments. The average metabolite linewidth in the resting 
condition was 8.6 ± 0.8 Hz and no significant narrowing of the linewidths was observed 
in the activated condition compared with the resting condition. The water signal was 
suppressed sufficiently as the residual water signal was less than the height of the NAA 
peak in every spectrum.  
A total of 15 metabolites were quantified consistently with Cramer–Rao lower bounds 
less than 20% for each of the resting, activated, and recovery spectra (Table 4-1). The 
time course of group-averaged GLU activation in 1 min increments is shown in Fig. 4-2 
(all stats were performed on the 4 min, 80 averaged spectra). The concentration increases 
upon onset of the Stroop Task, plateau, and then decrease over 2 min toward the baseline. 
When the GLU concentrations between the resting, Stroop, and recovery periods were 
compared, there was a significant 2.6 ± 1.0% (0.24 ± 0.09 µmol/g) increase in the 
activated state relative to the initial resting period (P= 0.02, one tailed), followed by a 
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non-significant −2.4 ± 1.2% (− 0.23 ± 0.13 µmol/g) trend for the GLU signal to return to 
baseline after the activation period had ended (P =0.06, one tailed). However, when GLU 
concentrations were normalized to their baseline value in the resting period, the relative 
decrease in the recovery period became significant before Bonferroni corrections (0.025 
< P < 0.05). Six of the seven participants showed this increase in GLU upon activation 
(1.0, 1.3, 5.3, −0.4, 6.0, 0.3, and 5.0%) and six of the seven participants showed the 
subsequent decrease (1.2, − 2.0, −8.8, − 1.5, −1.1, − 2.9, and – 1.6%).  
 
Table 4-1. Quantified metabolites with their resting concentrations (µmol/g) and 
relative changes (%) during the task completion and the recovery period presented 
as means ± SE 
 
 
Concentration Change  
(Task – Rest) 
Concentration Change 
(Recovery – Task) 
 Resting 
Concentration   
  (µmol/g) (%)    p            (%)    p 
GLN   2.4 ± 0.3 -0.2 ± 5.6 0.738 6.8 ± 4.7 0.179 
GLU   8.9 ± 0.3  2.6 ± 1.0 *0.021  -2.4 ±  1.2 0.046 
TAU   2.4 ± 0.3  5.1 ±  7.3 0.509  -1.4 ± 5.6 0.539 
ASP   2.5 ± 0.6  0.3 ± 5.9 0.853  -1.7 ± 3.5 0.404 
NAAG   1.1 ± 0.3 2.6 ± 7.2 0.730 -4.6 ± 7.6 0.505 
MYO   7.9 ± 0.5  0.9 ± 1.5 0.567 1.7 ± 1.4 0.261 
SER   2.0 ± 0.3 7.5 ± 6.7 0.237 -2.4 ± 6.3 0.482 
GLC   0.8 ± 0.2 -6.4 ± 10.2 0.955 14.9 ± 5.3 0.061 
NAA   7.9 ± 0.3   2.6 ± 1.8 0.199   -1.1 ± 0.5 0.309 
LAC   0.5 ± 0.1 22.9 ± 20.3 0.351 35.4 ± 13.1 0.155 
GLY   0.7 ± 0.1 2.1 ± 1.5 0.200 -12.2 ± 7.0 0.130 
SCY   0.4 ± 0.0 3.3 ± 2.8 0.279 1.5 ± 3.7 0.663 
ASC   1.0 ± 0.1 -11.5 ± 11.6  0.764 33.1 ± 17.5 0.030 
TCHO   2.1 ± 0.1 2.2 ± 1.2 0.111 -0.6 ± 0.6 0.399 
TCR   7.7 ± 0.3 2.2 ± 1.2 0.122 -0.0 ± 0.6 0.920 
GLX 11.3 ± 0.5 2.0 ± 1.7 0.302 -1.1 ± 1.1 0.324 
ASC, ascorbate; ASP, aspartate; GLC, glucose; GLN, glutamine; GLU, glutamate; GLY, 
glycine; GLX, glutamate + glutamine; LAC, lactate; MYO, myo-inositol; NAA, N-
acetylaspartate; NAAG, N-acetylaspartylglutamate; SCY, scyllo-inositol; SER, serine; 
TAU, taurine; TCHO (cho + PC + GPC), total choline; TCR (CR + PCR), total creatine. 
*p < 0.025 significance (Bonferroni adjusted) for a two-tailed comparison, with the 
exception of Glu, which is one-tailed due to it being a planned directional comparison  
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Figure 4-2. A time-course of the average glutamatergic response to the Stroop Task  
Each data point represents the temporal average of 20 spectra (1 min) per 
participant combined and quantified and subsequently averaged over all 
participants (n=7). Error bars indicate the inter-individual SEM at each point. The 
trend line is a fourth-order polynomial fit to the data. The shaded area indicates the 
4 min of Stroop activation. 
Other than GLU, the remaining metabolites were not significant in the rmMANOVA. It 
should be noted, though, that in the univariate pair-wise comparisons, ascorbate (Asc) 
increased 33.1 ± 17.5% (0.20 ± 0.06 µmol/ g) during the 4-min recovery period relative 
to the activation period (P= 0.03, two tailed). However, this is only a trend because of the 
Bonferroni correction.  
All participants recorded at least 90% correct responses. Group-averaged response times 
were 725 ± 278 ms for the congruent condition, 976 ± 261 ms for the incongruent 
condition, 750 ± 270 ms for the word-only condition, and 721 ± 230 ms for the color-
only condition. Only correct responses were considered. 
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4.4 Discussion 
Using a Stroop Task as the functional paradigm for an 1H-fMRS examination of the 
dynamic metabolic response to activation in the ACC, an observed significant increase of 
2.6 ± 1.0% was found in GLU upon onset of the task, followed by a non-significant trend 
to return to the baseline in a small sample size of healthy controls (n=7). The high 
percentage of correct responses shows that there was high compliance with the Stroop 
Task among the participants.  
The increase in GLU is comparable with recent 1H-fMRS studies of the occipital 
cortex1,2,6 and the motor cortex3, which found GLU increases from 2 to 4% over the 
course of minutes, with a subsequent decrease upon cessation of the stimuli. Figure 4-2 
indicates that the concentration increased to its new steady state within the first minute of 
activation. This is relatively faster than that in the above studies, which show that it takes 
1–2 min before the concentration reaches its new state. One possible explanation is that 
because of the involvement of ACC in attention networks16, and, specifically, selective 
encoding of stimulus properties15 the ACC had already been in a state of minor 
activation. This is consistent with the final data point of the first resting condition in Fig. 
4-2 that is seemingly already ascending toward the peak concentration. The resting GLU 
concentration is slightly lower than what was observed in other 1H-fMRS studies at 7 T1–
3,6; however, different scanners, techniques, and brain areas studied led to natural 
variation in the observed values between studies.  
One departure from previous 1H-fMRS studies at 7 T1–3,6 is that a significant difference in 
lactate or glucose was not observed. These are difficult metabolites to quantify reliably; 
thus, perhaps more participants would be needed to observe significant differences. It is 
also possible that the lactate response was specific to certain tasks or brain areas.  
It is conceivable that the ACC accumulates GLU faster than other brain regions upon 
stimulation as can be extrapolated from a study of the ACC using a painful stimulus4. 
Mullins and colleagues used 1H-fMRS at 3 T to detect a 9.3% increase in GLU and an 
11.4% increase in GLX (GLU+ GLN). The GLU increases observed by Mullins et al.4 
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are markedly higher than the response detected in the present study. This could be 
because of the nature of the experimental stimuli (pain versus cognitive task) such that 
the brain may have adapted a separate GLU response to painful stimuli as a similar 
increase in GLU was observed with a painful stimuli in the anterior insula cortex5. Two 
studies have used event-related 1H-fMRS to detect >10% increases in the lateral occipital 
cortex9,10. It is possible that with an event-related Stroop Task, larger similar increases in 
GLU in the ACC could be observed. However, with the current block design, the 
magnitude of GLU changes agrees more with the previous work in the visual cortex1,2,6 
and the motor cortex3.  
One study at 3 T presented GABA changes with a working memory task in the 
dorsolateral prefrontal cortex, but did not detect any changes in GLX (GLU + GLN)8. 
The study used a dedicated pulse sequence to detect GABA specifically, which can 
otherwise be a difficult metabolite to quantify as it was not consistently quantified 
reliably in this study. They observed an initial increase in GABA concentrations, but 
subsequent decreases with repeated runs of the task. In a future study, it would be 
interesting to observe how GLU would respond to repeated runs of the Stroop Task.  
Another study that was carried out at 3 T has used an 1H-fMRS technique to study the 
ACC using visually evoked sexual arousal7 and found significant 10–20% increases in 
GLX with activation. At lower field strength, it is often necessary to measure a 
combination of GLU and surrounding metabolites that can include GLN, glutathione, 
GABA, and sometimes macromolecules together as GLX. It is not clear which 
metabolites were included in their GLX definition, making it harder to compare these 
results. A common definition of GLX is simply GLU plus its precursor GLN, as was used 
in the pain study4 and the working memory study8 mentioned above. Using this 
definition, GLX was examined in this study, but no significant differences were 
observed.  
The increase in Asc in the recovery period, although not significant after Bonferroni 
correction or at the multivariate level, is intriguing. It has been reported previously by 
Wilson et al.28 that GLU triggers the release of Asc from astrocytes and increases the 
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extracellular concentration of Asc. Asc is an antioxidant. This is important because GLU 
neurotransmission leads to increased mitochondrial activity and as a result increased free 
radicals29. Wilson et al.28 showed that this effect takes some time to observe; thus, it is 
possible that the increase in GLU during the activated phase led to the delayed increase in 
Asc concentration that was observed in the recovery phase.  
GLU is the main excitatory neurotransmitter in the brain. It is synthesized from glucose 
in the mitochondria, released into the synaptic cleft through exocytosis, and then binds 
with the postsynaptic membrane to induce neurotransmission30. It is then taken up into 
the adjacent glial cell, where it is converted into GLN before being transferred back into 
the neuron and converted back into GLU30. There is an increase in glucose consumption 
during functional activation that specifically supports the increased turnover rate of the 
GLU/GLN cycle 11. Therefore, an increase in oxidative metabolism could lead to the 
increased number of GLU molecules flowing within the GLU/GLN cycle during the 
functional activation of the ACC with the Stroop Task leading to the increased GLU 
observed in bulk brain tissue using MRS. The lack of change in GLN concentrations may 
indicate that the conversion of GLN back into GLU in the neuron is not a rate-limiting 
step in the GLU/GLN cycle.  
This proof-of-concept study shows that the Stroop Task is a robust task that can be used 
for 1H-fMRS studies in the ACC. This introduces a new method to study the 
abnormalities of GLU modulation in brain disorders. Schizophrenia research may 
particularly benefit from this method as it is a population that has been shown to have 
abnormal resting levels of glutamatergic metabolites in the ACC compared with healthy 
controls12,13 and impaired ACC activation during performance of the Stroop Task17. 
Dysfunction of glutamatergic metabolism may manifest itself as an inability to 
dynamically upregulate GLU cycling or excessive upregulation of GLU, or even GLN, 
concentrations during performance of the Stroop Task. The limitations of the study 
include its small sample size and the possibility that the GLU changes observed are 
because of movement-induced phase shifts from the participant responding to the task, 
although it is unlikely that a phase shift would induce consistent increases in GLU rather 
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than decreases. Future studies should have a larger sample size and focus on 1H-fMRS in 
neuropsychiatric disorders. 
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Chapter 5  
5 Functional magnetic resonance spectroscopy of 
glutamate in schizophrenia and major depressive 
disorder: Anterior cingulate activity during a color-word 
Stroop task. 
The study presented in this chapter aimed to utilize functional magnetic resonance 
spectroscopy with a cognitive functional paradigm to obtain dynamic measurements of 
glutamate and glutamine in a psychiatric group for the first time. A version of this work 
is currently in press to be published in npj Schizophrenia (Nature Partner Journals 
Schizophrenia; NPJSCHZ#00068). 
 
5.1 Introduction 
Schizophrenia (SZ) has been suggested to be associated with dysfunction in brain areas 
that utilize glutamate (GLU) for neurotransmission1.  It has been postulated that GLU N-
methyl-D-aspartate (NMDA) receptor hypofunction may contribute to symptoms of SZ2–4 
and this body of literature has been recently reviewed5,6. This, and other lines of evidence 
has led to the notion that GLU abnormalities can explain a wider range of symptoms of 
SZ than dopamine abnormalities alone, thus characterization of GLU abnormalities in SZ 
is sorely needed in light of potential GLU-modulating treatment strategies6. 
Proton magnetic resonance spectroscopy (1H-MRS) has demonstrated abnormal brain 
GLU concentrations, with its metabolic precursor/by-product, glutamine (GLN), in 
individuals with SZ7,8. However, findings may not be specific to this illness. Both major 
depressive disorder (MDD) and bipolar disorder have demonstrated abnormalities of 
GLU in multiple brain areas using 1H-MRS9–11. While MDD has been consistently 
reported to have lower glutamatergic metabolites (GLU, GLN, or GLX (GLU+GLN)), 
bipolar disorder has demonstrated inconsistent results, with a tendency to be elevated9–11.  
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The consistency of studies of GLU in MDD makes it a preferable choice for a psychiatric 
control group.  
An increasing number of studies demonstrate the utility of functional 1H-MRS (1H-
fMRS) in dynamic measures of metabolic content12–24. Much like its parent technique, 
1H-MRS, 1H-fMRS assesses concentrations of brain metabolites that are orders of 
magnitude smaller than the water content. Essentially, 1H-fMRS is a time course of 1H-
MRS spectra that typically measures slow metabolic responses to prolonged stimuli in a 
small volume of tissue within the brain13–16,18–20.  
Increases in concentrations of glutamatergic metabolites have been demonstrated in 1H-
fMRS studies of healthy controls in the occipital lobe using visual stimuli14,16,17,19, the 
lateral occipital cortex using a repetition suppression task23,24, the motor cortex using a 
finger tapping paradigm18 and the anterior cingulate cortex (ACC) using pain 
paradigms21,22, a sexual arousal paradigm13, and the color-word Stroop task20. Increases 
in glutamatergic metabolites upon stimulation is not surprising given the tight coupling of 
GLU and GLN cycling to neural response25. 1H-fMRS with controlled rest and activation 
periods could provide unique information about the dynamic nature of glutamatergic 
abnormalities in SZ.  
In the simplest of tasks, stimuli received by the brain must be organized and encoded for 
further use by brain centers involved in cognition. It is postulated that deficits of stimulus 
encoding are central to cognitive deficits in schizophrenia26,27. Previous literature using 
the Stroop task in healthy controls and in SZ has shown that this is a task that both 
participant groups conduct to the same level of proficiency (rate of correct answers) and 
robustly activates the ACC, although with some hypofunction in SZ28,29.  
The purpose of this study is to measure ACC glutamatergic concentrations dynamically 
during the performance of a color-word Stroop task in SZ compared to healthy controls 
and psychiatric controls with MDD using a 1H-fMRS technique. It is hypothesized that 
there will be smaller GLU responses along with slower response times in the SZ group 
compared to both the healthy controls and MDD group due to the increased number of 
encoding subprocesses (constituent cognitive operations), indicating involvement of more 
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brain areas as well as diversion of activity away from the ACC26,30.  Within groups, it is 
hypothesized that there will be an increase in GLU concentrations during activation of 
the ACC, with a subsequent return to baseline after the task. Because neuronal GLU 
levels have been shown to be related to cognition31, it is expected that concentrations of 
the glutamatergic metabolites will negatively correlate with the response times. 
 
5.2 Methods 
5.2.1 Participants 
There were 16 participants in each of the healthy, MDD, and SZ groups who gave 
informed written consent according to the guidelines of the Review Board for Health 
Sciences Research Involving Human Subjects at the University of Western Ontario. The 
number of participants was chosen based on previous 1H-fMRS studies that have 
observed GLU changes of 2-4%14,16–20. Volunteers with neurological or major medical 
illnesses, clinically significant head injury, other psychiatric disorders, MRI contra-
indications, or substance abuse within the previous year were excluded from the study. 
Any healthy volunteer with a known family history of psychiatric disorder in a first or 
second degree relative was also excluded. 
A consensus diagnosis was established on all participants by a psychiatrist and trained 
assistant with the Structured Clinical Interview for DSM-IV32. SZ subjects were rated 
with the Scale for Assessment of Negative Symptoms and the Scale for the Assessment 
of Positive Symptoms33,34 and MDD patients were assessed with the Montgomery Asberg 
Depression Scale35 and the Young Mania Rating Scale36. Fourteen SZ patients were 
receiving atypical neuroleptics with Chlorpromazine Equivalent 409 ± 293mg (3 taking 
olanzapine; quetiapine/venlafaxine; 2 taking risperidone; quetiapine/paliperidone/ 
escitalopram; 4 taking paliperidone; clozapine; risperidone/escitalopram; quetiapine/ 
escitalopram) and 2 patients were not medicated. Ten of the 16 MDD patients were 
receiving antidepressant medications at the time of the scan (bupropion/citalopram/ 
methylphenidate; venlafaxine; lamotrigine; desvenlafaxine; bupropion/citalopram; 
escitalopram; citalopram; sertraline; citalopram/mirtazapine/quetiapine; levothyroxine/ 
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melatonin). Demographic information including age, handedness, education, parental 
education, clinical rating scores, and length of illness were collected according to our 
previous study37 and are shown in Table 5-1.  
 
Table 5-1. Participant demographics 
Group Controls MDD SZ 
Age 23.9 ± 4.7 21.7 ± 3.3 22.7 ± 2.9 
M/F 11/5 6/10 13/3 
R/L 14/2 14/2 15/1 
Educ 3.1 ± 0.9 2.6 ± 0.6 2.2 ± 0.8 
PEduc 3.1 ± 0.9 3.0 ± 0.6 3.3 ± 0.8 
H Anx  12.7 ± 10.9  
H Dep  12.4 ± 9.1  
Mania  5.4 ± 6.8  
Montg  17.4 ± 10.4  
CPZ (mg)   358 ± 307 
SANS   9.7 ± 7.7 
SAPS     7.6 ± 10.4 
 
M/F - male/female 
R/L - right/left 
Educ - education rating of the participant (1= in high school, 2=completed high school, 3=some college, 4= completed college) 
PEduc - education rating of the participant’s parent (1= in high school, 2=completed high school, 3=some college, 4= completed 
college) 
H Anx - Hamilton Anxiety Scale 
H Dep - Hamilton Depression Scale 
Mania - mania rating from the Montgomery Asperg Depression Scale 
Montg - result of the Montgomery Asperg Depression Scale 
CPZ - chlorapromazine equivalent 
SANS - Scale for Assessment of Negative Symptoms 
SAPS - Scale for Assessment of Positive Symptoms 
 
5.2.2 Anterior cingulate activation paradigm 
We have previously described details of the color-word Stroop Task chosen for the 
functional paradigm20. Briefly, it was a four-condition (congruent, incongruent, word-
only, color-only) by four-color (red, green, blue, yellow) design. The subjects were asked 
118 
 
to respond as quickly and accurately as possible on a four-button keypad with the color of 
the ink as the correct answer for all but the word-only conditions within which the answer 
was the color-word. Stimuli were presented for two seconds followed by one second of 
cross fixation. In the scanner, subjects first engage in cross-fixation for four minutes prior 
to a four-minute block of activation (Stroop1), which is then followed by four minutes of 
recovery (Recovery1). In contrast to the previous study by Taylor et al20, an additional 
four minutes of Stroop activation (Stroop2) was acquired after Recovery1, which was 
then followed by another four-minute recovery period (Recovery2). This additional block 
of activation will help assess the glutamatergic response to repeated, prolonged Stroop 
stimuli in the ACC. The procedure was written and presented using PsychoPy38, which 
also recorded accuracy and response times. A confirmatory fMRI was acquired post-1H-
fMRS to ensure activation within the fMRS voxel.  The fMRI lasted nine minutes and 
was divided into one-minute blocks cycling between resting (cross-fixation) and Stroop 
activation, for a total of four minutes of Stroop activation. Image preprocessing and 
statistical analysis were conducted using Statistical Parametric Mappping (SPM8; 
Wellcome Department of Neurology, London, UK) within Matlab 7.1 (The Mathworks 
Inc., MA).   
 
5.2.3 1H-fMRS Data Collection and Analysis 
All measurements were acquired on a 7.0 T Agilent/Magnex head-only MRI (Agilent, 
Inc, Walnut Creek, California, USA) with a Siemens AC84 head gradient coil (Siemens, 
Erlangen, Germany), located at the Center for Functional and Metabolic Mapping at 
Western’s Robarts Research Institute. A transmit-only receive-only (TORO) head coil 
with 15 transmitters and 23 receivers39 was used for all scans with a B1-shimming 
approach to facilitate optimized homogeneity correction of the transmit field for each 
scan40.  The magnetic field uniformity (B0-shim) was adjusted automatically over the 
field of view with first-order and second-order shims using RASTAMAP41.  
The 1H-MRS voxels were 2.0 × 2.0 × 2.0 cm (8 cm3) in size. In every individual, a voxel 
was centered medially and encompassed the bilateral ACC (Fig. 5-1) using two fast low-
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angle shot 2D anatomical imaging sequences in the sagittal (45 slices, repetition time 
(TR)=950 ms, echo time (TE)=5.23ms, flip-angle (α)=30°, gap between slices=1 mm, 
thickness=2 mm, field of view (FOV)=220 × 220 mm, matrix size=220 × 200) and axial 
(20 slices, TR=500ms, TE=5.23ms, α=30°, gap=1mm, thickness=2mm, FOV=220 × 
220mm, matrix size=220 × 220) directions, both with lipid saturation. The voxels were 
placed in the areas of the ACC where activation was expected based on previous fMRI 
studies that used a color-word Stroop task42,43.  
1H-MRS spectra were acquired individually throughout the Stroop paradigm using an 
ultra-short TE stimulated echo acquisition mode sequence with outer volume 
suppression44 (TR=3s, TE=10ms, mixing time (TM)=32ms, 4000 complex pairs, 4 steady 
state scans, 1s acquisition time, 8 step phase cycle) with 16 water unsuppressed spectra 
and 400 water suppressed spectra, 80 spectra for each 4 min section of the Stroop 
paradigm (Resting, Stroop1, Recovery1, Stroop2, Recovery2). An eight-pulse VAPOR 
preparation sequence, with an additional water suppression pulse during the TM period44, 
provided efficient water suppression. A separate metabolite-suppressed spectrum was 
acquired to assess the macromolecular content45 for each individual. This metabolite-
suppressed spectrum was modelled using a Hankel-Lanczos singular value 
decomposition (HLSVD)46,47 routine and included in the fitting template. Each 
acquisition produced 23 spectra, one for each receiver, which required channel 
combination before use48. Spectra were frequency and phase corrected before being 
averaged together. QUality Eddy Current Correction (QUECC)49 reduced linewidth 
distortions before spectral fitting with fitMAN, a time-domain fitting algorithm50. 
Metabolite concentrations were calculated with corrections for gray and white matter 
content, as previously described in Stanley et al51. All spectra were inspected visually for 
quality. To ensure reliable quantification, only metabolites with Cramer-Rao lower 
bounds (CRLB) less than 10% were included in the analysis. 
To illustrate the dynamic response of GLU throughout the acquisition, spectra were 
subdivided and averaged into 20 spectra (one-minute intervals).  These were fit for each 
person, then combined via a moving average for each group.  
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A 5x3 repeated-measures analysis of variance (rmANOVA) design using the metabolite 
concentrations at each 4 min (80 spectral averages) section of the functional paradigm 
was examined using SPSS v.20 (IBM Corp, Armonk, New York, USA) to determine 
significant variations over time and across groups. One-tailed tests were employed for 
GLU due to the directional hypotheses of concentration increases with activation by the 
Stroop Task followed by decreases during the recovery. GLN and GLX were similarly 
explored; GLX, with one-tailed tests as GLU is the main contributor to GLX 
concentration, and GLN with two-tailed tests. For pairwise comparison, the blocks of the 
Stroop paradigm were compared to both the previous block and the sequential block. 
Metabolite changes will similarly be explored with concentrations that are normalized to 
their resting values. To accommodate multiple comparisons, alpha was divided by four 
(p<0.05/4). Kolmogorov-Smirnov tests were used to ensure the assumption of normality. 
 
5.3 Results: 
Significant Family-Wise Error (FWE) corrected (p<0.05) activation of the ACC was 
observed in the confirmatory fMRI (Fig.5-1c). The activation observed was within the 
location of voxel placement in the ACC.  
Unsuppressed water spectra were acquired with average linewidths of 10.79±1.08 Hz 
after shimming and the water peak was effectively suppressed in the metabolite spectra 
(Fig. 5-2). GLU and GLN concentrations were estimated from the fit (Fig. 5-1) with 
CRLB less than 1% and 10%, respectively, indicating high quality fits of the data. A 
moving average of fluctuations in GLU levels throughout the activation paradigm is 
presented in Fig. 5-3 for each participant group.  
The rmANOVA (alpha=0.05) yielded a significant main effect of time for GLU 
(p<0.001) and GLX (p<0.001) but not GLN (p=0.132). Strongly significant increases 
occurred for GLU (p=0.002) and GLX (p=0.001) in Stroop1 over all groups. There were 
no significant time by group interactions (GLU, p=0.377; GLN, p=0.317; GLX, p=0.616) 
and there were no main effects of group (GLU, p=0.797; GLN, p=0.137; GLX, p=0.700).  
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The planned pairwise comparisons (alpha=0.05/4) of adjacent periods of the Stroop Task 
yielded significantly increased GLU (p=0.006) concentrations in the healthy controls 
during Stroop1 (Table 5-2). GLU then decreased towards the resting value in Recovery1 
(p=0.007). In the SZ group, GLX concentrations had a trend to increase Stroop1 
(p=0.016). The SZ group was the only group to show significant GLN changes, going 
from 1.21±0.52 mmol/kgww at rest to 1.44±0.50 mmol/kgww (p=0.004, two-tailed) in 
Stroop1, then returning to 1.18±0.48 mmol/kgww in Recovery1 (p=0.001, two-tailed). The 
MDD group did not show any significant changes in glutamatergic concentrations during 
Stroop1.  
Stroop2 yielded unexpected decreases in GLU and GLX concentrations relative to 
Recovery1. Using two-tailed tests (as the assumptions for one-tailed tests were no longer 
valid), the MDD group showed significantly decreased GLU and GLX (p=0.003, 
p=0.006, respectively) and the SZ group showed a near-significant decrease for GLU 
(p=0.024). 
Combining all groups yielded significant decreases in GLU (p=0.003) and GLX 
(p=0.008). Statistical comparisons using concentrations normalized to resting values 
yielded highly similar results (Table 5-3). A post-hoc test (alpha=0.05) comparing the 
GLU concentrations during the two Stroop conditions indicated lower concentrations in 
Stroop2 for the MDD group (p=0.001) and the SZ group (p=0.026) but not the healthy 
control group (p=0.053). GLU concentrations in Stroop2 were found to be lower in every 
group when the concentrations were normalized to the resting values (p=0.009, p=0.002, 
p=0.034 for control, MDD, and SZ groups, respectively).  
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Figure 5-1. (A) Sagittal and (B) transverse cross-sections depicting the position of 
the 1H-fMRS voxel located in the bilateral ACC of one participant. 
The voxel was centered on the junction of the right cingulate sulcus with the 
paracentral sulcus, angled to the AP line and placed superior to the first fold of grey 
matter above the corpus callosum in the sagittal cross-sections and centered on the 
interhemispheric fissure in the transverse cross-sections. (C) The Family-Wise 
Error (FWE) corrected (p<0.05) confirmatory fMRI on a normalized average brain 
for all groups showing significant activation within the ACC in the right hemisphere 
of all participant groups and Stroop conditions combined. 
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Table 5-2. Pairwise comparisons for adjacent blocks of the 1H-fMRS paradigm for GLU, GLN, and GLX concentrations 
Group Resting Stroop1 p(S1-B) Recovery1 p(R1-S1) Stroop2 p(S2-R1) Recovery2 p(R2-S2) 
HC [GLU] 8.79 ± 0.85 9.07 ± 0.91 0.004 8.85 ± 0.85 0.016 8.69 ± 1.08 0.261 8.95 ± 1.11 0.072 
[GLN] 1.37 ± 0.52  1.41 ± 0.56 0.533 1.46 ± 0.50 0.564 1.40 ± 0.56 0.443 1.43 ± 0.52 0.775 
[GLX] 9.98 ± 1.02 10.31 ± 0.97 0.012 10.13 ± 1.02 0.074 9.92 ± 1.38 0.224 10.2 ± 1.24 0.12 
MDD [GLU] 9.24 ± 1.4 9.38 ± 1.47 0.079 9.27 ± 1.53 0.121 8.91 ± 1.52 0.018 8.95 ± 1.4 0.788 
[GLN] 1.75 ± 0.84  1.84 ± 0.97 0.275 1.85 ± 1.00 0.858 1.86 ± 1.07 0.876 1.76 ± 0.81 0.285 
[GLX] 10.63 ± 2.16 10.86 ± 2.36 0.049 10.75 ± 2.45 0.184 10.31 ± 2.5 0.016 10.35 ± 2.16 0.823 
SZ [GLU] 9.11 ± 1.33 9.24 ± 1.23 0.105 9.20 ± 1.21 0.367 8.94 ± 1.49 0.076 8.91 ± 1.41 0.804 
[GLN]  1.29 ± 0.51  1.52 ± 0.48 0.005 1.24 ± 0.49 0.002 1.26 ± 0.38 0.811 1.30 ± 0.43 0.737 
[GLX] 10.16 ± 1.78 10.47 ± 1.72 0.015 10.21 ± 1.58 0.020 9.97 ± 1.87 0.173 9.96 ± 1.75 0.963 
All [GLU] 9.05 ± 1.21 9.23 ± 1.21 0.001 9.11 ± 1.21 0.018 8.85 ± 1.35 0.003 8.94 ± 1.29 0.288 
[GLN]  1.46 ± 0.65  1.58 ± 0.69 0.009 1.51 ± 0.71 0.142 1.50 ± 0.74 0.844 1.48 ± 0.61 0.769 
[GLX] 10.26 ± 1.71 10.55 ± 1.75 0.001 10.37 ± 1.77 0.065 10.07 ± 1.93 0.005 10.17 ± 1.73 0.314 
 
p(S1-B) = Stroop1 vs resting, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance 
p(R1-S1) = Recovery1 vs Stroop1, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance 
p(S2-R1) = Stroop2 vs Recovery1, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance 
p(R2-S2) = Recovery2 vs Stroop2, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance 
HC = Healthy controls 
MDD = Major Depressive Disorder 
SZ = Schizophrenia 
All = the combination of all participants across groups 
[GLU] = The concentration of glutamate (mmol/kgww)  
[GLN] = The concentration of glutamine (mmol/kgww) 
[GLX] = The concentration of GLX (glutamate + glutamine; mmol/kgww) 
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Table 5-3. Pairwise comparisons for adjacent blocks of the 1H-fMRS paradigm, normalized to the resting concentration for 
GLU, GLN, and GLX 
Group Resting Stroop1 p(S1-B) Recovery1 p(R1-S1) Stroop2 p(S2-R1) Recovery2 p(R2-S2) 
HC GLU_N 1.000 ± 0.000 1.032 ± 0.055 0.005 1.004 ± 0.059 0.006 1.001 ± 0.052 0.808 1.012 ± 0.075 0.340 
GLN_N 1.000 ± 0.000 1.044 ± 0.214 0.598 1.041 ± 0.282 0.968 0.982 ± 0.180 0.491 1.002 ± 0.157 0.715 
GLX_N 1.000 ± 0.000 1.033 ± 0.060 0.013 1.012 ± 0.062 0.027 1.003 ± 0.043 0.602 1.015 ± 0.075 0.363 
MDD GLU_N 1.000 ± 0.000 1.016 ± 0.049 0.082 1.003 ± 0.059 0.101 0.963 ± 0.055 0.005 0.969 ± 0.035 0.634 
GLN_N 1.000 ± 0.000 1.048 ± 0.249 0.547 1.068 ± 0.275 0.766 1.005 ± 0.290 0.451 0.954 ± 0.276 0.333 
GLX_N 1.000 ± 0.000 1.022 ± 0.060 0.066 1.009 ± 0.069 0.135 0.967 ± 0.084 0.011 0.974 ± 0.043 0.598 
SZ GLU_N 1.000 ± 0.000 1.016 ± 0.031 0.081 1.014 ± 0.061 0.420 0.981 ± 0.071 0.017 0.979 ± 0.076 0.892 
GLN_N 1.000 ± 0.000 1.264 ± 0.386 0.001 1.048 ± 0.381 0.002 1.071 ± 0.313 0.778 1.087 ± 0.326 0.757 
GLX_N 1.000 ± 0.000 1.034 ± 0.049 0.011 1.013 ± 0.08 0.027 0.982 ± 0.081 0.065 0.985 ± 0.087 0.840 
All GLU_N 1.000 ± 0.000 1.021 ± 0.045 0.002 1.007 ± 0.058 0.010 0.981 ± 0.061 0.002 0.986 ± 0.066 0.449 
GLN_N 1.000 ± 0.000 1.124 ± 0.309 0.014 1.053 ± 0.311 0.088 1.021 ± 0.267 0.490 1.016 ± 0.266 0.865 
GLX_N 1.000 ± 0.000 1.030 ± 0.056 0.001 1.011 ± 0.069 0.003 0.984 ± 0.074 0.006 0.991 ± 0.071 0.341 
 
p(S1-B) = Stroop1 vs resting, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance 
p(R1-S1) = Recovery1 vs Stroop1, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance 
p(S2-R1) = Stroop2 vs Recovery1, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance 
p(R2-S2) = Recovery2 vs Stroop2, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance 
HC = Healthy controls 
MDD = Major Depressive Disorder 
SZ = Schizophrenia 
All = the combination of all participants across groups 
GLU_N = The concentration of Glutamate normalized to the resting period 
GLN_N = The concentration of glutamine normalized to the resting period 
GLX_N = The concentration of GLX (glutamate + glutamine) normalized to the resting period 
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Table 5-4. Behavioural response times (correct-only) to the incongruent Stroop condition and correlation to glutamate and 
glutamine concentrations and percent changes during those trials 
 Trial 
Subject 
Group 
Response     
Time (s) 
Correlations 
GLU p ΔGLU p GLN p ΔGLN p 
Stroop1 
HC 0.92 ± 0.16 -0.42 0.077 0.04 0.446 -0.45 0.081 -0.34 0.151 
MDD 0.95 ± 0.12 -0.37 0.08 -0.30 0.126 -0.41 0.063 -0.67 0.003 
SZ 1.03 ± 0.08 -0.35 0.099 -0.23 0.207 -0.50 0.033 -0.65 0.006 
All  0.97 ± 0.13 -0.32 0.017 -0.15 0.166 -0.40 0.005 -0.33 0.019 
Stroop2 
HC 0.84 ± 0.15 -0.39 0.107 0.28 0.178 -0.60 0.026 -0.58 0.031 
MDD 0.89 ± 0.13 -0.30 0.133 -0.28 0.144 -0.20 0.249 -0.45 0.055 
SZ 0.93 ± 0.13 0.38 0.083 0.14 0.309 -0.17 0.287 -0.20 0.244 
All  0.89 ± 0.14 -0.08 0.313 0.04 0.387 -0.28 0.040 -0.28 0.045 
 
GLU = glutamate correlation coefficient (Pearson r) with response times 
ΔGLU = The normalized glutamate concentration change 
GLN =  glutamine correlation coefficient (Pearson r) with response times 
ΔGLN = The normalized glutamine concentration change correlation coefficient (Pearson r) with response times 
p = probability that the correlation is due to chance (alpha=0.05/4 (Bonferroni corrected), one-tailed), bolded values indicate statistical significance 
HC= healthy controls 
MDD = major depressive disorder 
SZ = Schizophrenia 
All = the combination of all participants across groups 
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Table 5-5. Correlation values between behavioural response times for each Stroop condition and GLU and GLN 
concentrations during Stroop1 
    Stroop1 Stroop2 
Group Metabolite Congruent Incongruent Word Only Color Only All Congruent Incongruent Word Only Color Only All 
HC 
GLU -0.394 -0.419 -0.152 -0.614 -0.471 -0.551 -0.454 -0.085 -0.558 -0.494 
ΔGLU 0.232 0.042 -0.070 0.034 0.074 0.173 0.253 0.190 0.443 0.255 
GLN -0.559 -0.453 -0.296 -0.552 -0.546 -0.424 -0.643 -0.468 -0.301 -0.540 
ΔGLN -0.131 -0.343 -0.245 -0.084 -0.242 0.000 -0.216 -0.386 -0.176 -0.209 
MDD 
GLU -0.009 -0.368 -0.390 -0.276 -0.304 0.076 -0.270 -0.181 0.013 -0.123 
ΔGLU -0.344 -0.304 -0.081 -0.348 -0.310 -0.212 -0.137 -0.298 -0.074 -0.203 
GLN -0.291 -0.443 0.029 0.105 -0.220 0.010 -0.250 -0.305 -0.229 -0.215 
ΔGLN 0.319 -0.525 0.217 0.432 0.172 -0.181 -0.583 -0.200 -0.472 -0.436 
SZ 
GLU 0.091 -0.352 0.192 0.129 0.028 0.115 0.334 0.002 0.454 0.302 
ΔGLU -0.088 -0.228 0.166 0.121 0.003 -0.062 -0.429 0.128 -0.238 -0.147 
GLN -0.077 -0.439 -0.296 -0.132 -0.267 -0.345 -0.290 -0.157 -0.259 -0.324 
ΔGLN -0.089 -0.676 -0.383 -0.366 -0.427 -0.024 -0.239 -0.019 -0.016 -0.094 
All 
GLU -0.055 -0.321 -0.140 -0.214 -0.222 -0.035 -0.097 -0.069 0.069 -0.041 
ΔGLU -0.092 -0.149 -0.017 -0.131 -0.115 -0.021 -0.092 0.033 -0.113 -0.063 
GLN -0.207 -0.404 -0.301 -0.214 -0.331 -0.163 -0.310 -0.259 -0.237 -0.284 
ΔGLN -0.003 -0.330 -0.150 -0.024 -0.154 0.017 -0.213 -0.068 -0.010 -0.092 
 
GLU = glutamate correlation coefficient (Pearson r) with response times 
ΔGLU = The normalized glutamate concentration change 
GLN =  glutamine correlation coefficient (Pearson r) with response times 
ΔGLN = The normalized glutamine concentration change correlation coefficient (Pearson r) with response times 
HC= healthy controls 
MDD = major depressive disorder 
SZ = Schizophrenia 
All = the combination of all participants across groups 
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Figure 5-2. (A) An example resting 80 average water suppressed spectrum.  
This is taken from the ACC of a volunteer with SZ. A 2Hz Lorentzian line 
broadening has been applied. (B) Resultant estimates of the glutamate and (C) 
glutamine spectral fits. (D) The residual (spectrum minus the fit of all metabolites) 
of the spectrum 
Every group was able to respond to the stimuli correctly with at least 90% accuracy. 
Mathematical modeling of Stroop performance confirmed an increased number of 
subprocesses (constituent cognitive operations) among the SZ group26,27,52,53. The 
response times to the incongruent condition during Stroop1 significantly correlated with 
GLN concentrations when averaged together over all groups (p=0.005; Table 5-4), 
whereas GLU concentrations only presented with a trend (p=0.017). The MDD and SZ 
groups responses significantly correlated with the normalized GLN responses (p=0.003, 
p=0.006, respectively), and no group’s response times were significantly correlated with 
the normalized GLU responses. No significant correlations were observed in Stroop2. 
The full table of correlations between GLU and GLN concentrations and response times 
for each of the four Stroop conditions can be found in Table 5-5.  
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5.4 Discussion: 
The GLU response in the ACC of healthy controls (3.2%) compares well with the 2.6% 
reported previously using the Stroop Task20 and with the 2-4% reported previously in 
other brain areas14,16–19. A main effect of time was observed for all groups in Stroop1 
compared to Resting, nevertheless, planned contrasts were significant for the healthy 
controls only.  GLU and GLN cycling correlates with neuronal glucose consumption in 
activated conditions25 and hypofunction of the ACC with color-word Stroop Tasks has 
been demonstrated in SZ with fMRI28,29. In SZ, it seems that the number of processing 
steps involved in stimulus encoding is increased26,27,52,53.  The increased processing steps 
may involve more brain areas than in controls and cause a blunted activation state of the 
ACC, which could explain the relatively smaller increase in GLU.  
Each point represents the percent change from resting concentration (averaged over 
four minutes) for (A) healthy, (B) Major Depressive Disorder, (C) Schizophrenia 
groups, and (D) all groups combined. Shaded areas indicate that the Stroop task is 
being performed during that time. Error bars represent inter-individual standard 
error of the mean 
Figure 5-3. Four-minute moving average time courses of glutamate concentrations. 
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The observed decreases in GLU and GLX during Stroop2 relative to Stroop1 and 
Recovery1, particularly in the patient groups, were unexpected.  Learning effects on GLU 
as the task progresses are a possible explanation owing to the increased amount of 
practice participants have received by the time of the second task. The observed decrease 
in response times during Stroop2 relative to Stroop1 does indicate that the task became 
easier.  This study is now the second to report a decrease in a neurotransmitter using a 
cognitive task with 1H-fMRS, as a similar result has been observed in prefrontal cortex 
GABA concentrations during a working memory task, which initially showed an increase 
in GABA concentrations followed by three subsequent runs with decreases15. This 
finding is not observed in the visual or motor tasks14,16–19, so it is not likely that the 
reduced GLU is due to an inadequate duration of Recovery1. Future fMRS studies using 
cognitive stimuli should observe a longer recovery time between functional runs to 
further explore this finding. 
The behavioural response times for the incongruent condition during Stroop1 negatively 
correlated with the GLN concentrations. More GLN readily available could mean quicker 
responses are possible because less time is required to create GLU for neurotransmission. 
The normalized changes in GLN during the task were much stronger predictors than 
GLU, which seemingly had no correlation, indicating the role of GLN in 
neurotransmission may have substantial influence on cognitive capabilities.     
No between-group comparisons yielded significant results but there are still some points 
worth noting for possible future testing. First, the resting GLU levels were slightly higher 
in the MDD and SZ groups than the healthy controls. Elevated GLU concentrations can 
lead to excitotoxicity54,55 so levels are carefully controlled by re-uptake transporters. It is 
possible that resting GLU in MDD and SZ groups are closer to a GLU ceiling making 
GLU upregulation more difficult. It should also be noted that GLU and GLN are involved 
in many other brain functions, including metabolism, which is likely also in a dynamic 
state. 
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Secondly, the SZ group appeared to have a slower GLU response and recovery to 
Stroop1 when compared to controls and MDD subjects yet showed significant differences 
in the GLN concentrations during Stroop1 and Recovery1. When GLU is released from 
the receptor on the post-synaptic membrane it is taken up into the adjacent glial cell55 and 
converted to GLN via glutamine synthetase so that it can be transferred back into the 
neuron55 where the GLN is converted back into GLU via the phosphate-activated enzyme 
glutaminase (PAG)56.  Insufficient PAG would slow the conversion of GLN to GLU, 
resulting in a slower GLU-GLN cycle and a prolonged recovery from a 
neurotransmission event. However, no significant difference was observed in the 
expression of PAG in the ACC in one post-mortem study57 and increased expression was 
found in the thalamus in another58. Another possible explanation comes from studies that 
have demonstrated that NMDA hypofunction causes increased glutamine synthetase 
activity resulting in increased GLN59. Consistent with this observation, another study has 
shown that increased ketamine administration in healthy controls leads to increased GLN 
concentrations in the ACC60. It is possible, that the increased GLN observed in the SZ 
group arose from NMDA hypofunction when the ACC was challenged.   
There is evidence to support a possible glutamatergic dysfunction in MDD as well9. 
While the exact mechanism is yet to be understood, some lines of evidence suggest 
astrocytic dysfunction may contribute to the pathophysiology of MDD9,61,62. Astrocytes 
are pivotal elements in the GLU-GLN cycle and it is possible that any disruption to the 
efficiency of their operations in MDD could have contributed to the lack of a significant 
increase during Stroop1, or to the significant decrease in Stroop2. Previous studies have 
demonstrated decreased ACC GLU in the MDD9–11, which was not observed in this 
study. This could be due to the different placement of voxels within the relatively large 
ACC or possibly a result of treatment effects.  It could also be due to the significant 
difference in gender in the subject population. In this study, the MDD group had a larger 
incidence of females than the healthy controls. This is another confound that is difficult 
to avoid, as women have a higher prevalence of MDD than males at a ratio of 1.64:1 in 
Canada63. This must be considered when interpreting the results as gender has previously 
been shown to influence GLU64 and GLN65 concentrations.      
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A limitation of the study is the possible influence of the medications, which have been 
shown to affect glutamatergic concentration levels66,67. Antipsychotic and antidepressant 
medications are often unavoidable confounds of studies involving SZ and MDD patients. 
Although the subjects in this study were in relatively early stages of the illness (30 ± 16 
months and 29 ± 14 months for the SZ and MDD groups, respectively), medications have 
been shown to influence the GLU concentration of medicated SZ patients in as early as 4 
weeks67.  This could have influenced the baseline levels of GLU and, possibly, the GLU 
responses to functional activation. 
Although the confirmatory fMRI suggests correct voxel placement, another limitation of 
this study is that there was no fMRI guidance prior to the 1H-fMRS acquisition. The 
confirmatory fMRI was acquired post-fMRS to decrease the impact of task learning 
effects to elicit the strongest ACC response, to which the reduction in response times and 
GLU changes observed during Stroop2 do suggest that considerable learning effects 
occur.  
Detailed analyses of the confirmatory fMRI and mathematical modeling of the 
behavioural response times are beyond the scope of this work and will be presented in 
other venues52.  
 
5.5 Conclusion: 
GLU concentrations measured with 1H-fMRS were demonstrated to significantly increase 
in a healthy control group upon functional activation of the ACC using a color-word 
Stroop task but not in a MDD or SZ group. This is the first study to perform 1H-fMRS in 
the ACC at 7 T in a psychiatric population. Use of a psychiatric control group (MDD) 
demonstrated that the increases in GLN were specific to SZ, but the blunted GLU 
response during Stroop1 was not. Observed response times of the MDD group were 
slower than the healthy controls, but were not as slow as the SZ group, indicating a 
stronger deterioration of function in SZ.  Future studies should try to include psychiatric 
control groups to assess the specificity of the results.  Future studies should examine 
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other cognitive tasks that activate the ACC, perhaps with varying levels of complexity to 
get a better understanding of the GLU and GLN response in SZ, with longer response 
times and varying stimulus encoding loads to study the GLU recovery process in greater 
detail.  
Supplementary information is available at npj Schizophrenia’s website.   
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Chapter 6  
6 Summary, Future Work, and Conclusions 
This section will begin with a discussion of each paper to put into perspective how they 
all fit together to complete a story.  There will then be suggestions for possible future 
avenues of research based on the results of this thesis, with some recommendations for 
ways in which the methodologies can be improved. This will be followed by a brief 
conclusion. 
   
6.1 Summary of chapters 
6.1.1 Simulations  
Simulations were designed to isolate common sources of variation in metabolite 
quantification precision (i.e. how consistent the measurements are), accuracy (i.e. how 
close the measured concentrations are to the correct values) and correlations between 
metabolite concentration estimates (i.e. how do the concentration estimates interact with 
each other) using simulated human brain spectra of four commonly used B0, 1.5 T, 3.0T, 
4.0T, and 7.0T. Three SNR were assumed for each B0, one with 64 spectral averages, 
another with 256 spectral averages, and one with a theoretical SNR of 1024 (practically 
unachievable in water suppressed human brain spectra). The precision and the 
completeness of the initial estimate of the metabolite fitting template were also assessed. 
The focus of the study was on J-coupled metabolites, such as GLU and GLN, but all 
metabolites were evaluated.  
With the exception of the fitting templates with omitted metabolites, the accuracy of 
metabolite concentration estimates was generally unaffected for all conditions studied. It 
was found that the precision generally improved as B0 increased, with the largest 
improvements in quantification precision coming from J-coupled metabolites.  J-coupled 
metabolites also had the strongest reductions in correlations between metabolite 
concentration estimates when B0 increased, meaning they can be quantified more 
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independently. Precision also improved when SNR increased as a consequence of 
increasing B0. An important observation that was independent of B0 is that the precision 
of the initial estimate of the spectral fitting template did affect quantification precision, so 
care is needed in providing a reasonable initial estimate.  
This study has confirmed the hypothesis that there are significant benefits to using higher 
B0 for 
1H-MRS studies aiming to reliably quantify GLU and GLN.  The increase in SNR 
reduces the number of averages necessary to acquire quality spectra, which is important 
for any application of 1H-fMRS. A stronger B0 will also help in quantifying lower 
concentration and heavily overlapped metabolites, such as GLY.  Therefore, a 7 T MRI 
and ultra-short echo time STEAM sequence were employed for all the 1H-MRS and 1H-
fMRS work included in this thesis.  
 
6.1.2 Single-voxel 1H-MRS  
The aim of this study was to examine concentrations of GLU, GLN, and GLY in the 
ACC and thalamus of SZ compared to healthy controls and MDD using the 
aforementioned benefits in metabolite quantification that is possible with a 7 T MRI. The 
key findings of the study were increased GLN and decreased GLY in the thalamus of 
people with SZ compared to the healthy control group, and decreased MYO in both the 
ACC and thalamus of the MDD group compared to the healthy control group and SZ 
groups. No differences in GLU were found in any group. It was the first study to examine 
GLY concentrations in the brains of a schizophrenic population in vivo using 1H-MRS.  
The increased GLN and decreased GLY in the SZ group fit well with the NMDA 
hypofunction model of SZ and agree with the hypotheses of increased GLN and 
abnormal GLY concentrations in SZ. As demonstrated in Fig 1-3, GLY availability is 
critical to GLU neurotransmission via the NMDA receptor. Therefore, insufficient 
concentrations of GLY in the synaptic cleft could lead to a deficiency in NMDA 
function.  The increased GLN fits into this model as well.  NMDA hypofunction 
increases the activity of glutamine synthetase, which then increases the concentrations of 
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GLN1.  The thalamus is involved in the transmission of most sensory input and is a 
central hub of the BGTHC circuits that mediate communications between motivation and 
action. It is a critical location for communication to areas involved in both the positive 
symptoms of SZ via the substantia nigra and nucleus accumbens, and the negative 
symptoms of SZ via the prefrontal cortex and the ACC.  There were no glutamatergic 
changes in the ACC of the SZ group relative to either healthy control or MDD groups. 
This was unexpected based on previous studies in the literature2, including previous 
results from this lab3,4, and contradicted that part of the hypothesis. This could be due to 
the time gap between diagnoses to the time of the scan, which was on average 30 months 
for this subject group. It has previously been shown that the concentration of GLN is 
initially higher in the ACC of people with SZ, and this concentration gradually decreases 
over time2,5. It is possible that there initially was an increase in GLN, but, due to the 
length of illness, the concentration decreased and was no longer significant.  
It was also expected that the MDD group would present with GLU abnormalities relative 
to the SZ and control groups.  There is growing evidence that excitatory synapses and 
NMDA receptors play a role in MDD symptomatology6. Ketamine, the NMDA 
antagonist known to induce SZ-like behavior in healthy controls7, when administered in 
low doses has anti-depressant properties in people with MDD6.  A dysfunction in the 
NMDA receptors in MDD could explain the lack of observed significant differences in 
GLN between the SZ group and the MDD group. 
It should be noted that the SZ and MDD groups in this study were no longer drug-naïve. 
It has previously been demonstrated that medications can influence GLU concentrations 
in a short time frame8,9 and that GLU concentrations vary throughout the disease 
progression2,5. It is, therefore, a possibility that medications and/or disease duration had 
some influence on the results. Obtaining data from unmedicated patients early in their 
illness is, of course, challenging. SZ is only prevalent in about 1% of the population with 
the typical disease onset during adolescence. A drug-naïve first-episode study would rely 
on an influx of young adolescents experiencing psychiatric symptoms that agree to 
volunteer for an MRI and often require their parents’ permission. With this study in 
particular, due to technical challenges associated with implementing the 1H-MRS 
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protocol on the 7 T scanner (planned decommissioning within 2 years of the start of the 
study), the available time-window only permitted the scanning of young patients with SZ, 
still early in their illness (30 ± 15 months), but not drug-naïve.  It is possible that this 
could have influenced GLU concentrations in the ACC and thalamus. Future studies 
should explore a longitudinal design starting at the first-episode, never-treated time point. 
Another confound of this study is that as many as 60% of people with SZ are smokers10, 
and smoking has been shown to affect GLU levels in the thalamus11. The prevalence of 
smokers in SZ is believed to be partially due to the increased dopamine activity from 
smoking10.  Cigarette smoking was not an exclusion criteria for this study, so it needs to 
be considered when interpreting the results.  
Reduced MYO concentrations were observed in the thalamus and the ACC of the MDD 
group relative to the healthy control and SZ groups.   MYO is an osmolyte in the brain 
and is a precursor to many phosphorylated derivatives and second messengers that have 
various important functions12.  It has also traditionally been a marker for glial cell 
integrity although some have questioned this claim12.  However, if the assumption is 
made that MYO concentrations are reflective of glial cell integrity, then these results do 
support the theory of a reduction in glial cell density in MDD. The glia are actively 
involved in the GLU-GLN cycle, so disruption of these processes could directly influence 
GLU neurotransmission and impede healthy brain function.  With MYO being involved 
in so many brain functions, it is difficult to interpret what exactly is causing this decrease 
in MYO.  It is curious, though, that treatments of mania often reduce MYO 
concentrations12 and that increased MYO concentrations have been reported in recovered 
MDD subjects13.  Although this is speculative, it seems likely that the MYO 
concentrations somehow influence (or are influenced by) mood.  Inositol has been 
examined as a possible treatment for MDD previously. The results are mixed, but one 
meta-analyses determined that there may be a clinical benefit to inositol as a treatment14. 
The number of studies, however, are still small12,13,14, so more are necessary to confirm 
this finding. 
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It is important to note that there was a significant difference in the number of females to 
males in the MDD group compared to the SZ and healthy control groups. This is difficult 
to avoid due to the increased prevalence of MDD in females compared to males (1.64:1 
in Canada). There have yet to be any studies that have demonstrated differences in MYO 
concentrations between males and females, but still an important point to consider.   
This study found interesting significant differences in metabolite concentrations between 
SZ, MDD, and healthy control subjects. However, this study was conducted in a resting 
state with one static measurement as hundreds of other studies of SZ with 1H-MRS have 
done. As the very definition of SZ is entirely based on behavioural abnormalities, one 
may wonder why an entire literature was formed around MRS measurements of resting 
individuals with SZ. Although good rationales and hypotheses have been developed to 
explain abnormalities in resting levels of glutamate in SZ, it is reasonable to think that 
NMDA hypofunction may affect the ability to dynamically modify GLU concentrations 
to transact functional activation.  It may be possible to visualize manifestations of NMDA 
hypofunction by acquiring dynamic measurements of metabolite concentrations using 1H-
fMRS of glutamate. GLU changes occurring during performance of a behavioural task 
had never been demonstrated using 1H-fMRS at 7 T in healthy humans. Before we could 
begin a study using this technique in individuals with SZ, the technique needed to be 
developed and demonstrated in healthy controls.   
   
6.1.3 1H-fMRS in healthy controls 
The purpose of this paper was to first demonstrate that 1H-fMRS with a cognitive 
behavioural task can induce detectable GLU changes using an ultra-high field 7 T MRI in 
healthy controls. Prior to this study, the only 1H-fMRS studies that had successfully 
demonstrated GLU changes upon functional activation were conducted in the visual 
cortex using a visual paradigm17–19, the motor cortex using a finger tapping paradigm20, 
the lateral occipital cortex using a repetition suppression task21,22, the anterior insula 
using a pain paradigm23, the dorsal anterior cingulate using a pain paradigm24, and the 
pregenual anterior cingulate using a pain paradigm25 and a sexual arousal paradigm26.  
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None of these past 1H-fMRS studies had used a cognitive paradigm.  Impairments in 
cognition have been well studied in SZ and there exists a number of well-established 
paradigms to study these impairments. After much debate over which cognitive task 
would provide the most robust activation of the ACC while allowing performance of the 
task in a prolonged manner and comparable performance accuracy between patients and 
controls, the color-word Stroop task was used as the cognitive task for this study, but 
certain implementation challenges remained and are discussed below.  
First, the location of the 1H-fMRS voxel has typically been placed in the area that elicits 
the strongest blood-oxygen level dependent (i.e. BOLD) response in fMRI to a specific 
task because of the assumption that the BOLD response is indicative of increased 
functional activation. Cognitive and behavioural tasks elicit weaker BOLD responses 
relative to the visual and motor tasks27, so it may be expected that a difference in GLU 
may be harder to detect. The Stroop task was chosen as the cognitive task to maximize 
the possibility of detecting GLU, as it still induces a relatively robust fMRI activation in 
the ACC (although not as prominent as visual and motor tasks in their respective brain 
regions).  
Cognitive tasks typically require some kind of motion to respond to the stimuli, usually 
via a button press or verbal communication. This creates the possibility of increased 
motion artifacts in the spectra. Although it is possible to have the subjects perform the 
cognitive stimuli silently in their minds, it would then not be possible to confirm the 
subject was attentive and performing the task with the presumed accuracy demonstrated 
during practice. This would also ignore a considerable amount of valuable data in the 
processing of the responses (i.e. mean response times, variances, percent correct, etc) 
between subject groups. Therefore, care was taken to setup the subject in the MRI in a 
position such that they are ready to respond in an attempt to minimize any movement 
when responding on the four-button keypad provided.  
An additional obstacle in using a cognitive task is that the neural response is more 
complex, such that different mechanisms become involved as the task is performed. The 
subject learns to perform the task more efficiently, which may blunt the response. Visual 
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and motor responses activate specific areas of the brain and can be activated repeatedly, 
so these 1H-fMRS studies have utilized fMRI guidance to locate the voxel.  With 
cognitive tasks, performing the fMRI guidance would mean that the subjects would have 
increased exposure to the task, which may reduce activation in the area of interest during 
the 1H-fMRS acquisition and make GLU changes harder to detect.  By locating a 
consistent site of activation, it is possible to use anatomical landmarks to avoid this 
problem.  
One final challenge is that some people will find certain cognitive tasks harder than other 
people. Prior to the 1H-fMRS acquisition, it is important to ensure all participants can 
perform the task to the same level of proficiency by giving them some practice and 
meeting a specific criterion. For this study, all subjects had to achieve 80% correct 
responses on a desktop computer outside of the scanner prior to being examined.  
A significant detectable increase in GLU concentrations in the ACC was observed in a 
small sample (n=7) of healthy controls after functional activation with the color-word 
Stroop task agreeing with the originally stated hypothesis. The magnitude of the GLU 
response was consistent with the visual and motor cortex 1H-fMRS studies that also used 
prolonged stimulation periods (i.e. on the order of minutes)17–20 but had a smaller 
response than event-related 1H-fMRS of the ACC using pain stimuli23–25. It is possible 
that there is a separate, rapid, GLU response to event-related stimuli, in particular, pain. 
Pain is one the bodies most ancient and evolved responses, so it is possible that it has 
adapted a separate GLU response for faster reactions, perhaps utilizing the rapid synaptic 
currents produced by the AMPA GLU receptors28.    
A limitation of this study is the small sample size of participants. Although the sample 
size was low, 6 of the 7 participants showed increases in GLU in the first run of the task 
and 6 of the 7 showed decreases in the recovery period.  This demonstrates that the Stoop 
task is a robust cognitive paradigm to detect GLU changes with functional activation in 
the ACC. 
With the Stroop 1H-fMRS paradigm able to successfully detect GLU increases in healthy 
controls, the next step was to examine GLU dynamically in psychiatric populations. 
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6.1.4 1H-fMRS in schizophrenia and major depressive disorder 
The objective of this study was to gain insight into the health of GLU neurotransmission 
and the GLU-GLN cycle in SZ using a dynamic 1H-MRS protocol. This was 
accomplished using a 1H-fMRS technique similar to the one developed in the previous 
chapter was applied to the ACC of SZ, MDD, and healthy control groups using a color-
word Stroop paradigm and a 7 T MRI.  Each participant underwent a twenty-minute 
Stroop paradigm consisting of five, four-minute blocks that cycled between resting and 
stimulated conditions (i.e. rest, Stroop, recovery, Stroop, recovery), in which eighty 
spectral averages were acquired during each block.  Prior to entering the MRI, each 
participant needed to perform the Stroop task with >80% accuracy to ensure comparable 
levels of proficiency between participants. Metabolite concentrations were extracted from 
the fits of the spectra from each block and tracked temporally. The healthy controls were 
the only group to significantly increase the concentrations of GLU during the first run of 
the task, which was then followed by a significant decrease in the recovery period. 
Neither the SZ nor MDD group presented with significant GLU concentration increases 
during the first run of the Stroop task, but the SZ group did present with significant 
increases in GLN concentrations.  The GLU concentrations in the MDD group decreased 
significantly during the second run of the task, and there was a significant decrease over 
all groups. In addition, there was an overall significant negative correlation between the 
GLN concentrations and the response times, suggesting that the GLN levels are important 
to efficient cognitive functioning. This was the first study to examine GLU 
concentrations using 1H-fMRS in a psychiatric population. 
The increase in GLU concentrations in the healthy control group is consistent with the 
Stroop 1H-fMRS from chapter 4 and is again comparable to the visual and motor 1H-
fMRS studies17–20. Both the MDD group and the SZ group did increase their GLU 
concentrations in the first run of the task, but not significantly. This blunted or aberrant 
response may suggest an inefficiency in the functioning of GLU within the ACC as 
NMDA receptors and excitatory synapses are implicated in both disorders6,29,30.  If the 
NMDA receptors are not functioning optimally then the GLU-GLN cycle will be directly 
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affected, which could explain the smaller increase (below statistical significance 
threshold) in GLU concentrations in the SZ group. Specifically in the SZ group, the 
increase in the GLN concentration could suggest hypofunction of NMDA receptors when 
the region is stimulated, as NMDA hypofunction leads to increased GLN concentrations1.  
The decrease in the GLU concentrations during the second run of the Stroop was an 
unexpected result, based on what has previously been reported in 1H-fMRS studies that 
have repeated visual or motor stimuli.  This suggests two possible explanations.  First, it 
is possible that the ACC is no longer required to the same magnitude due to processes 
involved in learning and improving the task, such that, with practice, different brain areas 
begin to contribute; Second, the GLU response observed is on the order of minutes, so it 
may be that four minutes was not enough for all the mechanisms involved to fully 
recover. 
An important outcome of this study is that the mental state of the participant needs to be 
controlled for in “resting” 1H-MRS studies examining GLU or GLN to avoid 
confounding the results. Instructions should be provided to the participant not unlike the 
instructions that would be given prior to a resting state fMRI scan: relax, close their eyes, 
try not to sleep and try to let their mind wander. Alternatively, a cross-fixation could be 
applied to control the mental state. This has not been a common procedure in past 1H-
MRS studies, which could have had some influence on the results. Going forward, a 
method for controlling the resting state should be a component of every 1H-MRS protocol 
examining GLU or GLN. 
There are similar limitations present in this study as the study mentioned in chapter 3. 
There was significantly more females in the MDD group than in the SZ and healthy 
control groups, the subjects were not drug-naïve, and smoking was not controlled for in 
the subject recruitment.  The effects of these limitations have already been discussed in 
detail in chapter 6.1.2. 
One limitation of studying cognitive tasks in psychiatric populations is that avolition is 
one of the key negative symptom of SZ, so the differences observed in the fMRI or 1H-
fMRS data could be due to a lack of effort. This is a difficult confound to control, but a 
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task that is challenging and engaging should help. In our Stroop task, we controlled 
performance based on the number of correct answers and we showed that participants 
with SZ were able to conduct the task with similar levels of proficiency (>90%). It may 
be debatable whether control for performance accuracy is equivalent to controlling for 
motivational/effort level. 
 
6.2 Future Work 
The results of these studies advance the literature and provide avenues for further 
exploration with more questions yet to be answered. There are many possible directions 
to move forward, some of which are briefly discussed below. 
 
6.2.1 Simulations 
This manuscript has received comments from reviewers after it was submitted for 
publication to Magnetic Resonance in Medicine and is currently in revisions in 
preparation to resubmit. The discussion below pertains to the comments and issues 
mentioned by the reviewers along with some suggestions for future work. 
This simulation study demonstrated that with higher B0 it is possible to improve 
metabolite quantification when using the time-domain fitting algorithm, fitMAN31.  
Whether these results are transmittable to other fitting algorithms has been brought into 
question. Many fitting algorithms share a common theme of reducing residuals between 
the data and the fit using a priori information.  It has previously been demonstrated that 
the frequency-domain fitting algorithm LCModel32 and the time-domain fitting algorithm 
AMARES33 produce very similar concentrations in a study utilizing metabolite 
phantoms. The challenges relating to metabolite quantification including SNR, metabolite 
signature overlap and J-dephasing are not specific to fitMAN and would be challenges in 
other fitting algorithms as well. Similarly, all minimization routines need to have an 
initial estimate to minimize. It is expected that identical results would be obtained using 
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other common fitting algorithms like LCModel or AMARES. A similar simulation study 
utilizing multiple fitting algorithms could be performed to confirm.  
Many 1H-MRS studies utilize Cramer-Rao Lower Bounds (CRLB) to report the quality of 
the spectral fits.   The CRLB are useful because they provide information on the 
minimum variance to be expected from the fitting parameters from a single fit.  The 
advantage of examining the coefficient of variation (CV) is that all sources of variation 
are considered, including the variation from the fitting parameters, and provides a more 
realistic expectation of variation one would expect from a spectral acquisition.  Still, due 
to the prevalence of CRLB in the research community, it would be wise to examine the 
same quantification relationships using the CRLB as well as the CV. This would provide 
information towards the minimum variance coming from the fitting of the parameters, 
and the difference would give an estimate on the variation that arises from other sources 
as well.  In general, simulations are a good way to examine sources of quantification 
variation, mainly because the sources can be isolated, and the simulations can be repeated 
in a Monte Carlo format to achieve a desired power.  
There are a number of ways in which the simulation study could be further explored. 
First, it should implement even more metabolites that are present in very low 
concentrations. There are still many more metabolites that contribute to the spectral area 
in 1H-MRS that cannot typically be quantified reliably. The increase in SNR obtained by 
working at 7 T pushes some lower concentration metabolites not typically part of human 
brain 1H-MRS quantification template above the detectability threshold. Addition of 
candidate metabolites to the simulation would be useful to get an idea of whether the 
spectral area from these metabolites are currently being consistently absorbed into the fit 
of any other specific metabolites when they are omitted from the fitting templates, which 
would lead to inaccuracies in measured metabolite concentrations.  
Another way to extend the simulation study would be to isolate the effects of each of the 
constrained parameters on quantification.  That is, to use inexact seeding for a single 
parameter, while using exact seeding for the remaining parameters.  This would 
characterize which parameters, when seeded poorly, reduce quantification performance 
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the most (i.e. chemical shift, amplitude, linewidth, or phase).  This would be an easy 
study to perform that can be run similarly with Monte Carlo simulations, all performed 
with a batch script on a computer.  A study like this would help to further our 
understanding of which parameters affect quantification precision and accuracy the most. 
Practical knowledge suggests, for example, that small errors in initial chemical shift have 
greater impact than smaller errors in initial amplitude or phase. However, the sensitivity 
of parameter seeding has not been formally studied (beyond what one can deduct from 
analytical formulations of CRLB and Fisher information matrices).  
 
6.2.2 Single-voxel 1H-MRS in SZ and MDD 
The 1H-MRS study of the ACC and the thalamus in people with SZ and MDD produced 
some interesting results that should certainly be explored further. Ideally, a similar study 
would be conducted to confirm the findings, specifically for the reduced GLY in the 
thalamus as the standard CRLB limit for this study was increased for GLY measurements 
from 20% to 30%. It would be a more conclusive result if the CRLB limit for GLY could 
be reduced to the more commonly accepted 20% limit. One way this could be done is by 
increasing the SNR via longer scans with more averages (i.e. from 64 averages to 256 
averages). Increased SNR can also be accomplished by increasing the size of the voxel, 
but this has its own drawbacks in that the voxel would be include brain areas beyond the 
thalamus.  
The spin-echo full-intensity acquired localized spectroscopy (SPECIAL) sequence34 is a 
relatively new 1H-MRS pulse sequence that is capable of getting the short TE that is 
possible with STEAM, while still getting the SNR that is possible with PRESS, and has 
been previously utilized at 7 T19,20. Implementation and optimization of a new pulse 
sequence is a significant endeavor. However, using a SPECIAL sequence with 256 
averages in the same region in the thalamus would, theoretically, improve the spectral 
SNR by a factor of 4 compared to the STEAM sequence with 64 averages that was used 
in this study.  Given that the SPECIAL sequence would not compromise the metabolite 
spectral lineshapes, a significant improvement in the precision of metabolite 
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concentration estimates would be expected. A SPECIAL pulse sequence should be 
implemented and optimized for future 1H-MRS studies. 
One group used an echo time-averaged (TEAV) sequence35 that utilizes the f1=0 
component of a PRESS-2D J-resolved acquisition36,37 to reliably detect GLY 
concentrations in vivo using 1H-MRS at 3 T before and after ingestion of GLY 
supplementation in healthy controls38. They were able to quantify GLY as a ratio to 
creatine measurements with CRLB of 20 ± 2.9% and 17 ± 5.1% for their before and after 
scans, respectively, although one subject’s CRLB exceeded 40% and was removed. It is 
likely that the achieved CRLB would have been improved to below the standard CRLB 
limit of 20% using a 7 T scanner.   
Using the improved quantification precision that would be attainable with these 
techniques, a study that examines the concentrations of GLY before and after oral 
administration in a SZ group compared to healthy controls and a placebo group would be 
valuable.  This would be especially useful if the target SZ group was first-episode and 
drug naïve at the start of the GLY administration and then were followed longitudinally 
over time.  If a detectable increase in GLY concentrations after oral administration is 
found in the thalamus of people with SZ, then a correlation between SANS and SAPS 
scores, or any changes in them, would be especially interesting. 
The same can be said for the MDD group and the observed reduced MYO concentrations.  
A study that tracks MYO levels before and after its ingestion over a period of time and 
similarly tracked the levels of depression would be valuable.  Using the SPECIAL pulse 
sequence would not really be necessary to measure MYO concentrations as it is not 
usually a difficult metabolite to quantify reliably, but would add to quantification 
precision nonetheless. 
Unfortunately, 1H-MRS voxels tend to be larger than what is ideal to study a brain area of 
interest due to the inherent SNR limitation in 1H-MRS. At higher B0, the voxels can 
afford to be smaller so that the results will have increased specificity for a particular brain 
area. Although the technology may not be there yet, it would, one day, be interesting to 
study the individual thalamic nuclei that compose the thalamus using high B0 and small 
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voxels. In a typical MRI image (T1 or T2 weighted), thalamic nuclei are not readily 
resolvable. However, using a segmentation algorithm called Thalamus Optimzed Multi-
Atlas Segmentation (THOMAS)39, it may be possible to localize a specific thalamic 
nucleus to place a small 1H-MRS voxel.  There are a couple of limitations to this 
approach. First, it would likely require longer acquisition times to account for the reduced 
SNR in a small voxel. Second, the probability of significant subject motion displacing the 
voxel from the nucleus of interest is greatly increased both due to the size of the voxel 
and, as a consequence of the smaller voxel, the increased acquisition times.  Still, a study 
like this could one day aid in the understanding of glutamatergic abnormalities in SZ. 
Clozapine is the only accepted pharmaceutical to treat the negative symptoms of SZ, and 
it is believed to influence GLY in some way40–42.  A 1H-MRS study comparing the GLY 
concentrations of people with SZ taking clozapine to people with SZ not taking clozapine 
and healthy controls would be of interest. A similar study has been performed examining 
the serum concentrations of people with SZ taking clozapine compared to those not 
taking it and found lower GLY levels in the people taking clozapine40. Another study 
examined plasma levels of people with treatment-resistant SZ before and after taking 
clozapine and found an increase in GLY levels after clozapine treatment42. The benefit of 
1H-MRS compared to plasma and serum studies is the localization of the voxels to 
specific brain regions, while plasma and serum studies are not specific to any brain 
region.     
 
6.2.3 1H-fMRS 
This 1H-fMRS study of the SZ and MDD groups is likely the first study of many that will 
utilize 1H-fMRS with a behavioural task to study a neurological condition. As this was 
the first study of its kind, it certainly raises follow-up questions for future work. Some 
suggestions for future studies and ways in which the current studies could be improved 
are mentioned below. 
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 The GLU concentration reduction in the second run of the task needs to be further 
understood. This is not the first study to demonstrate a reduction in a neurotransmitter 
following a 1H-fMRS behavioural task. Michels et al43 similarly found an initial increase 
in GABA concentrations followed by multiple reductions in each subsequent run of a 
working memory task. A 1H-fMRS study with a Stroop paradigm should examine 
metabolite concentrations in multiple groups of healthy controls, each with a different 
recovery time between blocks of activation, to characterize the reduced GLU response. 
An additional third block of Stroop stimuli could be added as well to see if GLU 
concentrations would continue the same pattern of successive reductions in concentration 
with each block of activation. 
It may be useful to know when GLU levels start to decrease after the start of the Stroop 
stimuli block.  If it is during the Stroop stimuli block, this would reduce the average GLU 
level observed. The rate and timing of GLU increases and decreases can similarly provide 
valuable information towards to the health of GLU dynamics in SZ. In addition, if the 
reduction in GLU concentrations is due to insufficient recovery times between blocks, 
then it may be feasible to perform fMRI guidance of the fMRS voxel with a sufficiently 
long recovery time between the sequences.  It is possible that some people activate the 
ACC in a slightly different location than others when performing the Stroop. fMRI 
guidance would address this limitation of the results.  
As mentioned for the static metabolite measurements from the ACC and thalamus, the 
1H-fMRS study would benefit from the additional SNR from the SPECIAL sequence. 
The improved SNR may lead to improved temporal resolution to track the GLU 
concentrations while the subjects are performing the tasks.  
Of course, more cognitive tasks should also be explored using 1H-fMRS in the ACC and 
in other regions as well. It would be of interest to utilize a cognitive task that can vary in 
level of difficulty, such as the Sternberg Memory Task44, and see if GLU concentration 
changes correlate with the level of difficulty.  The Stroop Task and/or the Sternberg 
Memory Task should be tested using an event-related 1H-MRS design to assess any 
immediate GLU changes that occur when the area is stimulated. In addition, future 
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studies should aim to correlate the BOLD fMRI response to the behavioural response 
times and to the GLU changes. This would require identical BOLD fMRI and GLU 
fMRS paradigms.  
It would also be of great interest to perform the 1H-fMRS study after administration of an 
NMDA antagonist, such as ketamine.  This would help to further clarify whether these 
results are indicative of NMDA hypofunction in SZ. 
 
6.3 Closing remarks 
Each of the chapters in this thesis contributes to the overall agenda to study the health of 
GLU neurotransmission in SZ. Using the state-of-the-art 7 T MRI, it was possible to 
acquire high quality 1H-MRS data and then to evolve the existing 1H-MRS methodology 
into a technique that reliably measures dynamic concentrations of metabolites, 1H-fMRS. 
The in vivo work presented in this thesis include the first study to measure GLY 
concentrations in the ACC and thalamus using 1H-MRS, the first study to measure GLU 
changes using a Stroop cognitive 1H-fMRS paradigm, and, finally, the first study to 
measure GLU changes dynamically in a psychiatric population.    
A consistent theme throughout this thesis is NMDA hypofunction in SZ, and the results 
certainly provide strong support for such a theory.  However, simply knowing that there 
is NMDA hypofunction in SZ will not be enough. The studies in this thesis have laid the 
ground work for monitoring of GLU dynamics during rest and activation. This tool can 
be used to examine disease-related abnormalities in GLU dynamics and the effect of 
GLU-modulating treatments. There is still much work that needs to be done.  With each 
new study, a new building block is laid and our understanding of GLU abnormalities in 
SZ progresses towards one day having effective treatments for the full range of 
symptoms of SZ.   
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